Methods for genome assembly, haplotype phasing, and target-independent nucleic acid detection
Extra-long-range read pairs generated from reconstituted chromatin address the challenges of NGS data in large repeat regions, enabling accurate de novo assembly and phasing, particularly for personalized medicine applications.
Patent Information
- Application Number
- JP2021170390
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-02-11
- Filing Date
- 2021-10-18
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2036-10-18
AI Technical Summary
Next-generation sequencing (NGS) data struggles to reach large repeat regions of the genome due to short read lengths and small insertion sizes, making de novo assembly challenging and preventing the confirmation of phasing information over long distances.
Generating extra-long-range read pairs (XLRPs) spanning several hundred kilobases to megabases by utilizing reconstituted chromatin to covalently bond distant DNA segments, allowing for sequence verification and phase information through chromatin's three-dimensional structure.
Enables cost-effective, high-quality de novo assembly and accurate rearrangement data, particularly useful for personalized medicine, by overcoming genomic barriers posed by large repeat regions and providing chromosome-level phasing with high precision.
Smart Images

Figure 0007948754000006 
Figure 0007948754000007 
Figure 0007948754000008
Abstract
Description
TECHNICAL FIELD
[0001] <Cross Reference> This application claims the benefit of U.S. Provisional Patent Application No. 62 / 243,576, filed on October 19, 2015, which is incorporated herein by reference in its entirety; U.S. Provisional Patent Application No. 62 / 243,591, filed on October 19, 2015, which is incorporated herein by reference in its entirety; U.S. Provisional Patent Application No. 62 / 255,953, filed on November 16, 2015, which is incorporated herein by reference in its entirety; and U.S. Provisional Patent Application No. 62 / 294,198, filed on February 11, 2016, which is incorporated herein by reference in its entirety.
[0002] Statement Regarding Federally Sponsored Research This invention was made with government support under Contract No. 5R44HG008719-02 awarded by the National Human Genome Research Institute of the United States Government. BACKGROUND ART
[0003] Generating high-quality, highly contiguous genomic sequences remains theoretically and practically challenging. High-throughput sequencing enables genetic analysis of organisms residing in a variety of desired biomedical, ecological, or biochemical environments. Shotgun sequencing of environmental samples, which often include microorganisms that are not amenable to culture, can reveal the genes and biochemical processes present in organisms of a given environment. Careful filtering and analysis of such data can also reveal signs of phylogenetic relatedness among reads in the data. However, high-quality de novo assembly of such highly complex datasets is generally considered difficult. SUMMARY OF THE INVENTION
[0004] A persistent drawback of next-generation sequencing (NGS) data is its inability to reach large repeat regions of the genome due to the short read lengths and relatively small insertion sizes. This deficiency significantly impacts de novo assembly. Because the nature and arrangement of genomic rearrangements are uncertain, it is impossible to link and rearrange contigs separated by long repeat regions. Furthermore, phasing information cannot be confirmed because, over long distances, it is not possible to confidently associate variants with haplotypes. This disclosure addresses all of these problems simultaneously by generating extra-long-range read pairs (XLRPs) spanning approximately several hundred kilobases and up to megabases of genomic distance with appropriate input DNA. Such data is invaluable in overcoming the substantial barriers presented by large repeat regions in the genome, including centromeres, enabling cost-effective de novo assembly and generating rearrangement data with sufficient completeness and accuracy for personalized medicine.
[0005] The use of reconstituted chromatin is crucial in forming associations between very distant but molecularly linked segments of DNA. This disclosure allows for the covalent bonding of distant segments through the three-dimensional structure of chromatin, thereby physically connecting previously separated portions of the DNA molecule. Subsequent processing allows for sequence verification of the associated segments, yielding read pairs whose separation on the genome extends up to the full length of the input DNA molecule. Since the read pairs originate from the same molecule, they also contain phase information.
[0006] Many aspects of health and fitness are influenced by the rich microbial communities in the gastrointestinal tract, on the skin, and at other locations. This specification describes simple and powerful methods for revealing the full genomic complexity of such microbial communities. These techniques can enable rapid, accurate, and quantitative assays of the full genetic repertoire at locations such as the human body (e.g., the gut) and other sites where microbial communities are found.
[0007] Such techniques include, for example, in vitro proximity ligation methods for fecal metagenomics applications. These techniques can provide powerful and efficient methods for de novo metagenomics assembly, enabling research and biomedical analysis beyond methods such as single-locus molecular counting or statistical estimation.
[0008] The technologies described herein can provide a single, integrated workflow for the precise assembly of all major components of complex metagenomics. These technologies enable a comprehensive understanding of how microbiomes (e.g., gut microbiome) influence human health and disease, other animals, plants, other biological forms, and the environment.
[0009] The techniques disclosed herein can provide efficient capture and representation of microbial diversity in samples such as human fecal samples. Furthermore, computational methods for metagenomics assembly that utilize the rich data types generated by these techniques are also disclosed. Such computational methods can achieve highly continuous scaffold and strain deconvolution. The techniques of this disclosure can provide robust and extremely simple research protocols and software products that give a comprehensive view of the dynamic microbial environment (e.g., human gut) from small samples (e.g., fecal samples) in days.
[0010] In some embodiments, the disclosure provides a method for generating high-quality assemblies with far less data than previously required. For example, the method disclosed herein provides a genome assembly from only two lanes of Illumina HiSeq data.
[0011] In other embodiments, the disclosure provides a method for generating chromosome-level phasing using long-range read-pair techniques. For example, the method disclosed herein can phase more than 90% of heterozygous single nucleotide polymorphisms (SNPs) for an individual to a precision of at least 99%. This precision is comparable to phasing produced by substantially more expensive and cumbersome methods.
[0012] In some cases, methods capable of generating genomic DNA fragments up to megabase scales are usable in conjunction with the methods disclosed herein. Long DNA fragments can be generated to confirm the ability of the methods to produce read pairs extending to the longest fragments provided by extraction. In some cases, XLRP libraries can be generated by extracting and using DNA fragments longer than 150 kbp.
[0013] This disclosure provides a method for significantly accelerating and improving de novo genome assembly. The method disclosed herein utilizes a data analysis method that enables rapid and inexpensive de novo assembly of genomes from one or more subjects. This disclosure specifies that the method disclosed herein can be used in a variety of applications, including haplotype phasing and metagenomics analysis.
[0014] In some embodiments, the Disclosure provides a method for genome assembly, which includes the steps of generating a plurality of contigs, generating a plurality of read pairs from data generated by exploring the physical arrangement of chromosomes, chromatin, or reconstituted chromatin, mapping or assembling the plurality of read pairs to the plurality of contigs, constructing an adjacency matrix of the contigs using the read mapping or assembly data, and analyzing the adjacency matrix to determine the paths through the contigs, which represent their order and / or orientation relative to the genome. In some embodiments, the Disclosure specifies that at least about 90% of the read pairs are weighted by obtaining a function of the distance of each read to the edge of the contigs, thereby incorporating information about which read pairs exhibit short-range contacts and which read pairs exhibit longer-range contacts. In other embodiments, the adjacency matrix can be rescaled to reduce the weight of many contacts on some contigs that represent indiscriminate regions of the genome, such as conserved binding sites for one or more drugs that modulate chromatin scaffold interactions, such as the transcriptional repressor CTCF. In other embodiments, the disclosure provides a method for genome assembly of a human subject, thereby generating multiple contigs from the DNA of the human subject, and thereby generating multiple read pairs by analyzing the chromosomes, chromatin, or reconstituted chromatin of the human subject made from the subject's naked DNA.
[0015] In some embodiments of this specification, the advantage is a reduction in the number of steps required to isolate the tagged complex to provide phase information. In many techniques in the prior art, the complex includes a tagged nucleic acid or a tagged binding moiety, such as a biotin-tagged protein or nanoparticles, to facilitate the binding of the complex to a solid surface labeled with avidin or streptavidin. In some methods and compositions of this disclosure, the solid surface is coated with a moiety that binds to the complex, either directly or via a solvent, so that the complex does not need to be modified with a ligand to facilitate binding to the solid surface. Many moieties are contemplated herein, such as hydrophilic moieties, hydrophobic moieties, positively charged moieties, uncharged moieties, PEGs, polyamines, amino moieties, polycarboxylic acid moieties, or other moieties or combinations thereof. In some cases, the surface is a SPRI surface, such as a SPRI surface that binds the binding moiety-nucleic acid complex directly or via a solvent.
[0016] This disclosure specifies that multiple contigs can be generated by using a shotgun sequencing method, which includes the steps of: fragmenting a long stretch of DNA from a subject into random fragments of varying sizes; sequencing the fragments using a high-throughput sequencing method to generate multiple sequencing reads; and assembling the sequencing reads to form multiple contigs.
[0017] In some embodiments, the disclosure specifies that multiple read pairs can be generated by exploring the physical arrangement of chromosomes, chromatin, or reconstituted chromatin using a chromatin capture technique. In some embodiments, the chromatin capture technique includes crosslinking chromosomes, chromatin, or reconstituted chromatin with a fixative such as formaldehyde to form DNA-protein crosslinks; cleaving the crosslinked DNA-proteins with one or more nuclease enzymes (e.g., restriction enzymes) to generate multiple DNA-protein complexes including adherent ends; filling the adherent ends with nucleotides containing one or more markers such as biotin to create blunt ends that will later be joined together; fragmenting the multiple DNA-protein complexes into fragments; pulling down the junctions containing the fragments using one or more markers; and sequencing the junctions containing the fragments using a high-throughput sequencing method to generate multiple read pairs. In some embodiments, multiple read pairs for the method disclosed herein are generated from data produced by exploring the physical arrangement of reconstituted chromatin.
[0018] In some embodiments, the Disclosure provides a method for generating tagged sequences, the method comprising the steps of: binding a DNA molecule to an association molecule; cleaving the bound DNA-protein to generate a plurality of DNA-protein complexes including segment ends; ligating the segment ends to a tag; and sequencing the junction containing the fragment using a high-throughput sequencing method to generate a plurality of read pairs. Many association molecules that bind DNA are intended, including strictly defined chromatin elements such as histones, but also non-polypeptide DNA-binding association molecules such as DNA-binding proteins, transcription factors, nucleoproteins, transposons, or nanoparticles having a surface containing DNA-affinity molecules, as well as more generally defined chromatin elements. In some cases, the tag is ligated to the segment ends, for example, using a ligase or using a transposase packed with the tag molecule. In some cases, segment ends containing a common tag are assigned to a common origin molecule, often indicating a phase. In some embodiments, the plurality of read pairs for the method disclosed herein are constructed from data generated by exploring the physical arrangement of the reconstituted chromatin.
[0019] In various embodiments, this disclosure specifies that multiple read pairs can be determined by exploring the physical arrangement of chromosomes or chromatin isolated from cultured cells or primary tissue. In other embodiments, multiple read pairs can be determined by exploring the physical arrangement of reconstituted chromatin formed by compounding naked DNA obtained from samples of one or more subjects with isolated histones.
[0020] This disclosure provides a method for determining haplotype phasing, which includes the step of identifying one or more heterozygous sites in a plurality of read pairs, and the phasing data of an allele variant can be determined by identifying a read pair containing a pair of heterozygous sites.
[0021] In various embodiments, the Disclosure provides a method for high-throughput bacterial genome assembly, comprising the step of generating multiple read pairs by exploring the physical arrangement of chromosomes of multiple microorganisms using a modified chromatin capture-based method, the improved method comprising the steps of: capturing microorganisms from a given environment; and adding a fixative such as formaldehyde to form crosslinks within each microbial cell, wherein the mapping of read pairs to various contigs indicates which contigs belong to the same species.
[0022] In some embodiments, the Disclosure provides a method for genome assembly, the method comprising: (a) generating a plurality of contigs; (b) determining a plurality of read pairs from data generated by exploring the physical arrangement of chromosomes, chromatin, or reconstructed chromatin; (c) mapping the plurality of read pairs to the plurality of contigs; (d) constructing an adjacency matrix of the contigs using the read-mapping data; and (e) analyzing the adjacency matrix to determine paths through the contigs that represent their order and / or orientation relative to the genome.
[0023] The present disclosure provides a method capable of generating a plurality of read pairs by probing the physical arrangement of chromosomes, chromatin, or reconstituted chromatin using a chromatin capture technique. In some embodiments, the chromatin capture technique comprises (a) cross-linking chromosomes, chromatin or reconstituted chromatin with a fixing agent to form DNA-protein cross-links; (b) cleaving the cross-linked DNA-protein with one or more nuclease (e.g., restriction) enzymes to generate a plurality of DNA-protein complexes comprising sticky ends; (c) filling the sticky ends with nucleotides containing one or more markers to create blunt ends that are subsequently ligated together; (d) cleaving the plurality of DNA-protein complexes into fragments; (e) pulling down junctions containing fragments using the one or more markers; and (f) sequencing the junctions containing fragments using a high-throughput sequencing method to generate the plurality of read pairs.
[0024] In certain embodiments, the plurality of read pairs is determined by probing the physical arrangement of chromosomes or chromatin isolated from cultured cells or primary tissue. In other embodiments, the plurality of read pairs is determined by probing the physical arrangement of reconstituted chromatin formed by complexing naked DNA obtained from a sample of one or more subjects with isolated histones.
[0025] In some embodiments, at least about 60%, about 70%, about 80%, about 90%, about 95%, or about 99% or more of the plurality of read pairs are weighted by taking a function of the read distance to the edge of the contig to incorporate the higher probability of short contacts over long contacts. In some embodiments, the adjacency matrix is rescaled to reduce the weight of many contacts on several contigs that represent promiscuous regions of the genome.
[0026] In certain embodiments, the indiscriminate regions of the genome comprise one or more conserved binding sites for one or more agents that modulate scaffold interactions of chromatin. In some examples, the agent is the transcriptional repressor CTCF.
[0027] In some embodiments, the methods disclosed herein provide a method for genome assembly of a human subject, whereby a plurality of contigs are generated from the DNA of the human subject, whereby a plurality of read pairs are generated by analyzing the chromosomes, chromatin, or reconstituted chromatin of the human subject prepared from the naked DNA of the subject.
[0028] In other embodiments, the present disclosure provides a method for determining haplotype phasing, comprising the step of identifying one or more heterozygous sites in a plurality of read pairs, wherein phasing data for allelic variants can be determined by identifying read pairs comprising a pair of heterozygous sites.
[0029] In yet another embodiment, the present disclosure provides a method for metagenomic assembly, wherein a plurality of read pairs are generated by probing the physical arrangement of chromosomes of a plurality of microorganisms using a modified chromatin capture-based method, the method comprising the steps of collecting the microorganisms from an environment, and adding a fixative to form crosslinks within each microbial cell, wherein mapping of the read pairs to various contigs indicates which contigs are from the same species. In some embodiments, the fixative is formaldehyde.
[0030] In some embodiments, the disclosure provides a method for assembling a plurality of contigs starting from a DNA molecule, the method comprising the steps of generating a plurality of read pairs from the DNA molecule and assembling the contigs using the read pairs, wherein at least 1% of the read pairs extend for 50 kB or more on the DNA molecule, and the read pairs are generated within 14 days. In some embodiments, at least 10% of the read pairs extend for a distance of 50 kB or more on the DNA molecule. In some embodiments, at least 1% of the read pairs extend for a distance of 100 kB or more on the DNA molecule. In some cases, the read pairs are generated within 7 days.
[0031] In some embodiments, the disclosure provides a method for assembling multiple contigs starting from a DNA molecule, the method comprising the steps of generating multiple read pairs from a single DNA molecule in vitro and assembling contigs using the read pairs, wherein at least 1% of the read pairs extend over a distance of 30 kB or more on the single DNA molecule. In some embodiments, at least 10% of the read pairs extend over a distance of 30 kB or more on the single DNA molecule. In other embodiments, at least 1% of the read pairs extend over a distance of 50 kB or more on the single DNA molecule.
[0032] In further embodiments, the disclosure provides a haplotype phasing method comprising the steps of generating a plurality of read pairs from a single DNA molecule and assembling a plurality of contigs of a DNA molecule using the read pairs, wherein at least 1% of the read pairs extend at a distance of 50 kB or more on the single DNA molecule, and the haplotype phasing is performed with an accuracy of 70% or more. In some embodiments, at least 10% of the read pairs extend at a distance of 50 kB or more on the single DNA molecule. In other embodiments, at least 1% of the read pairs extend at a distance of 100 kB or more on the single DNA molecule. In some embodiments, the haplotype phasing is performed with an accuracy of 90% or more.
[0033] This disclosure provides a haplotype phasing method comprising the steps of generating multiple read pairs from a single DNA molecule in vitro and assembling multiple contigs of a DNA molecule using the read pairs, wherein at least 1% of the read pairs extend at a distance of 30 kB or more on the single DNA molecule, and the haplotype phasing is performed with an accuracy of 70% or more. In some embodiments, at least 10% of the read pairs extend at a distance of 30 kB or more on the single DNA molecule. In other embodiments, at least 1% of the read pairs extend at a distance of 50 kB or more on the single DNA molecule. In yet another embodiment, the haplotype phasing is performed with an accuracy of 90% or more. In some embodiments, the haplotype phasing is performed with an accuracy of 70% or more.
[0034] In some embodiments, the Disclosure provides a method for generating a first read pair from a first DNA molecule, the method comprising: (a) binding a first DNA molecule in vitro to a plurality of association molecules, wherein the first DNA molecule comprises a first DNA segment and a second DNA segment; (b) tagging the first DNA segment and the second DNA segment, thereby forming at least one tagged DNA segment; and (c) sequencing the tagged DNA segment or at least a recognizable portion of the tagged DNA segment, such as a portion adjacent to the tag or a portion opposite to the tagged end, wherein the plurality of association molecules are not covalently modified with affinity labels before and during steps (a) and (b).
[0035] In one embodiment, the present disclosure provides a method for generating a tagged sequence from a first DNA molecule, the method comprising: (a) crosslinking the first DNA molecule in vitro to a plurality of association molecules; (b) immobilizing the first DNA molecule on a solid support; (c) cleaving the first DNA molecule to generate a first DNA segment and a second DNA segment; (d) tagging the first DNA segment and the second DNA segment to form at least one tagged DNA segment; and sequencing the tagged DNA segment or at least a recognizable portion of the tagged DNA segment, such as a portion adjacent to the tag or a portion opposite to the tagged end, or sequencing a recognizable portion of each end of the tagged DNA segment to obtain the tagged sequence, the first DNA molecule being directly bound to the solid support. In some examples, the solid support comprises polymer beads (e.g., SPRI beads) that bind to DNA without further modification with any affinity labels (e.g., biotin, streptavidin, avidin, polyhistidine, digoxigenin, EDTA, or derivatives thereof).
[0036] In some embodiments, multiple associated molecules from reconstituted chromatin, etc., are crosslinked to a first DNA molecule. In some examples, the associated molecules include amino acids. In some cases, the associated molecules are peptides or proteins. In some examples, the associated molecules are histone proteins. In some cases, the histone proteins are from a different source than the first DNA molecule. In various examples, the associated molecules are transposases. In some cases, the first DNA molecule is non-covalently bonded to the associated molecules. In other cases, the first DNA molecule is covalently bonded to the associated molecules. In some examples, the first DNA molecule is crosslinked to the associated molecules. In some embodiments, the first DNA molecule is crosslinked with a fixative. In some embodiments, the fixative is formaldehyde. In various embodiments, the method includes immobilizing multiple associated molecules on a solid support. In some cases, the solid support is beads. In some examples, the beads include polymers. In some examples, the fixative is polystyrene. In some examples, the polymer is polyethylene glycol (PEG). In some examples, the beads are magnetic beads. In some cases, the beads are reversible immobilization (SPRI) beads of the solid phase. In some cases, the solid support contains a surface with multiple carboxyl groups. In various cases, the solid support does not covalently bond to any polypeptide (e.g., streptavidin). In some cases, the associated molecule does not covalently bond to the affinity label (e.g., biotin) before immobilization to the solid support.
[0037] In some embodiments, the first and second DNA segments are generated by cleaving the first DNA molecule. In some cases, the first DNA molecule is cleaved after being bound to multiple association molecules. In some cases, the first DNA molecule is cleaved using a restriction enzyme (e.g., MbolI). In some cases, the first DNA molecule is cleaved using a transposase (e.g., Tn5). In other cases, the first DNA molecule is cleaved using a physical method (e.g., sonication, mechanical shearing). In some embodiments, the segments of the first and second DNA are modified with affinity labels. In some examples, the affinity label may contain biotin, which can be captured with streptavidin beads, avidin beads, or derivatives thereof. In some examples, the affinity label is biotin-modified nucleoside triphosphate (dNTP). In some examples, the affinity label is biotin-modified deoxyribocytosine triphosphate (deoxycytidine triphosphate). In some cases, the affinity label is biotin-modified deoxyribocytosine triphosphate (dGTP). In some cases, the affinity label is biotin-modified deoxyribocytosine triphosphate (dATP). In some cases, the affinity label is biotin-modified deoxyribocytosine triphosphate (dUTP). In some cases, the first DNA segment is tagged with the first tag at least at the first end, and the second DNA segment is tagged with the second tag at least at the second end. In some cases, the first tag and the second tag are identical. In various cases, the first and second DNA segments are tagged using a transposase (e.g., Tn5). In some cases, the first DNA segment is tagged with the second DNA segment, and the second DNA segment is tagged with the first DNA segment. For example, the first DNA segment is linked to the second DNA segment. In some cases, the first DNA segment is linked to the second DNA segment using ligase.In some cases, linked DNA segments are cleaved before sequencing in step (c). In one example, linked DNA segments are cleaved using restriction enzymes (e.g., ExoIII). In other cases, linked DNA segments are cleaved using physical methods (e.g., sonication, mechanical shearing).
[0038] In some embodiments, the first DNA segment is washed less than about 10 times before being linked to the second DNA segment. In some embodiments, the first DNA segment is washed less than about 6 times before being linked to the second DNA segment. In some embodiments, the method includes the step of binding the linked DNA segments to a sequencing adapter.
[0039] In one embodiment, the method includes the step of assembling a plurality of contigs using tagged sequences. In some embodiments, each of the first and second DNA segments is bound to at least one affinity marker, and the linked DNA segments are captured using the affinity marker. In various embodiments, the method includes the step of phasing the first and second DNA segments using tagged sequences. In some cases, “tagging” is achieved by ligating the first DNA segment to the second DNA segment, thereby generating a read-pair segment.
[0040] In some embodiments, the method includes the steps of (a) providing a plurality of associated molecules, such as from reconstituted chromatin, to at least a second DNA molecule; (b) crosslinking the associated molecules to the second DNA molecule to form a second complex in vitro; (c) cleaving the second complex to generate a third DNA segment and a fourth segment; (d) linking the third DNA segment to the fourth DNA segment to form a second linked DNA segment; and (e) sequencing the second linked DNA segment to obtain a second read pair. In some examples, less than 40% of the DNA segments from the DNA molecule are linked to DNA segments from any other DNA molecule. In some examples, less than 20% of the DNA segments from the DNA molecule are linked to DNA segments from any other DNA molecule.
[0041] In some embodiments, the Disclosure provides a method for generating a first read pair from a first DNA molecule containing a predetermined sequence, the method comprising: (a) providing one or more DNA-binding molecules to the first DNA molecule, wherein the one or more DNA-binding molecules bind to the predetermined sequence; (b) crosslinking the first DNA molecule in vitro, wherein the first DNA molecule contains a first DNA segment and a second DNA segment; (c) linking the first DNA segment to the second DNA segment, thereby forming a first linked DNA segment; and (d) sequencing the first linked DNA segment, thereby obtaining a first read pair, wherein the probability of the predetermined sequence appearing in the read pair is influenced by the binding of the DNA-binding molecules to the predetermined sequence.
[0042] In some embodiments, the DNA-binding molecule is a nucleic acid that can hybridize to a predetermined sequence. In some examples, the nucleic acid is RNA. In other examples, the nucleic acid is DNA. In other embodiments, the DNA-binding molecule is a small molecule. In some examples, the small molecule binds to the predetermined sequence with a binding affinity of less than 100 μM. In some examples, the small molecule binds to the predetermined sequence with a binding affinity of less than 1 μM. In some embodiments, the DNA-binding molecule is immobilized on a surface or a solid support.
[0043] In some embodiments, the probability of a predetermined sequence appearing in a read pair decreases. In other embodiments, the probability of a predetermined sequence appearing in a read pair increases.
[0044] This disclosure provides a method for generating multiple tagged sequences from multiple DNA molecules, the method comprising: (a) binding multiple DNA molecules to multiple association molecules in vitro; (b) cleaving each of the DNA molecules to generate at least multiple DNA segments; (c) tagging at least a portion of the DNA segments to form multiple tagged DNA segments; and (d) sequencing the tagged DNA segments, or at least a recognizable portion of the tagged DNA segments, such as a portion adjacent to the tag or a portion opposite to the tagged end, to obtain multiple tagged sequences, wherein the multiple association molecules are not covalently modified with affinity labels before and during steps (a) and (b). In some cases, less than 40% of the DNA segments from the DNA molecules are linked to DNA segments from any other DNA molecules. In some cases, less than 20% of the DNA segments from the DNA molecules are linked to DNA segments from any other DNA molecules.
[0045] In some embodiments, the associated molecule comprises amino acids linked by peptide bonds. In some embodiments, the associated molecule is a polypeptide or protein. In some examples, the associated molecule is a histone protein. In some examples, the histone protein is from a different source than the DNA molecule. For example, the histone protein may be isolated from a non-human organism, and the DNA molecule may be isolated from a human organism. In various examples, the associated molecule is a transposase (e.g., Tn5). In some cases, the first DNA molecule is non-covalently bonded to the associated molecule. In other cases, the first DNA molecule is covalently bonded to the associated molecule. In some examples, the first DNA molecule is crosslinked to the associated molecule. In some embodiments, the DNA molecule is crosslinked with a fixative. For example, the fixative may be formaldehyde. In some cases, the method includes the step of immobilizing multiple associated molecules on multiple supports. In some cases, the solid supports are beads. In some examples, the beads contain a polymer. In some examples, the fixative is polystyrene. In some examples, the polymer is polyethylene glycol (PEG). In some examples, the beads are magnetic beads. In some examples, the beads are SPRI beads. In various examples, the solid support contains a surface with multiple carboxyl groups. In various cases, the solid support does not covalently bond to any polypeptide (e.g., streptavidin). In some cases, the associated molecule does not covalently bond to the affinity label (e.g., biotin) before immobilization on the solid support.
[0046] In some cases, the first DNA molecule is cleaved after being bound to multiple association molecules. In some cases, the first DNA molecule is cleaved using a restriction enzyme (e.g., MboII). In some cases, the first DNA molecule is cleaved using a transposase (e.g., Tn5). In some embodiments, a portion of the DNA segment is modified with an affinity label. In some cases, the affinity label contains biotin. In some examples, the affinity label is biotin-modified nucleoside triphosphate (dNTP). In some examples, the biotin-modified nucleoside triphosphate (dNTP) is biotin-modified deoxyribocytosine triphosphate (dCTP). In some cases, a portion of the DNA segment is tagged at least at a first end by a first tag. In some examples, the DNA segment is tagged using a transposase. In various examples, a portion of the DNA segment is tagged by linking each of the above DNA segments to at least one other DNA segment. In some cases, a portion of a DNA segment is linked to another DNA segment using a ligase. In some cases, the linked DNA segments are cut before step (c). In various cases, the linked DNA segments are cut using physical methods (e.g., sonication, mechanical shearing). In some embodiments, the above method includes the step of binding the linked DNA segments to a sequencing adapter.
[0047] In some embodiments, DNA segments are washed less than about 10 times before being linked to form linked DNA segments. In some cases, DNA segments are washed less than about 6 times before being linked to form linked DNA segments. In various cases, the method includes the step of assembling multiple contigs of DNA molecules using tagged segments. In some cases, the method includes preparing DNA segments using tagged segments.
[0048] This disclosure provides an in vitro library comprising a plurality of read pairs, each containing at least a first sequence element and a second sequence element, the first and second sequence elements originating from a single DNA molecule, and at least 1% of the read pairs containing the first and second sequence elements separated by at least 50 kB on a single DNA molecule. In some embodiments, at least 10% of the read pairs contain the first and second sequence elements separated by at least 50 kB on a single DNA molecule. In other embodiments, at least 1% of the read pairs contain the first and second sequence elements separated by at least 100 kB on a single DNA molecule. In some embodiments, less than 20% of the read pairs contain one or more predetermined sequences. In some embodiments, less than 10% of the read pairs contain one or more predetermined sequences. In some embodiments, less than 5% of the read pairs contain one or more predetermined sequences.
[0049] In some embodiments, a predetermined sequence is determined by one or more nucleic acids that can hybridize to the predetermined sequence. In some examples, the one or more nucleic acids are RNA. In other examples, the one or more nucleic acids are DNA. In some examples, the one or more nucleic acids are immobilized on a surface or solid support.
[0050] In some embodiments, a predetermined sequence is determined by one or more small molecules. In some examples, one or more small molecules bind to the predetermined sequence with a binding affinity of less than 100 μM. In some examples, one or more small molecules bind to the predetermined sequence with a binding affinity of less than 1 μM.
[0051] This disclosure provides a composition comprising a DNA fragment and several associated molecules, such as those derived from reconstituted chromatin, wherein (a) the associated molecules are crosslinked to the DNA fragment in an in vitro complex, and (b) the in vitro complex is immobilized on a solid support.
[0052] This disclosure provides a composition comprising a DNA fragment, a plurality of association molecules, and a DNA-binding molecule, wherein (a) the DNA-binding molecule binds to a predetermined sequence on the DNA fragment, and (b) the association molecule crosslinks to the DNA fragment. The DNA-binding molecule is a nucleic acid that can optionally hybridize to a predetermined sequence. In some examples, the nucleic acid is RNA. In other examples, the nucleic acid is DNA. In some examples, the nucleic acid is immobilized on a surface or solid support. In other embodiments, the DNA-binding molecule is a small molecule. In some examples, the small molecule binds to the predetermined sequence with a binding affinity of less than 100 μM. In other examples, the small molecule binds to the predetermined sequence with a binding affinity of less than 1 μM.
[0053] This disclosure provides compositions comprising multiple associated molecules bound to a DNA fragment in an in vitro complex, the in vitro complex being immobilized on a solid support, the solid support not covalently bound to any polypeptide. In some cases, the solid support is not covalently bound to streptavidin. In some cases, the solid support is beads. In some examples, the beads contain a polymer. In some examples, the fixative is polystyrene. In some examples, the polymer is polyethylene glycol (PEG). In some examples, the beads are magnetic beads. In some examples, the beads are reversible immobilization (SPRI) beads of the solid phase. In some cases, the solid support contains a surface containing multiple carboxyl groups. In various cases, the solid support is not covalently bound to any polypeptide (e.g., streptavidin).
[0054] In some cases, the associated molecule contains amino acids linked by peptide bonds. In some cases, the associated molecule is a peptide or protein. In some cases, the associated molecule is a histone protein. In some cases, the histone protein is from a different source than the first DNA molecule. In some cases, the associated molecule is a transposase. In some cases, the first DNA molecule is non-covalently bonded to the associated molecule. In other cases, the first DNA molecule is non-covalently bonded to the associated molecule. In some cases, the first DNA molecule is crosslinked to the associated molecule. In some embodiments, the first DNA molecule is crosslinked with a fixative. In some embodiments, the fixative is formaldehyde.
[0055] In some embodiments, DNA fragments are modified with affinity labels. In some examples, the affinity label may contain biotin, which can be captured with streptavidin beads, avidin beads, or derivatives thereof. In some examples, the affinity label is biotin-modified nucleoside triphosphate (dNTP). In some examples, the affinity label is biotin-modified deoxyribocytosine triphosphate (deoxycytidine triphosphate). In some cases, the linked DNA segments are further cleaved before sequencing in step (c). In some examples, the linked DNA segments are cleaved using restriction enzymes (e.g., ExoIII). In other cases, the linked DNA segments are cleaved using physical methods (e.g., sonication, mechanical shearing).
[0056] The methods and compositions disclosed herein are useful for assembling genomic information into a scaffold containing entire phased chromosomes. In some cases, the information generated herein guides the assembly of previously generated sequence information into a scaffold containing entire phased chromosomes. In some cases, the methods and compositions disclosed herein are used to assemble de novo generated nucleic acid information into a phased scaffold containing entire chromosomes.
[0057] Tag information is useful with respect to phase information, although it does not always correspond strictly to the phase. Referring generally to the disclosures herein, the presence of a common tag pattern on a pair of sequence reads indicates that the reads either 1) originate from a common molecule or 2) are shared by chance.
[0058] In most cases, common tagging does not occur by chance, and therefore, the most commonly tagged sequences, especially those independently mapped to a common contig, can be presumed to map to a common phase of that contig, i.e., the same haploid molecule in a diploid organism. A group of reads that map together to one or a few contigs suspected to be adjacent and share a tag sequence may be in a phase on a single molecule. A group of reads that share a common tag sequence but map to a contig suspected to be on a different chromosome, for example, is more likely to have acquired that common tag sequence by chance. Multiple examples of sequence clusters that share the exact tag sequence but map to two different contigs or suspected chromosomes may, however, indicate that a translocation has occurred, causing one chromosomal fragment to join a second fragment, and that the reads are indeed in a phase on a chromosome that is a result of the translocation.
[0059] The presence of different tag patterns within a pair of sequence reads indicates that the sequences did not originate from a common molecule immediately prior to tagging. However, if multiple identical or duplicate copies of a nucleic acid molecule are present in a single sample, it is possible to generate two sets of sequence reads with different tag patterns. This indicates that the sequence reads originated from different molecules in the sample, but nevertheless map to the same one in the phase chromosome in a diploid cell. In other words, tag pattern information indicates whether the sequences originated from a common molecule, and generally, tag pattern information correlates with phase information. However, as discussed above, in cases of inconsistency, tag pattern information better indicates the common origin molecule. If the origin molecule and the phase determination of the nucleic acid show some inconsistency, those skilled in the art can resolve such inconsistencies so that some phase information can nevertheless be determined from the tag pattern information generated by the method herein.
[0060] A method for generating a tagged sequence from a first DNA molecule is disclosed herein, the method comprising: (a) binding the first DNA molecule to a plurality of association molecules to form a first complex, wherein the first DNA molecule comprises a first DNA segment and a second DNA segment; (b) tagging the first DNA segment and the second DNA segment to form at least one tagged DNA segment; (c) binding the complex to a solid support having a surface that directly binds to the components of the complex; and (d) sequencing a recognizable portion of the tagged DNA segment, such as a portion adjacent to the tag or a portion opposite to the tagged end, thereby obtaining the tagged sequence, wherein the plurality of association molecules are not covalently modified with affinity labels before or during steps (a) and (b).
[0061] A method for generating a tagged sequence from a first DNA molecule is disclosed herein, the method comprising: (a) binding the first DNA molecule to a plurality of association molecules; (b) immobilizing the first DNA molecule on a solid support; (c) cleaving the first DNA molecule to generate a first DNA segment and a second DNA segment; (d) tagging the first DNA segment and the second DNA segment to form at least one tagged DNA segment; and (e) sequencing the tagged DNA segment to obtain the tagged sequence, wherein the first DNA molecule is directly bound to the solid support.
[0062] A method for generating multiple tagged sequences from multiple DNA molecules is disclosed herein, the method comprising: (a) binding the multiple DNA molecules to a plurality of association molecules; (b) cleaving the multiple DNA molecules to generate a plurality of DNA segments; (c) tagging at least a portion of the DNA segments to form a plurality of tagged DNA segments; and (d) sequencing the tagged DNA segments to obtain a plurality of tagged sequences, wherein the plurality of association molecules are not covalently modified with affinity labels before or during steps (a) and (b).
[0063] A composition comprising multiple associated molecules bound to a DNA fragment in an in vitro complex is disclosed herein, wherein the in vitro complex is immobilized on a solid support and the solid support is not covalently bound to any polypeptide.
[0064] A method for generating multiple tagged sequences from multiple DNA molecules is disclosed herein, the method comprising: (a) obtaining multiple DNA molecules bound to multiple association molecules; (b) cleaving the DNA molecules to generate at least multiple DNA segments; (c) tagging at least a portion of the DNA segments to form multiple tagged DNA segments; and (d) sequencing the tagged DNA segments to obtain multiple tagged sequences, wherein the total amount of the multiple DNA molecules is less than about 5 micrograms (μg).
[0065] A method for identifying the microbial host of an antibiotic resistance gene is disclosed herein, the method comprising: a) obtaining a stable sample from an individual having conditions that demonstrate the antibiotic resistance of the microorganism; b) processing the stable sample to cleave double-stranded DNA in the stable sample; c) labeling the exposed DNA ends; d) ligating the labeled exposed DNA ends to form labeled paired ends; and e) sequencing the entire labeled paired ends to generate a paired sequence, wherein a sequence adjacent to the antibiotic resistance gene sequence indicates the microbial host of the antibiotic resistance gene.
[0066] A method for determining genomic linkage information for heterogeneous nucleic acid samples is disclosed herein, the method comprising: (a) obtaining a stable heterogeneous nucleic acid sample; (b) processing the stable sample to cleave double-stranded DNA in the stable sample; (c) labeling exposed DNA ends; (d) ligating the labeled exposed DNA ends to form labeled paired ends; (e) sequencing the entire labeled paired ends to generate a plurality of paired sequence reads; and (f) assigning each half of the paired sequence reads of the plurality of sequence reads to a common nucleic acid origin molecule.
[0067] A method for metagenomics assembly is disclosed herein, the method comprising the steps of (a) collecting microorganisms from a given environment, (b) obtaining a plurality of contigs from the microorganisms, (c) generating a plurality of read pairs from data generated by exploring the physical arrangement of the reconstituted chromatin, and (d) mapping the plurality of read pairs to the plurality of contigs, thereby creating read-mapping data, wherein the mapping of read pairs to different contigs indicates that the different contigs are from a common species.
[0068] A method for detecting a pathogen in a host population is disclosed herein, the method comprising: a) obtaining a stable sample from each of several individuals suspected of carrying a common pathogen; b) processing the stable sample to cleave double-stranded DNA in the stable sample; c) tagging the exposed DNA ends of a first portion of the stable sample using a first barcode tag and tagging the exposed ends of a second portion of the stable sample using a second barcode tag; d) sequencing the entire barcode-tagged ends to generate a sequence tagged with multiple barcodes; and e) assigning the sequence reads tagged with a common barcode of the sequence reads to a common origin organism, the common origin organism of individuals suspected of carrying a common pathogen being the pathogen.
[0069] A method for identifying a microbial host of an antibiotic resistance gene is disclosed herein, the method comprising: a) obtaining a stable sample from an individual having conditions that demonstrate antibiotic resistance of the microorganism; b) processing the stable sample to cleave double-stranded DNA in the stable sample; c) tagging the exposed DNA ends of a first portion of the stable sample using a first barcode tag and tagging the exposed ends of a second portion of the stable sample using a second barcode tag; and d) sequencing the entire barcode-tagged ends to generate a sequence tagged with multiple barcodes, wherein a sequence having the same barcode tag as the barcode tag of the antibiotic resistance gene sequence indicates a microbial host of the antibiotic resistance gene.
[0070] A method for determining genomic linkage information for heterogeneous nucleic acid samples is disclosed herein, the method comprising: (a) obtaining a stable heterogeneous nucleic acid sample; (b) processing the stable sample to cleave double-stranded DNA in the stable sample; (c) tagging the exposed DNA ends of a first portion of the stable sample using a first barcode tag and tagging the exposed ends of a second portion of the stable sample using a second barcode tag; (d) sequencing the entire barcode-tagged ends to generate a plurality of barcode-tagged sequence reads; and (e) assigning the common-tagged sequence reads to a common nucleic acid origin molecule.
[0071] A method for detecting pathogens in a host population is disclosed herein, the method comprising: a) obtaining a stable sample from each of a plurality of subjects; b) processing the stable sample to cleave double-stranded DNA in the stable sample, thereby generating exposed DNA ends; c) labeling at least a portion of the exposed DNA ends; d) ligating the exposed DNA ends to form labeled paired ends; e) sequencing at least a recognizable portion of the labeled paired ends to generate a plurality of read pairs; and f) assigning each half of the read pairs to a common origin organism, the origin organism common to the subjects being detected as a pathogen.
[0072] A method for identifying a microbial host of an antibiotic resistance gene is disclosed herein, the method comprising: a) obtaining a stable sample from a subject having conditions that demonstrate antibiotic resistance of a microorganism; b) processing the stable sample to cleave double-stranded DNA in the stable sample, thereby generating exposed DNA ends; c) labeling at least a portion of the exposed DNA ends; d) ligating the labeled exposed DNA ends to form labeled paired ends; and e) sequencing at least a recognizable portion of the ligated paired ends to generate a paired sequence, wherein the paired sequence adjacent to the antibiotic resistance gene sequence indicates the microbial host of the antibiotic resistance gene.
[0073] A method for determining genomic linkage information relating to heterogeneous nucleic acid samples is disclosed herein, the method comprising: (a) stabilizing heterogeneous nucleic acid samples; (b) processing the stabilized sample to cleave double-stranded DNA in the stabilized sample, thereby generating exposed DNA ends; (c) labeling at least a portion of the exposed DNA ends; (d) ligating the labeled exposed DNA ends to form labeled paired ends; (e) sequencing at least a recognizable portion of the labeled paired ends to generate a plurality of read pairs; and (f) assigning each half of the read pairs to a common origin nucleic acid molecule.
[0074] A method for metagenomics assembly is disclosed herein, the method comprising the steps of (a) collecting microorganisms from a given environment, (b) obtaining a plurality of contigs from the microorganisms, (c) generating a plurality of read pairs from data generated by exploring the physical arrangement of the reconstituted chromatin, and (d) mapping the plurality of read pairs to the plurality of contigs, thereby creating read-mapping data, wherein the mapping of read pairs to different contigs indicates that the different contigs originate from a common organism.
[0075] A method for detecting a bacterial infectious pathogen is disclosed herein, the method comprising: (a) obtaining a plurality of contigs from a bacterial infectious pathogen; (b) generating a plurality of read pairs from data generated by exploring the physical arrangement of reconstructed chromatin; (c) mapping the plurality of read pairs to the plurality of contigs, thereby creating read-mapping data; (d) adjusting the contigs using the read-mapping data in order to assemble the contigs into a genome assembly; and (e) using the genome assembly to determine the presence of the bacterial infectious pathogen.
[0076] A method for obtaining genome sequence information from a living organism is disclosed herein, the method comprising: (a) obtaining a stable sample from the living organism; (b) processing the stable sample to cleave double-stranded DNA in the stable sample, thereby generating exposed DNA ends; (c) tagging at least a portion of the exposed DNA ends to generate a tagged DNA segment; (d) sequencing at least a recognizable portion of the tagged DNA segment, thereby obtaining a tagged sequence; and (e) mapping the tagged sequence to generate genome sequence information of the living organism, the genome sequence information covering at least 75% of the genome of the living organism.
[0077] A method for analyzing a sample is disclosed herein, the method comprising: (a) obtaining a stable sample containing nucleic acids from a plurality of organisms; (b) processing the stable sample to cleave double-stranded DNA in the stable sample, thereby generating exposed DNA ends; (c) ligating the labeled exposed DNA ends to form labeled paired ends; (d) sequencing the entire labeled paired ends to generate a plurality of paired sequence reads; and (f) assigning each half of the paired sequence reads of the plurality of sequence reads to a common origin organism.
[0078] A method for analyzing the molecular diversity of nucleic acids in heterogeneous samples is disclosed herein, the method comprising: a) obtaining a stable nucleic acid sample comprising a diverse group of nucleic acids stabilized such that, for at least one member of a diverse group of nucleic acids, a first nucleic acid segment and a second nucleic acid segment are held together independently of their common phosphate diester backbone, wherein the phosphate diester backbone is cleaved between the first nucleic acid segment and the second nucleic acid segment; and b) the first nucleic acid segment and the second nucleic acid segment being identifiable as arising from a common nucleic acid of the diverse group of nucleic acids. The method includes the steps of: a) tagging the first nucleic acid segment and the second nucleic acid segment; c) sequencing at least an identifiable portion of the first nucleic acid segment and its tag, and an identifiable portion of the second nucleic acid segment and its tag; d) assigning the first nucleic acid segment and the second nucleic acid segment to scaffolds corresponding to the tags; and e) determining a number corresponding to how many scaffolds will be generated, such that multiple segments of multiple diverse nucleic acids are assigned to at least one scaffold, the number of generated scaffolds corresponding to the diversity of nucleic acid molecules of heterogeneous samples. In some embodiments, the step of tagging the first nucleic acid segment and the second nucleic acid segment includes adding a first oligo to the first nucleic acid segment and adding a second oligo to the second segment, the first oligo and the second oligo sharing a common sequence. In some embodiments, nucleic acid segments having the common oligo sequence are assigned to a common scaffold. In some embodiments, the method further includes mapping the identifiable portion of the first nucleic acid segment to a contig dataset and including any matching contigs from the contig dataset into the common scaffold. In some embodiments, the contig datasets are generated simultaneously. In some embodiments, the contig datasets are obtained from a database.In some embodiments, the step of tagging the first nucleic acid segment and the second nucleic acid segment includes the step of ligating the first nucleic acid segment to the second nucleic acid segment, where the first and second nucleic acid segments are assigned to a common scaffold. In some embodiments, the method further includes the steps of mapping the identifiable portion of the first nucleic acid segment to a contig dataset and including any matching contigs from the contig dataset to the common scaffold. In some embodiments, the contig datasets are generated simultaneously. In some embodiments, the contig datasets are obtained from a database. In some embodiments, the heterogeneous sample contains multiple allele variants. In some embodiments, the number of allele variants is greater than the number of scaffolds. In some embodiments, the number of allele variants is equal to the number of scaffolds generated. In some embodiments, the phosphate diester backbone is cleaved after the step of obtaining a stable sample. In some embodiments, the stable sample is brought into contact with a crosslinking agent. In some embodiments, the stable sample is an FFPE sample. In some embodiments, the method further includes the step of bringing the heterogeneous sample into contact with reverse transcriptase. In some embodiments, the method further includes the step of searching for at least one of the above scaffolds against a nucleic acid sequence database. In some embodiments, the method further includes the step of classifying the above scaffold as novel if no nucleic acid sequence that uniquely maps to the above scaffold is found in the above database. In some embodiments, the method further includes the step of classifying the above scaffold as corresponding to a sample condition if a plurality of samples related to the sample condition have the above scaffold, and a plurality of samples lacking the above condition lack the above sample. In some embodiments, heterogeneous samples include nucleic acids that map to at least two individuals of a common species. In some embodiments, heterogeneous samples include nucleic acids that map to at least two species.In some embodiments, a heterogeneous sample contains nucleic acids that are mapped to at least three species. In some embodiments, a heterogeneous sample contains nucleic acids that are mapped to at least four species. In some embodiments, sequence reads are assembled into at least two nucleic acid scaffolds independent of exogenous sequence information. In some embodiments, sequence reads are assembled into at least three nucleic acid scaffolds independent of exogenous sequence information. In some embodiments, sequence reads are assembled into at least two nucleic acid scaffolds such that at least 50% of the first genome and at least 50% of the second genome are represented by at least two nucleic acid scaffolds. In some embodiments, sequence reads are assembled into at least two nucleic acid scaffolds such that at least 60% of the first genome and at least 60% of the second genome are represented by at least two nucleic acid scaffolds. In some embodiments, sequence reads are assembled into at least two nucleic acid scaffolds such that at least 70% of the first genome and at least 70% of the second genome are represented by at least two nucleic acid scaffolds. In some embodiments, sequence reads are assembled into at least two nucleic acid scaffolds such that at least 80% of the first genome and at least 80% of the second genome are represented by at least two nucleic acid scaffolds. In some embodiments, the method includes a step of using SPRI beads. In some embodiments, the stable sample contains at most about 5 micrograms of DNA.
[0079] <Integration by reference> All published applications, patents, and patent applications referenced herein are incorporated herein by reference to the same degree as if each individual published application, patent, or patent application were specifically and individually directed to be incorporated by reference. All published applications, patents, and patent applications referenced herein are incorporated herein by reference as a whole, just as any other document cited herein. [Brief explanation of the drawing]
[0080] Novel features of this disclosure are described in particular in the appended claims. A better understanding of the features and advantages of this disclosure can be obtained by referring to the following detailed description and appended drawings illustrating exemplary embodiments in which the principles of this disclosure are applied.
[0081] [Figure 1] A diagram of genome assembly using high-throughput sequencing is presented. The genome to be assembled is shown (top). Typically, genomes have many repetitive sequences that are difficult to assemble. Random high-throughput sequence data from the genome (center) is collected and assembled into "contigs" of specific regions within the genome (bottom). Contig assembly generally ends up with many repetitive sequences. The final output is a set of thousands of contigs whose order and orientation relative to each other are unknown. In the diagram, these are arbitrarily numbered from longest to shortest. [Figure 2] The chromatin capture-based protocol of this disclosure is shown: (A) demonstrates the plicatility in which DNA is crosslinked and processed into biotinylated junction fragments prepared for sequencing; (BD) provides contact map data on human chr14 for various restriction enzymes. As shown, most contacts are localized along the chromosome. [Figure 3]The present disclosure provides a method for using chromatin capture sequence data to assist in genome assembly, (A) illustrating the case where DNA is crosslinked and processed using a chromatin capture-based protocol, (B) demonstrating the case where read-pair data is mapped to assembled contigs and generated from random shotgun sequencing and assembly, and (C) illustrating that after filtering and weighting, an adjacency matrix can be constructed that combines all the inter-contig read-pair data. This matrix can be reordered to indicate a suitable assembly path. As shown, the majority of read pairs are mapped within contigs. From this, we can learn the distribution of contact distances (see, for example, Figure 6). Read pairs mapped to various contigs provide data on which contigs are adjacency in a suitable genome assembly. [Figure 4] A typical protocol of this disclosure is shown, in which DNA fragments are first generated and prepared, followed by in vitro chromatin assembly, the chromatin / DNA complex is then fixed with formaldehyde and pulled down with SPRI beads, the complex is then digested with restriction enzymes to generate adherent ends, the adherent ends are then filled with biotinylated dCTP and internally sulfated GTP, and after blunt end ligation, the chromatin / DNA complex undergoes proteinase digestion and shearing, the DNA fragments are then pulled down with SPRI beads and ligated with sequencing adapters, and finally the DNA fragments are selected by size and sequenced. [Figure 5] This diagram illustrates the ambiguities that arise in genome assembly and alignment from repeating regions in the genome. (A) Linkage uncertainty stems from read pairs that cannot bridge repeating regions. (B) Segment placement uncertainty due to read pairs being unable to reach peripheral repeating regions. [Figure 6] This shows the distribution of genomic distances between read pairs from a human XLRP library. The maximum distance achievable with other techniques is shown for comparison. [Figure 7]This illustrates the fading accuracy for a sample with a well-characterized haplotype, NA12878. The distances shown are the distances between the fading SNPs. [Figure 8] Various components of a typical computer system according to various embodiments of this disclosure are illustrated. [Figure 9] This is a block diagram illustrating a typical computer system architecture that can be used in connection with various embodiments of the present disclosure. [Figure 10] This figure illustrates a typical computer network that can be used in connection with various embodiments of the present disclosure. [Figure 11] This is a block diagram illustrating the architecture of another typical computer system that can be used in connection with various embodiments of the present disclosure. [Figure 12A] A typical schematic diagram of the proximity ligation procedure is shown. [Figure 12B] A typical schematic diagram of two pipelines for sample preparation for metagenomic analysis is shown. [Figure 12C] A typical schematic diagram of scaffolding technology is shown. [Figure 13A] In accordance with the aspects of this disclosure, particle size analysis of DNA fragments from fecal DNA samples is shown. [Figure 13B] This paper demonstrates a method for generating a sequencing library using in vitro assembled chromatin aggregates. [Figure 14] In accordance with the aspects of this disclosure, the size distribution of the inserts in the shotgun library is shown. [Figure 15] This shows the size distribution of reads from a library prepared using in vitro assembled chromatin mapped to the same scaffold. [Figure 16] The scatter plots of hits from libraries prepared for shotgun sequencing and libraries prepared using in vitro assembled chromatin aggregates are shown. [Figure 17]This shows a scatter plot of assembled chromatin with shotgun hits / in vitro per contig based on contig length. [Figure 18] TapeStation traces showing the fragment size distribution for fecal DNA preparations (blue; spikes near the top of the Y-axis at 100 bp and 15000 bp on the x-axis) and Streptomyces coelicolor DNA (green; spikes at sample intensities of 100 bp and 15000 bp) are of similar lengths. [Figure 19] This shows the multiplicative coverage distribution in these shotgun data for each level of DNA in spiked-in Streptomyces coelicolor. [Figure 20] The total amount of Streptomyces coelicolor genomes present as contigs for 1% (red, left), 5% (green, center), and 10% (blue, right) of the shotgun dataset is shown. [Figure 21] This graph shows read pairs from a proximity ligation library mapped to known genome sequences of Streptomyces coelicolor, with the X-axis representing the distance in kilobases and the Y-axis representing the cumulative distribution of all read pairs. [Figure 22A] In 5% of the experiments, a dot plot of the known Streptomyces coelicolor genome (X-axis) is drawn for the three scaffolds generated as described herein. [Figure 22B] In 10% of the experiments, a dot plot of the known Streptomyces coelicolor genome (X-axis) is drawn for one scaffold generated as described herein. [Figure 23A] A graph showing the size of DNA fragments from a fecal DNA preparation kit is plotted. [Figure 23B] Plot a graph showing the number of lead pairs versus the distance of the lead pairs reached. [Figure 24] A single scaffold containing 89% of the 8.67 Mb S. coelicolor genome is drawn. [Figure 25]This plots a typical ratio of read coverage versus shotgun data in spike-in experiments within the Chicago assembly data. [Figure 26A] A graph showing the relationship between coverage depth and GC content for the scaffold in a spike-in experiment is plotted. [Figure 26B] We plot the in vitro chromatin assembly connectivity of each scaffold as a small part of all the chains to the 1st to 4th most coupled scaffolds, and the graph of the Euclidean distance in the GC+ multiple coverage space between scaffold pairs. [Figure 27] A graph is drawn showing the effect of strain variation on scaffolding performance. [Modes for carrying out the invention]
[0082] As used herein and in the appended claims, the singular forms ("a," "an," and "the") include plural references unless otherwise explicitly stated in the context. Thus, for example, a reference to "contig" includes multiple such contigs, and a reference to "searching for the physical arrangement of chromosomes" includes a reference to one or more methods for searching for the physical arrangement of chromosomes and their equivalents that are known to those skilled in the art.
[0083] Similarly, the use of "and" means "and / or" unless otherwise specified. Likewise, "comprise," "comprises," "include," "comprising," and "including" are interchangeable and not intended to be restrictive.
[0084] If the description of various embodiments includes the use of the term “includes,” a person skilled in the art will understand that in some specific examples, embodiments can be described in a binary manner using expressions such as “essentially consisting of” or “consisting of.”
[0085] As used herein to describe a number, the term "about" refers, unless otherwise specified, to a range of values including numbers plus or minus 10% of that number.
[0086] As used herein, the terms “read,” “sequence read,” or “sequencing read” refer to the sequence of a DNA or RNA nucleic acid fragment or segment determined during the execution of a single reaction or sequencing reaction.
[0087] As used herein, the term “contig” refers to adjacent regions of a DNA sequence. A “contig” can be determined by any number of methods known in the art, by comparing the sequencing of duplicate sequences and / or by comparing sequence reads against a database of known sequences to identify which sequence reads are likely to be contiguous.
[0088] The terms "polynucleotide," "nucleotide," "nucleic acid," and "oligonucleotide" are often used interchangeably. These generally refer to polymeric forms of nucleotides of any length (either deoxyribonucleotides or ribonucleotides) or analogs thereof. Polynucleotides contain base monomers linked together by phosphate diester bonds across their ribose skeleton. Polynucleotides may also have any three-dimensional structure and may perform any known or unknown function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of genes or gene fragments, intergenetic DNA, loci (multiple loci) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA), nucleolar small RNA, ribozymes, complementary DNA (cDNA), which is the DNA representation of mRNA typically obtained by reverse transcription or amplification of messenger RNA (mRNA); DNA molecules produced synthetically or by amplification, genomic DNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. Polynucleotides may include modified nucleotides such as methylated nucleotides and nucleotide analogs. Where present, modifications to the nucleotide structure may be given before or after polymer assembly. Generally, oligonucleotides contain only a few bases, while polynucleotides can contain any number of bases but are generally longer, while nucleic acids can refer to polymers of any length, including the length of a chromosome or an entire genome. Similarly, the term nucleic acid is often used collectively, so that a nucleic acid sample does not necessarily refer to a single nucleic acid molecule; more precisely, nucleic acids can refer to a sample containing multiple nucleic acid molecules. The term nucleic acid can encompass double-stranded or triple-stranded nucleic acids as well as single-stranded molecules.In double-stranded or triple-stranded nucleic acids, the nucleic acid strands do not need to have the same extent; for example, a double-stranded nucleic acid does not need to be double-stranded along the entire length of both strands. The term nucleic acid can also encompass any chemical modifications of its, such as methylation and / or capping. Nucleic acid modifications may include the addition of chemical groups to individual nucleic acid bases or to the nucleic acid as a whole, incorporating additional charge, polarizability, hydrogen bonding, electrostatic interactions, and functionality. Such modifications may include sugar modifications at the 2'-position, pyrimidine modifications at the 5-position, purine modifications at the 8-position, extra-cytosine amine modifications, 5-bromouracil substitutions, skeletal modifications, and base modifications such as isobases, i.e., unusual base pairings such as isocytidine and isoguanidine.
[0089] As used herein, the term "subject" may refer to any eukaryote or protokaryote.
[0090] As used herein, the term "naked DNA" may refer to DNA that is substantially free of complexed DNA-binding proteins. For example, this may refer to DNA complexed with approximately 10%, 5%, or less than 1% of the endogenous proteins found in the cell nucleus, or approximately 10%, 5%, or less than 1% of the endogenous DNA-binding proteins regularly bound to nucleic acids in vivo, or approximately 10%, 5%, or less than 1% of other nucleic acid-binding moieties such as exogenously added nucleic acid-binding proteins or nanoparticles. In some cases, naked DNA refers to DNA that is not complexed with DNA-binding proteins.
[0091] The terms “polypeptide” and “protein” are often used interchangeably and generally refer to polymeric forms of amino acids, or their analogues linked to polypeptide bonds. Polypeptides and proteins can be polymers of any length. Polypeptides can also have any three-dimensional structure and may perform any known or unknown function. Polypeptides and proteins may undergo modifications including phosphorylation, lipidation, prenylation, sulfation, hydroxylation, acetylation, and disulfide bond formation. In some cases, “protein” refers to polypeptides that have a known function or are known to occur naturally in biological systems, but this distinction is not always observed in the art.
[0092] As used herein, nucleic acids are “stable” when bound by binding sites or multiple binding sites, such that a different segment of the nucleic acid is held in a single complex independent of a common phosphate diester backbone. Stable nucleic acids in a complex remain bound independently of their phosphate diester backbone so that treatment with restriction endonucleases does not cause the complex to break down, and cleavage of the inner double-stranded DNA is accessible even without a complex that has lost its integrity.
[0093] Alternatively, or in combination, nucleic acid complexes, which include nucleic acids and nucleic acid binding sites, are “stabilized” by treatments that increase their binding or provide resistance to degradation or dissolution. Examples of stabilizing complexes include treating them with fixatives such as formaldehyde or psoralen to make them resistant to degradation or dissolution after restriction endonuclease treatment or treatment that induces nucleic acid shear, or treating them with UV light to induce crosslinking between or between nucleic acids and binding sites.
[0094] As used herein, the term “scaffold” generally refers to a set of ordered and oriented contigs that are separated by gaps of known length but unknown sequences, or by gaps of unknown length but known to exist on a single molecule, or by mate pairs of sequencing reads. When contigs are separated by gaps of known length, the sequences of the gaps may be determined by a variety of methods, including PCR amplification and subsequent sequencing (for smaller gaps) and bacterial artificial chromosome (BAC) cloning methods and subsequent sequencing (for larger gaps).
[0095] As used herein, the term “stable sample” refers to a nucleic acid that is stable with respect to an associated molecule by intermolecular interactions such that the nucleic acid and the associated molecule are bound in a manner resistant to molecular manipulations such as restriction endonuclease treatment, DNA shearing, labeling of nucleic acid cleavage, or ligation. Known nucleic acids in the art include, but are not limited to, DNA and RNA, and their derivatives. Intermolecular interactions may be covalent or non-covalent. Typical methods of covalent bonding include crosslinking techniques, conjugation reactions, or other methods known to those skilled in the art. Typical methods of non-covalent interactions include ionic bonding, hydrogen bonding, halogen bonding, van der Waals forces (e.g., dipole interactions), π-effects (e.g., π-π interactions, cation-π and anion-π interactions, polar π interactions, etc.), hydrophobic effects, and other non-covalent interactions known to those skilled in the art. Examples of associated molecules include, but are not limited to, chromosomal proteins (e.g., histones), transposes, and any nanoparticles known to interact with nucleic acids covalently or non-covalently.
[0096] As used herein, the term “heterogeneous sample” refers to a biological sample containing a diverse population of nucleic acids (e.g., DNA, RNA), cells, organisms, or other biomolecules. Often, nucleic acids originate from more than one organism. For example, a heterogeneous nucleic acid sample may contain at least approximately 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 20,000, 50,000, 100,000, 200,000, 500,000, 1,000,000, 2,000,000, 5,000,000, 10,000,000, or more DNA molecules. Furthermore, each DNA molecule may contain at least one, at least two, or more complete or partial genomes of various organisms, so that heterologous nucleic acid samples may contain at least approximately 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 20,000, 50,000, 1,000,000, 2,000,000, 5,000,000, 10,000,000, or more complete or partial genomes of various organisms. Examples of heterogeneous samples include, but are not limited to, various sources including the subject's blood, sweat, urine, feces, or skin; or environmental sources (e.g., soil, seawater); food sources; waste disposal sites such as dumps, sewers, or public toilets; or waste bins.
[0097] A “partial genome” of an organism may contain at least approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more of the organism’s entire genome, or it may include a sequence dataset containing at least approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more of the sequence information of the entire genome.
[0098] As used herein, the term "reconstructed chromatin" may refer to the formed chromatin created by complexing isolated nucleoproteins with naked DNA.
[0099] As used herein, the term “tagged sequence” can refer to a DNA sequence that includes additional sequences that can be used to identify or associate sequences for analytical purposes. For example, a group of tagged sequences that share the same tag can be binned together. In some examples, tagged sequences in the same bin may be further assigned a common phase or a common origin molecule. Typical methods of “tagging,” but not limited to, include introducing a tag using an enzyme (e.g., a transposase, ligase) and / or covalently joining DNA segments to obtain read pairs. A tagged sequence is “sequenced,” for example, by obtaining terminal reads, one terminal read containing the tag sequence and the other terminal read containing the sequence of the tagged segment. In some cases, the complete tag, tag-segment junction, and complete segment are sequenced. However, this is not always necessary to make tagging and sequencing effective. Conversely, in many cases, sequencing of the identifiable portion of the tag end and the identifiable portion of the segment end is sufficient to cause “sequencing of the tagged segment,” particularly when contig information is available, such as previously generated or concurrently generated contig information, though not exclusively. Similarly, paired-end tag sequences are “sequencing” by obtaining terminal reads that, in some cases, contain the identifiable sequences of the respective linked segments. Paired-end fragments may also be fully sequenced to obtain a junction sequence, but this is not always necessary to make paired-end tagging and sequencing effective. Accordingly, as used herein, “sequencing a tagged segment” or “sequencing paired-end reads” does not necessarily involve obtaining the complete inter-terminal sequence of the linked molecule. Linked fragments are sometimes said to be “sequencing” as long as an identifiable sequence of one end of the molecule is obtained, so as to obtain the identity of the nucleic acids joined to form the linked molecule.In some cases, sequencing involves end-to-end sequencing extending to the ligation junction. In some cases, sequencing involves generating reads from one end of the ligated molecules.
[0100] As used herein, the term "read pair" or "read-pair" can refer to two or more elements linked together to provide sequence information. In some cases, the number of read pairs may refer to the number of mappable read pairs. In other cases, the number of read pairs may refer to the total number of read pairs generated.
[0101] The terms “bond,” “connect,” “associate,” “associate,” or “associate,” or their derivatives, as used herein, refer to the stabilization of one molecule into another through intermolecular interactions. In nature, intermolecular interactions may be covalent or non-covalent. Typical methods of covalent bonding include crosslinking techniques, conjugation reactions, or other methods known to those skilled in the art. Typical methods of non-covalent interactions include ionic interactions, hydrogen bonds, halogen bonds, van der Waals forces (e.g., dipole interactions), π-effects (e.g., π-π interactions, cation-π and anion-π interactions, polar π interactions, etc.), hydrophobic effects, and other non-covalent interactions known to those skilled in the art.
[0102] As used herein, the terms “immobilize” or “fixed” refer to stabilizing a molecule or complex with respect to an object. For example, a DNA complex is immobilized to a solid support when it is stable to that support. In some cases, an immobilized DNA complex remains stable to the solid support even when subjected to various washing processes.
[0103] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this disclosure pertains. Any methods or reagents similar to or equivalent to those described herein may be used when carrying out the disclosed methods or compositions, but typical methods and materials are described herein.
[0104] This disclosure typically provides methods for generating very long-distance read pairs, and utilizes that data to improve all of the aforementioned explorations. In some embodiments, this disclosure provides a method for generating a very sequentially accurate human genome assembly having only ~3 million read pairs. In other embodiments, this disclosure provides a method for phasing more than 90% of heterozygous variants in the human genome with greater than 99% accuracy. Furthermore, the range of read pairs generated by this disclosure can be extended to span much larger genomic distances. The assembly is generated from a standard shotgun library in addition to the very long-distance read pair library. In yet another embodiment, this disclosure provides software that can utilize both of these sets of sequencing data. The phased variants are generated together with a single long-distance read pair library, from which reads are mapped to a reference genome and then used to assign the variant to one of the chromosomes of the individual's two parents. Finally, this disclosure provides extraction of even larger DNA fragments using known techniques to generate exceptionally long reads.
[0105] The mechanism by which these repeats interfere with the assembly and alignment processes is fairly straightforward and ultimately a result of ambiguity (Figure 5). For large repeat regions, one issue is span. If a read or pair of reads is not long enough to extend over the repeat region, it is not possible to confidently connect the regions bordering the repeat element. For smaller repeat elements, the issue is primarily placement. If a region is adjacent to two repeat elements common in the genome, determining its exact placement becomes difficult, if not impossible, due to the similarity of the adjacent elements to all others of their class. In both cases, it is the lack of characteristic information within the repeat that makes the placement of a particular repeat difficult for identification. What is needed is the ability to experimentally establish connections between unique segments enclosed or separated by repeat regions.
[0106] The methods described herein will significantly advance the field of genomics by overcoming substantial barriers caused by these repeating regions, thereby enabling significant progress in many areas of genome analysis. To perform de novo assembly using conventional techniques, those skilled in the art must either settle for assemblies fragmented into many small scaffolds, or spend vast amounts of time and money generating libraries of large inserts or employing other techniques to generate more continuous assemblies. Such techniques may include obtaining very deep sequencing coverage, constructing BAC or fosmid libraries, optical mapping, or, most likely, a combination of several of these techniques. Due to stringent funding and time constraints, most small laboratories cannot afford such techniques, hindering the study of non-model organisms. Because the methods described herein can generate very long read pairs, de novo assembly can be achieved in a single sequencing run. This will result in orders of magnitude savings in assembly costs and reduce the required time from months or years to weeks. In some cases, the methods disclosed herein enable the generation of multiple read pairs in less than 14 days, less than 13 days, less than 12 days, less than 11 days, less than 10 days, less than 9 days, less than 8 days, less than 7 days, less than 6 days, less than 5 days, less than 4 days, or within any two ranges of the aforementioned specified periods. For example, the method can be considered to generate multiple read pairs in about 10 to 14 days. Even constructing genomes for most microenvironments of living organisms will become commonplace, and phylogenetic analysis can realize projects such as genome 10k without being plagued by insufficient comparisons.
[0107] Similarly, structural and phasing metagenomic analysis for medical purposes remains challenging. Cancer exhibits remarkable heterogeneity, even within individuals with the same type of cancer or even within the same tumor. Extracting causal factors from inevitable effects requires low cost, extremely high accuracy, and high throughput for each sample. In the field of personalized medicine, one of the gold standards of genomic care is a sequenced genome with all fully characterized and phasing variants, including major and minor structural rearrangements and novel mutations. Achieving this with conventional techniques requires the same kind of effort as de novo assembly, which is currently very expensive, time-consuming, and labor-intensive, making it unsuitable for routine medical procedures. The disclosed method can rapidly generate complete and accurate genomes at low cost, thereby creating many highly sought-after capabilities in the study and treatment of human diseases.
[0108] Finally, applying the methods disclosed herein to phasing can combine the precision of familial analysis with the convenience of statistical methods, resulting in savings—money, labor, and samples—compared to using either method alone. De novo variant phasing, a highly desirable phasing analysis prohibited by conventional techniques, is readily feasible using the methods disclosed herein. This is particularly important because the majority of human variants are rare (small allele frequencies of less than 5%). Phasing information is valuable for population genetic studies, gaining significant advantages from networks of haplotypes (collections of variants assigned to a single chromosome) that are highly coupled to unlinked genotypes. Haplotype information can enable higher-resolution studies of historical changes in population size, migration, and exchange between subpopulations, and can track specific variants down to specific parents and grandparents. This, when collected in a single individual, reveals the genetic transmission of disease-associated variants and interactions between variants. The methods disclosed herein can ultimately enable the preparation, sequencing, and analysis of very long-range read pairs (XLRP) libraries.
[0109] In some embodiments of this disclosure, a tissue or DNA sample from a subject can be provided, and the method can return an assembled genome, alignment using called variants (including large structural variants), calling of phased variants, or any additional analysis. In other embodiments, the method disclosed herein can directly provide an XLRP library to an individual.
[0110] In various embodiments of this disclosure, the methods disclosed herein can generate read pairs over very long distances that were previously separated by great distances. This upper limit on distance may be improved by the ability to capture large-sized DNA samples. In some cases, read pairs may extend to 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 4000, 5000 kbp or more in genomic distance. In some examples, read pairs may extend to 500 kbp in genomic distance. In other examples, read pairs may extend to 2000 kbp in genomic distance. The methods disclosed herein can integrate and build upon the standard configurations of molecular biology and are suitable for increasing efficiency, specificity, and genomic coverage. In some cases, read pairs can be generated in less than approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 60, or 90 days. In some examples, read pairs can be generated in less than approximately 14 days. In some examples, read pairs can be generated in less than approximately 10 days. In some cases, the method of the present disclosure can provide accuracy of at least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or about 100% for read pairs, with accuracy of about 5%, about 10%, about 15%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or about 100% or more when accurately ordering and / or oriented multiple contigs. For example, the method can provide accuracy of about 90-100% when accurately ordering and / or oriented multiple contigs.
[0111] In other embodiments, the methods disclosed herein can be used in conjunction with currently employed sequencing techniques. For example, the methods can be used in combination with well-tested and / or widely deployed sequencing instruments. In some embodiments, the methods disclosed herein can be used in conjunction with techniques and methods derived from currently used sequencing techniques.
[0112] The method disclosed herein dramatically simplifies de novo genome assembly for a wide range of organisms. Using conventional techniques, such assemblies are currently limited by short inserts in economical mate-pair libraries. While it may be possible to generate read pairs at genomic distances up to 40–50 kbp, which are available in fosmids, these are expensive, cumbersome, and too short to reach the longest repeat extensions (including those within the centromere, which in humans range in size from 300 kbp to 5 Mbp). The method disclosed herein can reach long distances (e.g., megabases or longer), thereby providing read pairs that can overcome the integrity problems of these scaffolds. Accordingly, generating chromosome-level assemblies could become routine by utilizing the method disclosed herein. More difficult means of assembly—currently requiring an incredible amount of time and money in laboratories and prohibiting the cataloging of extended genomes—would become unnecessary, freeing up resources for more meaningful analysis. Similarly, obtaining long-range phasing information can provide even greater power to population genome studies, phylogenetic studies, and disease studies. The methods disclosed herein enable accurate phasing for many individuals, thereby expanding the breadth and depth of our ability to explore genomes at the population and depth-time levels.
[0113] In the field of personalized medicine, XLRP read pairs generated from the methods disclosed herein represent a significant advance in accurate, inexpensive, phased, and rapidly generated individual genomes. Current methods are inadequate in their ability to phase long-range variants, thereby hindering the characterization of the phenotypic effects of heterozygous genotypes of compounds. Furthermore, substantial structural variants of disease-related genomics are difficult to accurately identify and characterize with current techniques due to their large size compared to the reads and read pair inserts used to study them. Read pairs ranging from tens of kilobases to megabases help alleviate this problem, thereby enabling highly parallel and personalized analysis of structural variants.
[0114] Fundamental evolutionary and biomedical research is driven by technological advancements in high-throughput sequencing. Whole-genome sequencing and assembly were once the source of large genome sequencing centers, but commercially available sequencers are now inexpensive enough that most research universities own one or more of these instruments. Generating vast amounts of DNA sequence data is now relatively inexpensive. However, generating high-quality, highly continuous genome sequences with current technology remains challenging, both theoretically and practically. Furthermore, since most organisms that art practitioners wish to analyze, including humans, are diploid, each individual has two haploid copies of its genome. At heterozygous sites (e.g., where an allele given by the mother differs from an allele given by the father), it is difficult to know which set of alleles came from which parent (known as haplotype phasing). This information can be used to conduct many evolutionary and biomedical studies, such as studies on the association between disease and transformation.
[0115] In various embodiments, the Disclosure provides methods for genome assembly that combine paired-end sequencing and DNA preparation techniques for high-throughput discovery of short-term, medium-term, and long-term bindings within a given genome. The Disclosure further provides methods for using these bindings to assist genome assembly in haplotype phasing and / or metagenomic studies. While the methods presented herein can be used to determine the assembly of a subject genome, it should also be understood that the methods presented herein can be used to determine the assembly of a portion of a subject genome, such as a chromosome, or the assembly of variable-length subject chromatin.
[0116] In some embodiments, the Disclosure provides one or more methods disclosed herein, comprising the step of generating multiple contigs from sequencing fragments of target DNA obtained from a subject. Elongated target DNA can be fragmented by cutting, shearing, or a combination thereof with one or more nuclease enzymes (e.g., restriction enzymes). The resulting fragments can be sequenced using a high-throughput sequencing method to obtain multiple sequencing reads. Examples of high-throughput sequencing methods that can be used with the methods of the Disclosure include, but are not limited to, the 454 pyrosequencing method developed by Roche Diagnostics, the "cluster" sequencing method developed by Illumina, the SOLiD and ion semiconductor sequencing methods developed by Life Technologies, and the DNA nanoball sequencing method developed by Complete Genomics. Contigs can then be formed by assembling the overlapping ends of various sequencing reads. Alternatively, the fragmented target DNA can be cloned into a vector. Cells or organisms are then transfected with the DNA vector to form a library. After replicating the transfected cells or organism, the vector is isolated and sequenced to generate multiple sequencing reads. Then, the overlapping ends of the various sequencing reads can be assembled to form a contig.
[0117] As shown in Figure 1, genome assembly, especially that using high-throughput sequencing techniques, can have problems. Often, assemblies consist of thousands or tens of thousands of short contigs. The order and orientation of these contigs are generally unknown, limiting the usefulness of genome assembly. While techniques exist to order and orient these scaffolds, they are generally expensive, require considerable effort, and often fail to discover interactions over very long distances.
[0118] Samples containing the target DNA used to generate contigs can be obtained from a subject by any number of means, including collecting bodily fluids (e.g., blood, urine, serum, lymph, saliva, anal and vaginal secretions, sweat, and semen), collecting tissue, or collecting cells / organisms. The resulting sample may consist of a single type of cell / organism or multiple types of cells / organisms. DNA can be extracted and prepared from the subject's sample. For example, the sample may be treated to lyse cells containing polynucleotides using known lysis buffers, sonication techniques, electroporation, etc. The target DNA may be further purified to remove contaminants such as proteins by alcohol extraction, cesium gradient, and / or column chromatography.
[0119] Other embodiments of this disclosure provide methods for extracting very high molecular weight DNA. In some cases, data from XLRP libraries can be improved by increasing the size of the input DNA fragments. In some examples, extracting megabase-sized fragments of DNA from cells can generate megabase-separated read pairs in the genome. In some cases, the generated read pairs can provide sequence information of about 10 kB, about 50 kB, about 100 kB, about 200 kB, about 500 kB, about 1 Mb, about 2 Mb, about 5 Mb, about 10 Mb, or about 100 Mb or larger. In some examples, the read pairs can provide sequence information of about 500 kB or larger. In some examples, the read pairs can provide sequence information of about 2 Mb or larger. In some cases, very large molecular weight DNA can be extracted by very gentle lysis (Teague, B. et al. (2010) Proc. Nat. Acad. Sci. USA 107(24), 10848-53) and agarose plug (Schwartz, DC, & Cantor, CR (1984) Cell, 37(1), 67-75). In other cases, very large molecular weight DNA can be extracted using commercially available equipment capable of purifying DNA molecules up to megabase length.
[0120] In various embodiments, this disclosure provides one or more methods disclosed herein that include a step of exploring the physical arrangement of chromosomes in living cells. Examples of techniques for exploring the physical arrangement of chromosomes by sequencing include the "C" family of techniques such as chromosome structural capture ("3C"), circularized chromosome structural capture ("4C"), carbon copy chromosome capture ("5C"), and other chromatin capture-based methods; and ChIP-based methods such as ChIP-loop and ChIP-PET. These techniques utilize the fixation of chromatin in living cells to solidify spatial relationships within the nucleus. Subsequent processing and sequencing of the products allows researchers to recover a matrix of approximate links in genomic regions. Detailed analysis reveals that these links are physically positioned within the living nucleus, and these links can be used to construct a three-dimensional geometric map of chromosomes. These techniques describe alternative spatial organization of chromosomes in living cells and provide a precise understanding of functional interactions within chromosomal loci. One problem that plagued these functional studies was the presence of nonspecific interactions, i.e., bindings in the data that were solely due to chromosomal proximity. In the disclosure, these nonspecific intrachromosomal interactions are captured by the methods presented herein to provide valuable information for assembly.
[0121] In some embodiments, intrachromosomal interactions correlate with chromosomal connectivity. In some cases, intrachromosomal data can aid in genome assembly. In some cases, chromatin is reconstructed in vitro. This can be advantageous because chromatin—particularly histones, the major protein components of chromatin—is crucial for fixation under the most common "C" family of techniques for detecting chromatin structure and three-dimensional structure by sequencing: 3C, 4C, 5C, and chromatin capture. Chromatin is highly nonspecific in terms of sequence and generally assembles uniformly across the genome. In some cases, genomes of species that do not use chromatin can be assembled on reconstructed chromatin, thereby expanding the field of view to encompass all areas of life.
[0122] Chromatin structure capture techniques are summarized in Figure 2. In summary, crosslinking is performed between genomic regions that are physically very close together. Crosslinking of proteins (such as histones) to DNA molecules (e.g., genomic DNA) within chromatin is described in more detail elsewhere herein or can be achieved by appropriate methods known in the art. In some cases, two or more nucleotide sequences, or more precisely, two or more nucleic acid segments, can be crosslinked by proteins bound to one or more nucleotide sequences. One method is to expose chromatin to ultraviolet irradiation (Gilmour et al., Proc. Nat'l. Acad. Sci. USA 81:4275-4279, 1984). Crosslinking of polynucleotide segments may be performed using other methods such as chemical or physical (e.g., optical) crosslinking. Suitable chemical crosslinking agents include, but are not limited to, formaldehyde and psoralen (Solomon et al., Proc. NatL. Acad. Sci. USA 82:6470-6474, 1985; Solomon et al., Cell 53:937-947, 1988). For example, crosslinking can be performed by adding 2% formaldehyde to a mixture containing DNA molecules and chromatin proteins. Other examples of agents that can be used to crosslink DNA include, but are not limited to, UV light, mitomycin C, nitrogen mustard, melphalan, 1,3-butadiene diepoxide, cis-diamine dichloroplatinum(II), and cyclophosphamide. Strictly speaking, the crosslinking agent forms crosslinks that fill relatively short distances (e.g., about 2 Å), thereby selecting close interactions that can be reversed.
[0123] In some embodiments, DNA molecules may be immunoprecipitated before or after crosslinking. In some cases, DNA molecules may be fragmented. The fragments may be contacted with a binding partner, such as an antibody that specifically recognizes and binds to acetylated histones (e.g., H3). Examples of such antibodies, but not limited to, include anti-acetylated histone H3, available from Upstate Biotechnology (Lake Placid, NY). Polynucleotides from the immunoprecipitate can then be collected from the immunoprecipitate. Before fragmenting the chromatin, acetylated histones can be crosslinked to adjacent polynucleotide sequences.
[0124] In some embodiments, a DNA molecule binds to multiple association molecules, and these association molecules are not covalently modified with affinity labels (e.g., biotin, streptavidin, avidin, polyhistidine, EDTA, etc.). In some cases, the association molecules are isolated directly from living organisms. In some examples, the association molecules contain amino acids. In some examples, the association molecules contain polypeptides or proteins. In some examples, the association molecules contain histone proteins. In various examples, the association molecules come from a different source than the DNA molecule. For example, the DNA molecule can be crosslinked to multiple histones, and these histones are not covalently modified with affinity labels. In even further examples, the association molecule is a transposase. In some examples, the first DNA molecule is noncovalently bound to the association molecule. In other examples, the first DNA molecule is noncovalently bound to the association molecule. In some cases, the first DNA molecule is crosslinked to the association molecule. In some examples, the first DNA molecule is crosslinked to the association molecule using a fixative (e.g., formaldehyde). However, in some cases, DNA molecules contain DNA segments that can be modified with affinity labels. In some examples, the affinity label contains biotin. In some examples, the affinity label is biotin-modified nucleoside triphosphate (dNTP). In some examples, the affinity label is biotin-modified deoxyribocytosine triphosphate (dCTP). In various cases, affinity labels are used to isolate or purify DNA segments.
[0125] Using association molecules without covalent modifications reduces the number of steps in the methods provided in this disclosure and / or enhances efficiency. In some cases, DNA segments are washed about 20, 18, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or less than once before being linked to form linked DNA segments. In some cases, DNA segments are washed about 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or less than five times before being linked to form linked DNA segments. In some cases, DNA segments are washed about 12, 11, 10, 9, 8, 7, or less than six times before being linked to form linked DNA segments. In some embodiments, DNA segments are washed about 10 times or less before being linked to form linked DNA segments. In one example, DNA segments are washed about 8 times or less before being linked to form linked DNA segments. In some embodiments, the DNA segments are washed less than about six times before being linked to form linked DNA segments.
[0126] In some embodiments, the bound DNA molecules are immobilized on a solid support. In some cases, the solid support is beads. In some examples, the beads contain a polymer. In some examples, the fixative is polystyrene. In other examples, the polymer is polyethylene glycol (PEG). In various examples, the beads are magnetic beads. In some examples, the beads are reversible solid phase immobilization (SPRI) beads. In other cases, the solid support is an array. In some examples, the solid support is not covalently bound to an affinity label (e.g., biotin, streptavidin, avidin, polyhistidine, EDTA, or derivatives thereof). In various examples, the solid support is not chained to any polypeptide (e.g., streptavidin, avidin, polyhistidine tags, or derivatives thereof).
[0127] Rather than covalently modifying the associated molecule to facilitate its isolation by binding to the surface of a solid support (e.g., a surface coated with streptavidin to bind to biotin covalently bonded to the associated molecule), the solid support is sometimes modified to bind to the associated molecule without covalent modification. In some cases, this is direct binding of the associated molecule to the surface of the associated molecule. Alternatively, in some cases, binding occurs mediated by at least one component in the solvent. In some cases, the solid support is coated using a moiety that directly binds to the associated molecule. In some cases, the solid surface is coated using a moiety that directly binds to nucleic acids. Suitable coatings in various embodiments include polyamines, positively charged moieties, carboxyl groups, and uncharged moieties.
[0128] In some cases, crosslinked DNA molecules are processed to fractionate or cleave polynucleotides in a mixture. Fractionation techniques are known in the art and include, for example, shearing techniques for producing smaller genomic fragments. Fragmentation can be carried out using established methods for fragmenting chromatin, including, for example, sonication, shearing and / or the use of nucleases (e.g., restriction enzymes) or cleavage enzymes (e.g., dsDNA fragmentases). Restriction enzymes may have restriction sites of 1, 2, 3, 4, 5, or 6 base lengths. Nucleases may be endonucleases, exonucleases, or endo-exonucleases. Examples of nucleases include, but are not limited to, DNase I and MNase. Examples of restriction enzymes include, but are not limited to, AatII, Acc65I, AccI, AciI, AclI, AcuI, AfeI, AflII, AflIII, AgeI, AhdI, Al eI, AluI, AlwI, AlwNI, ApaI, ApaLI, ApeKI, ApoI, AscI, AseI, AsiSI, AvaI, AvaII, AvrII, BaeGI, Ba eI, BamHI, BanI, BanII, BbsI, BbvCI, BbvI, BccI, BceAI, BcgI, BciVI, BclI, BfaI, BfuAI, BfuCI, Bg lI, BglII, BlpI, BmgBI, BmrI, BmtI, BpmI, Bpul0I, BpuEI, BsaAI, BsaBI, BsaHI, BsaI, BsaJI, BsaWI , BsaXI, BscRI, BscYI, BsgI, BsiEI, BsiHKAI, BsiWI, BslI, BsmAI, BsMbI, BsmFI, BsmI, BsoBI, Bsp1 286I, BspCNI, BspDI, BspEI, BspHI, BspMI, BspQI, BsrBI, BsrDI, BsrFI, BsrGI, BsrI, BssHII, BssK I, BssSI, BstAPI, BstBI, BstEII, BstNI, BstUI, BstXI, BstYI, BstZ17I, Bsu36I, BtgI, BtgZI, BtsC I, BtsI, Cac8I, ClaI, CspCI, CviAII, CviKI-1, CviQI, DdcI, DpnI, DpnII, DraI, DraIII, DrdI, EacI,EagI, EarI, EciI, Eco53kI, EcoNI, EcoO109I, EcoP15I, EcoRI, EcoRV, FatI, FauI, Fnu4HI, FokI, FseI, FspI, HaeII, HaeIII , HgaI, HhaI, HincII, HindIII, HinfI, HinPlI, HpaI, HpaII, HphI, Hpy166II, Hpy188I, Hpy188III, Hpy99I, HpyAV, HpyCH4I II, HpyCH4IV, HpyCH4V, KasI, KpnI, MboI, MboII, MfeI, MluI, MlyI, MmeI, MnlI, MscI, MseI, MslI, MspAlI, MspI, MwoI, NaeI , NarI, Nb.BbvCI, Nb.BsmI, Nb.BsrDI, Nb.BtsI, NciI, NcoI, NdeI, NgoMIV, NheI, NlaIII, NlaIV, NmeAIII, NotI, NruI, NsiI , NspI, Nt.AlwI, Nt.BbvCI, Nt.BsmAI, Nt.BspQI, Nt.BstNBI, Nt.CviPII, PacI, PaeR7I, PciI, PflFI, PflMI, PhoI, PleI, Pm eI, PmlI, PpuMI, PshAI, PsiI, PspGI, PspOMI, PspXI, PstI, PvuI, PvuII, RsaI, RsrII, SacI, SacII, SalI, SapI, Sau3AI, Sau Examples include 96I, SbfI, ScaI, ScrFI, SexAI, SfaNI, SfcI, SfiI, SfoI, SgrAI, SmaI, SmlI, SnaBI, SpeI, SphI, SspI, StuI, StyD4I, StyI, SwaI, T, TaqαI, TfiI, TliI, TseI, Tsp45I, Tsp509I, TspMI, TspRI, Tth111I, XbaI, XcmI, XhoI, XmaI, XmnI, and ZraI. The resulting fragments may vary in size. The resulting fragments may also contain single-stranded overhands at the 5' or 3' end. Nucleases can be nucleic acid-induced nucleases. Nucleic acid-induced nucleases include Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2, Cm5, and Csf1,It may be an RNA-inducible nuclease from the Cas family of nucleases (e.g., Cas9), including CAS Class I Type I, CAS Class I Type III, CAS Class I Type IV, CAS Class II Type II, and CAS Class II Type V.
[0129] In some embodiments, sonication techniques can be used to obtain fragments of about 100 to 5000 nucleotides. Alternatively, fragments of about 100 to 1000, about 150 to 1000, about 150 to 500, about 200 to 500, or about 200 to 400 nucleotides can be obtained. Samples can be prepared for sequencing of linked sequence segments that are crosslinked. In some cases, a single short extension of a polynucleotide can be prepared, for example, by linking two intramolecularly crosslinked sequence segments. Sequence information can be obtained from samples, either by further detail elsewhere herein or by using any suitable sequencing technique known in the art, such as high-throughput sequencing methods. For example, ligation products can be subjected to paired-end sequencing to obtain sequence information from each end of a fragment. Multiple pairs of sequence segments can be represented by the obtained sequence information by relating haplotyping information across a linear distance separating the two sequence segments along the polynucleotide.
[0130] One characteristic of the data generated by chromatin capture is that most read pairs are found to be closely and linearly adjacent when remapped to the genome; that is, most read pairs are found to be close to each other within the genome. In the resulting dataset, the likelihood of intrachromosomal contact is, on average, much higher than the likelihood of interchromosomal contact, as would be expected when chromosomes occupy distinct regions. Furthermore, while the likelihood of interaction decreases sharply with linear distance, even loci >200Mb segregated on the same chromosome are more likely to interact than loci on different chromosomes. When detecting long-range intrachromosomal and especially interchromosomal contacts, this "background" of short- and medium-range intrachromosomal contacts is background noise that is removed using chromatin capture analysis.
[0131] Notably, chromatin capture experiments in eukaryotes have revealed two classical interaction patterns, in addition to species-specific and cell-type-specific chromatin interactions. One pattern, namely distance-dependent sex decline decomposition (DDD), is a general trend of decreasing interaction frequency depending on genomic distance. The second pattern, namely cis-trans ratio (CTR), is a remarkably high interaction frequency between loci located on the same chromosome, even when separated by tens of megabases of sequences, for loci on different chromosomes. These patterns may also reflect general macromolecular dynamics, as do certain nuclear constituent features such as the formation of chromosomal regions, which are phenomena of interphase chromosomes that tend to occupy distinct amounts in the nucleus even with slight mixing, as well as the likelihood that proximal loci interact randomly. While the exact details of these two patterns may vary between species, cell type, and cellular conditions, they are universal and prominent. Because these patterns are so strong and consistent, they are used to assess the quality of experiments and are usually normalized from the data to reveal detailed interactions. However, in the methods disclosed herein, genome assembly can utilize the three-dimensional structure of the genome. The characteristics of classical chromatin-trapping interaction patterns (i.e., their ubiquity, strength, and consistency) that hinder the analysis of specific looping interactions make them a powerful tool for assessing the genomic location of contigs.
[0132] In certain implementations, investigating the physical distances between read pairs within a chromosome reveals several useful features of the data regarding genome assembly. Firstly, short-distance interactions are more common than long-distance interactions (see, e.g., Figure 6). That is, each read in a read pair is more likely to bind to a nearby region in the actual genome than to a much more distant region. Secondly, there is a long tail of intermediate- and long-distance interactions. That is, read pairs convey information about placement within a chromosome over distances of kilobases (kB) or megabases (Mb). For example, read pairs can provide sequence information of approximately 10kB, 50kB, 100kB, 200kB, 500kB, 1Mb, 2Mb, 5Mb, 10Mb, or over 100Mb. These features of the data indicate that nearby genomic regions on the same chromosome are likely to be physically close—a predictable result since they are chemically bound to each other by the DNA backbone. Genome-wide chromatin interaction datasets, such as those generated by chromatin capture, will provide long-range information about sequence grouping and linear organization along all chromosomes.
[0133] While experimental methods for chromatin capture are direct and relatively inexpensive, current protocols for genome assembly and haplotyping require a vast amount of material—10⁶–10⁸ cells, which may not be available from, among other things, certain human patient samples. In contrast, the methods disclosed herein include those that enable accurate and predictive results for genotype assembly, haplotype phasing, and metagenomics using very little material from cells. For example, approximately 0.1 μg, 0.2 μg, 0.3 μg, 0.4 μg, 0.5 μg, 0.6 μg, 0.7 μg, 0.8 μg, 0.9 μg, 1.0 μg, 1.2 μg, 1.4 μg, 1.6 μg, 1.8 μg, 2.0 μg, 2.5 μg, 3.0 μg, 3.5 μg, 4.0 μg, 4.5 μg, 5.0 μg, 6.0 μg, 7.0 μg, 8.0 μg, 9.0 μg DNA in amounts of approximately 10 μg, 15 μg, 20 μg, 30 μg, 40 μg, 50 μg, 60 μg, 70 μg, 80 μg, 90 μg, 100 μg, 150 μg, 200 μg, 300 μg, 400 μg, 500 μg, 600 μg, 700 μg, 800 μg, 900 μg, or less than 1000 μg may be used in conjunction with the methods disclosed herein. In some examples, the DNA used in the methods disclosed herein can be extracted from approximately 1,000,000, approximately 500,000, approximately 100,000, approximately 50,000, approximately 10,000, approximately 5,000, approximately 1,000, approximately 5,000, or approximately 1,000, approximately 500, or less than approximately 100 cells.
[0134] In some cases, approximately 80%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or less than 0.1% of DNA segments from any other DNA molecule are linked. In other cases, 50%, 40%, 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, or less than 5% of DNA segments from any other DNA molecule are linked. In some cases, 40%, 30%, 20%, 15%, or less than 10% of DNA segments from any other DNA molecule are linked. In some cases, less than 40% of DNA segments from any other DNA molecule are linked. In some cases, less than 20% of DNA segments from a single DNA molecule are linked to DNA segments from any other DNA molecule. In other cases, less than 10% of DNA segments from a single DNA molecule are linked to DNA segments from any other DNA molecule.
[0135] Universally, procedures for exploring the physical arrangement of chromosomes, such as chromatin capture techniques, utilize chromatin formed within cells / organisms, such as chromatin isolated from cultured cells or primary tissues. This disclosure provides not only the use of such techniques using chromatin isolated from cells / organisms, but also reconstituted chromatin. Reconstituted chromatin is distinguished from chromatin formed within cells / organisms by various characteristics. Firstly, for many samples, the collection of naked DNA samples can be achieved using a variety of non-invasive to invasive methods, such as by collecting bodily fluids, swabbing the buccal or rectal area, or collecting epithelial samples, etc. Secondly, chromatin reconstitution substantially hinders interchromosomal and other long-range interactions, which produce artifacts for genome assembly and haplotype phasing. In some cases, a sample may have interchromosomal or intermolecular crosslinks of less than approximately 20, 15, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, 0.4, 0.3, 0.2, or 0.1% according to the methods and compositions of this disclosure. In some examples, a sample may have less than approximately 5% interchromosomal or intermolecular crosslinks. In some examples, a sample may have less than approximately 3% interchromosomal or intermolecular crosslinks. In some examples, a sample may have less than approximately 1% interchromosomal or intermolecular crosslinks. Thirdly, the frequency of sites that can be crosslinked, and therefore the frequency of intramolecular crosslinks within polynucleotides, can be controlled. For example, the DNA-to-histone ratio can be altered so that the nucleosome density can be adjusted to a desired value. In some cases, the nucleosome density is reduced to below physiological levels. Accordingly, the distribution of crosslinks can be modified to favor long-range interactions. In some embodiments, subsamples having variable crosslink density may be prepared to cover both short-range and long-range bindings.For example, the crosslinking conditions are that at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% of the crosslinks are sample DN. It is configurable to occur between DNA segments separated by at least approximately 50kb, 60kb, 70kb, 80kb, 90kb, 100kb, 110kb, 120kb, 130kb, 140kb, 150kb, 160kb, 180kb, 200kb, 250kb, 300kb, 350kb, 400kb, 450kb, or 500kb on molecule A.
[0136] In various embodiments, this disclosure provides various methods that enable the mapping of multiple read pairs to multiple contigs. There are several commercially available computer programs for mapping read pairs to contig sequences. The data from these read-mapping programs provides data that describes how specific a particular read-mapping is within the genome. From a population of reads that are confidently specific within a contig, we can infer the distribution of read-to-read distances for each read pair. These are the data shown in Figure 6. For read pairs in which reads are confidently mapped to different contigs, this mapping data implicitly implies a join between the two contigs in question. It also implicitly implies a distance between the two contigs that is proportional to the distribution of distances learned from the analysis described above. Thus, each read pair in which reads are mapped to different contigs implicitly implies a join between those two contigs in the correct assembly. The joins inferred from all such mapped read pairs are summarized in an adjacency matrix where each contig is represented by both rows and columns. Read pairs that join contigs are represented as non-zero values in the corresponding rows and columns displaying the contigs, meaning the contig to which the reads in the read pair are mapped. Most read pairs are mapped within contigs, from which the distribution of distances between read pairs can be learned, and using read pairs that map to different contigs, an adjacency matrix of the contigs can be constructed.
[0137] In various embodiments, the disclosure provides a method comprising the step of constructing an adjacency matrix of contigs using read-mapping data from read-pair data. In some embodiments, the adjacency matrix uses a weighting scheme for read pairs that incorporates a tendency for short-range interactions to be greater than for long-range interactions (see, for example, Figure 3). Read pairs spanning short distances are generally more common than read pairs spanning longer distances. A function describing the probability of a particular distance can be tuned using read-pair data mapped to a single contig to learn this distribution. Thus, one important feature of read pairs mapped to various contigs is their position on the contig to which they are mapped. For read pairs both mapped near one end of a contig, the inferred distance between these contigs may be short, and therefore the distance between the joined reads may be small. Because short distances between read pairs are more common than long distances, this construction provides stronger evidence that these two contigs are adjacent than evidence that the read mapping is far from the edge of the contig. Therefore, bindings in the adjacency matrix are further weighted by the read distance to the edge of the contig. In some embodiments, the adjacency matrix is rescaled to reduce the weight of many junctions on some contigs that represent indiscriminate regions of the genome. Such regions of the genome are identifiable by having a high proportion of read mappings to them, but are deductively likely to contain false read mappings that may mislead the assembly. In further embodiments, this scaling can be directed by searching for one or more conserved binding sites for one or more agents that modulate chromatin scaffold interactions, such as the transcriptional repressor CTCF, endocrine receptors, cohesin, or covalently modified histones.
[0138] In some embodiments, the Disclosure provides one or more methods disclosed herein, comprising the step of analyzing an adjacency matrix to determine a path through contigs representing order and / or orientation to the genome. In other embodiments, a path through contigs can be selected so as to reach each contig exactly once. In some embodiments, a path through contigs is selected so as to maximize the sum of edge weights reached by the path through the adjacency matrix. In this method, the most reliable contig joining is proposed for proper assembly. In yet another embodiment, a path through contigs can be selected so as to reach each contig exactly once and so as to maximize the edge weighting of the adjacency matrix.
[0139] In diploid genomes, it is often important to know which allele variants are linked on the same chromosome. This is known as haplotype phasing. With short reads from high-throughput sequence data, it is rarely possible to directly observe which allele variants are linked. Computational inference of haplotype phasing can be unreliable over long distances. This disclosure provides one or more methods that enable the determination of which allele variants are linked using allele variants on a read pair.
[0140] In various embodiments, the methods and compositions of this disclosure enable haplotype phasing of diploid or polyploid genomes with respect to multiple allele variants. The methods described herein can also be used to determine whether linked allele variants are linked based on variant information from read pairs and / or assembled contigs. Examples of allele variants, but not limited to, those known from 1000genomes, UK10K, HapMap, and other projects for discovering genetic variation between humans. The association of specific genes with disease can be much more easily revealed by having haplotype phasing data, such as the discovery of unlinked inactivating mutations in both copies of SH3TC2 that cause Charcot-Marie-Tooth neuropathy (Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. N. Engl. J. Med. 362:1181-91, 2010) and unlinked inactivating mutations in both copies of ABCG5 that cause hypercholesterolemia 9 (Rios J, Stein E, Shendure J, et al. Hum. Mol. Genet. 19:4313-18, 2010).
[0141] Humans are heterozygous at one out of every 1,000 sites on average. In some cases, a single lane of data using a high-throughput sequencing method can generate at least approximately 150,000,000 read pairs. A read pair can be about 100 base pairs long. From these parameters, it is estimated that one-tenth of all reads from a human sample contain heterozygous sites. Therefore, on average, it is estimated that one-hundredth of all read pairs from a human sample contain one pair of heterozygous sites. Accordingly, approximately 1,500,000 read pairs (one-hundredth of 150,000,000) provide fading data using a single lane. With approximately 3 billion bases in the human genome and one out of every 1,000 being heterozygous, there are approximately 3 million heterozygous sites in the average human genome. With approximately 1,500,000 read pairs representing one pair of heterozygous sites, the average coverage of each heterozygous site phased using a single lane of a high-throughput sequencing method is approximately (1X) using a typical high-throughput sequencing instrument. Thus, a diploid human genome can be reliably and completely phased into a single lane of high-throughput sequencing data relating sequence variants from samples prepared using the methods disclosed herein. In some examples, the data lane may be a set of DNA sequence read data. In some examples, the data lane may be a set of DNA sequence read data from a single run of a high-throughput sequencing instrument.
[0142] Because the human genome consists of two homologous sets of chromosomes, understanding the precise genetic makeup of an individual requires a description of the maternal and paternal copies, or haplotypes of the genetic material. Obtaining haplotypes in individuals is useful in several ways. Firstly, haplotypes are clinically useful in predicting the outcome of donor-host matching in organ transplantation and are increasingly used as a means of detecting disease associations. Secondly, in genes exhibiting compound heterozygosity, haplotypes provide information on whether two harmful variants are located on the same allele, significantly impacting predictions of whether the inheritance of these variants is harmful. Thirdly, haplotypes from populations of individuals have provided information about population structure and the evolutionary history of humankind. Finally, the wide range of allele imbalances recently described in gene expression indicate that genetic or epigenetic differences between alleles can also contribute to quantitative differences in expression. Understanding haplotype structure helps to describe the mechanisms of variants that contribute to allele imbalances.
[0143] In some embodiments, the methods disclosed herein include techniques (e.g., in vitro or in vivo) for immobilizing and capturing bindings in distant regions of the genome required for long-distance linkage and phasing. In some cases, the methods include the step of constructing and sequencing an XLRP library to transmit very genomically distant read pairs. In some cases, interactions arise primarily from random bindings within a single DNA fragment. In some examples, segments that are closely spaced within a DNA molecule interact frequently and with high probability, allowing for the inference of genomic distances between segments, while interactions between distant parts of the molecule are less frequent. Consequently, there is a phylogenetic relationship between the number of pairs linking two loci and their proximity on the input DNA. This disclosure can generate read pairs that can reach the largest DNA fragment at extraction, as demonstrated in Figure 2. The input DNA for this library has a maximum length of 150 kbp, which is the longest significant read pair we have observed from sequencing data. This suggests that, given larger input DNA fragments, this method can link to more genomically distant loci. Complete genome assembly may also be possible by applying improved assembly software tools specifically suited to handling the type of data generated by this method.
[0144] Extremely high phasing accuracy can be achieved with data purified using the methods and compositions disclosed herein. Compared to conventional methods, the methods described herein can phase a higher proportion of variants. Phasing is achievable while maintaining a high level of accuracy. This phase information can be extended over longer distances, for example, about 200 kbp, 300 kbp, 400 kbp, 500 kbp, 600 kbp, 700 kbp, 800 kbp, 900 kbp, 1 Mbp, 2 Mbp, 3 Mbp, 4 Mbp, 5 Mbp, or more than 10 Mbp. In some embodiments, more than 90% of heterozygous SNPs for human samples can be phased with over 99% accuracy using fewer than 250 million reads or read pairs, for example, using just one lane of Illumina HiSeq data. In other cases, approximately 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more than 99% of heterozygous SNPs for human samples can be phased with an accuracy of approximately 70%, 80%, 90%, 95%, or more than 99% using fewer than approximately 250 million or 500 million reads or read pairs, for example, using just one or two lanes of Illumina HiSeq data. For example, 95% or more of heterozygous SNPs for human samples can be phased with an accuracy of approximately 95% or more than 99% using fewer than approximately 250 million or 500 million reads. In some cases, additional mutants can be made more finely graftable by increasing the read length to approximately 200 bp, 250 bp, 300 bp, 350 bp, 400 bp, 450 bp, 500 bp, 600 bp, 800 bp, 1000 bp, 1500 bp, 2 kbp, 3 kbp, 4 kbp, 5 kbp, 10 kbp, 20 kbp, 50 kbp, or 100 kbp.
[0145] In other embodiments of this disclosure, data from XLRP libraries can be used to verify the phasing capability of long-range read pairs. As shown in Figure 6, the accuracy of these results is comparable to the best techniques previously available, but extended to significantly longer distances. Current sample preparation protocols for specific sequencing methods recognize variants within the read length (e.g., 150 bp) of the targeted restriction site for phasing. In one example, from an XLRP library constructed for NA12878, a benchmark sample for assembly, 44% of the 1,703,909 heterozygous SNPs present were phased with an accuracy of over 99%. In some cases, this percentage can be extended to almost all variable sites using a discerning selection of restriction enzymes or various combinations of enzymes.
[0146] In some embodiments, the compositions and methods described herein enable the examination of metagenomics, for example, metagenomics found in the human gut. Accordingly, the partial or whole genome sequences of some or all organisms present in a given ecological environment can be investigated. Examples include random sequencing of all intestinal microorganisms, microorganisms found in specific areas of the skin, and microorganisms living in areas with toxic waste. The composition of these microbial populations in these environments, as well as the interrelated biochemical aspects encoded by their respective genomes, can be determined using the compositions and methods described herein. The methods described herein can enable metagenomic studies from complex biological environments, such as environments containing 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 5000, 10000, or more organisms and / or variants of organisms.
[0147] The high precision required for cancer genome sequencing is achievable using the methods and systems described herein. When sequencing cancer genomes, inaccurate reference genomes can make base calling difficult. Heterogeneous samples and small starting materials, such as those obtained by biopsy, present additional challenges. Furthermore, the detection of large structural variants and / or loss of heterozygosity, as well as the ability to distinguish between somatic variants and base calling errors, are often essential for cancer genome sequencing.
[0148] The systems and methods described herein may generate accurate long sequences from complex samples containing 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or more diverse genomes. Mixed samples of normal, benign, and / or tumor origin may optionally be analyzed without the need for normal controls. In some embodiments, accurate long sequences are generated using start samples as small as 100 ng, or as small as several hundred genome equivalents. The systems and methods described herein may also enable the detection of large structural variants and rearrangements, and phasing variant calls may be obtained over long sequences spanning approximately 1 kbp, 2 kbp, 5 kbp, 10 kbp, 20 kbp, 50 kbp, 100 kbp, 200 kbp, 500 kbp, 1 Mbp, 2 Mbp, 5 Mbp, 10 Mbp, 20 Mbp, 50 Mbp, or more than 100 Mbp of nucleotides. For example, phasing variant calls can be obtained over long sequences of approximately 1 Mbp or 2 Mbp.
[0149] Haplotypes determined using the methods and systems described herein may be assigned to computational resources, such as computational resources via a network, including cloud systems. Short variant calls can be modified as needed using relevant information stored in the computational resources. Structural variants can be detected based on combined information from short variant calls and information stored in the computational resources. Problematic parts of the genome, such as segment duplication, regions prone to structural mutation, highly variable and medically relevant MHC regions, centromere and telomere regions, and other heterochromatin regions, including, but not limited to, repeating regions, regions with low sequence precision, high variant ratios, ALU repeats, segment duplication, or other relevant problematic parts known in the art, can be reassembled to increase precision.
[0150] Sample types can be assigned sequence information locally or on computationally connected resources such as the cloud. If the source of the information is known, for example, if the source is from cancer or normal tissue, the source can be assigned to the sample as part of the sample type. Other examples of sample types include, but are not limited to, tissue type, sample collection method, presence or absence of infection, type of infection, processing method, and sample size. If complete or partial comparison genome sequences, such as a normal genome in comparison with a cancer genome, are available, the differences between sample data and the comparison genome sequences can be determined and optionally output.
[0151] The method is used for analyzing genetic information of a desired selective genomic region and genomic regions that may interact with said selective region. Amplification methods such as those disclosed herein can be used in apparatus, kits, and methods known in the art for genetic analysis, including but not limited to U.S. Patent Applications 6,449,562, 6,287,766, 7,361,468, 7,414,117, 6,225,109, and 6,110,709. In some cases, the amplification methods of this disclosure can be used to amplify target nucleic acids for DNA hybridization studies to determine the presence or absence of polymorphism. Polymorphism (i.e., alleles) may be associated with diseases or genetic disorders. In other cases, polymorphism may be associated with diseases or sensitivity to diseases, for example, polymorphism may be associated with poisoning, degenerative and age-related diseases, cancer, etc. In other cases, polymorphism may be associated with beneficial features such as increased coronary artery health, resistance to diseases like HIV or malaria, or resistance to adult diseases like osteoporosis, Alzheimer's disease, or dementia.
[0152] The compositions and methods of this disclosure can be used for diagnostic, prognostic, therapeutic, patient stratification, drug development, treatment selection, and screening purposes. This disclosure offers the advantage that the methods of this disclosure allow for the analysis of many different target molecules from a single biomolecular sample at once. This makes it possible, for example, to perform multiple diagnostic tests on a single sample.
[0153] The compositions and methods of this disclosure can be used in genomics. The methods described herein can quickly derive answers that are highly desirable for this application. The methods and compositions described herein can be used in the process of finding biomarkers that can be used for diagnosis or prognosis and as indicators of health and disease. The methods and compositions described herein can be used to screen pharmaceuticals, for example, in drug development, treatment selection, determination of the effectiveness of treatment, and / or identification of targets for drug development. Since proteins are the final gene products in the body, the ability to test gene expression in screening assays for pharmaceuticals is extremely important. In some embodiments, the methods and compositions described herein measure both protein and gene expression simultaneously, which provides most of the information regarding the particular screening being performed.
[0154] The compositions and methods of this disclosure can be used in gene expression analysis. The methods described herein distinguish nucleotide sequences. Differences between target nucleotide sequences may be, for example, single nucleic acid base differences, nucleic acid deletions, nucleic acid insertions, or rearrangements. Such sequence differences relating to more than one base can also be detected. The processes of this disclosure can detect infectious diseases, genetic disorders, and cancer. Furthermore, it is useful in environmental monitoring, forensic science, and food science. Examples of gene analysis that can be performed on nucleic acids include, for example, SNP detection, STR detection, RNA expression analysis, promoter methylation, gene expression, virus detection, viral subtype classification, and drug resistance.
[0155] This method can also be applied to the analysis of biomolecular samples obtained from or derived from patients to determine whether disease cell types are present in the sample, the stage of the disease, the patient's prognosis, the patient's ability to respond to a particular treatment, or the best treatment for the patient. This method can also be applied to identify biomarkers for specific diseases.
[0156] In some embodiments, the methods disclosed herein are used for the diagnosis of disease. As used herein, the terms “diagnose” or “diagnose” a disease may include predicting or diagnosing a disease, determining predisposition to a disease, monitoring treatment for a disease, diagnosing the treatment response to a disease, or diagnosing the prognosis of a disease, the progression of a disease, or the response of a disease to a particular treatment. For example, a blood sample can be analyzed according to any of the methods described herein to determine the presence and / or amount of markers of disease or malignant cell types in the sample.
[0157] In some embodiments, the methods and compositions disclosed herein are used for the diagnosis and prognosis of diseases.
[0158] Many immune, proliferative, and malignant diseases and disorders are particularly susceptible to the methods described herein. Immune diseases and disorders include allergic diseases and disorders, disorders of immune function, and autoimmune diseases and disorders. Allergic diseases and disorders include, but are not limited to, allergic rhinitis, allergic conjunctivitis, allergic asthma, atopic eczema, atopic dermatitis, and food allergies. Immunodeficiency disorders include, but are not limited to, severe combined immunodeficiency (SCID), eosinophilic syndrome, chronic granulomatous disease, type I and type II leukocytosis, hyper-IgE syndrome, Chediak-Higashi syndrome, neutropenia, neutropenia, aplasia, agammaglobulinemia, hyper-IgM syndrome, DiGeorge syndrome / palatocardiofacial syndrome, and interferon-gamma-TH1 pathway disorders. Autoimmune and immunological dysregulations include, but are not limited to, rheumatoid arthritis, diabetes mellitus, systemic lupus erythematosus, Graves' disease, Graves' ophthalmopathy, Crohn's disease, multiple sclerosis, psoriasis, systemic sclerosis, goiter and lymphoid goiter (Hashimoto's thyroiditis, lymphadenoid goiter), alopecia areata, autoimmune myocarditis, lichen sclerosing, autoimmune uveitis, Addison's disease, atrophic gastritis, myasthenia gravis, idiopathic thrombocytopenic purpura, hemolytic anemia, primary biliary cirrhosis, Wegener's granulomatosis, polyarteritis nodosa, and inflammatory bowel disease (including harmful allograft rejection and tissue, ranging from allergic reactions to infectious microorganisms or environmental antigens).
[0159] Proliferative diseases and disorders that can be evaluated by the methods of this disclosure include, but are not limited to, neonatal hemangiomatosis; secondary progressive multiple sclerosis; chronic progressive myelodegenerative diseases; neurofibromatosis; ganglioneuromatosis; keloid formation; Paget's disease of the bone; fibrocystic disease (e.g., of the breast or uterus); sarcoidosis; peony's and Dupuytren's fibrosis, cirrhosis, atherosclerosis, and restenosis of blood vessels.
[0160] The malignant diseases and disorders that can be evaluated by the methods of this disclosure include both hematological malignancies and solid tumors.
[0161] Because these malignancies involve innate cellular variations in the blood, hematological malignancies are particularly susceptible to the effects of the methods of this disclosure when the sample is a blood sample. These malignancies include non-Hodgkin lymphoma, Hodgkin lymphoma, non-B cell lymphoma, and other lymphomas, acute or chronic leukemia, erythrocytosis, thrombocytemia, multiple myeloma, myelodysplastic disorders, myeloproliferative disorders, myelofibrosis, atypical immune lymphocyte proliferation, and plasmacytosis.
[0162] Plasma cell disorders that can be evaluated by the methods of this disclosure include multiple myeloma, amyloidosis, and Waldenström macroglobulinemia.
[0163] Examples of solid tumors include, but are not limited to, colon cancer, breast cancer, lung cancer, prostate cancer, brain tumors, central nervous system tumors, bladder tumors, melanoma, liver cancer, osteosarcoma and other bone cancers, testicular and ovarian cancers, head and neck tumors, and cervical neoplasms.
[0164] Genetic disorders can also be detected by the process of this disclosure. This can be done by prenatal or postnatal screening for chromosomal and genetic abnormalities, or for genetic disorders. Examples of detectable genetic disorders include: 21-hydroxylase deficiency, cystic fibrosis, fragile X syndrome, Turner syndrome, Duchenne muscular dystrophy, Down syndrome or other trisomies, heart disease, monogenic disorders, HLA typing, phenylketonuria, sickle cell anemia, Tisachs disease, thalassemia, Klinefelter syndrome, Huntington's disease, autoimmune diseases, lipidosis, obesity deficiency, hemophilia, congenital metabolic disorders, and diabetes mellitus.
[0165] The methods described herein can be used to diagnose pathogenic infections, such as intracellular bacterial and viral infections, by determining the presence and / or amount of bacterial or viral markers in a sample.
[0166] A wide variety of infectious diseases can be detected by the processes described in this disclosure. Infections can be caused by infectious pathogens such as bacteria, viruses, parasites, and fungi. Resistance of various infectious pathogens to pharmaceuticals can also be determined using this disclosure.
[0167] Bacterial infectious agents that can be detected by the present disclosure include Escherichia coli, Salmonella, Shigella, KlESBiella, Pseudomonas, Listeria monocytogenes, Mycobacterium tuberculosis, Mycobacterium aviumintracellulare, Yersinia, Francisella, Pasteurella, Brucella, Clostridia, Bordetella. pertussis, Bacteroides, Staphylococcus aureus, Streptococcus pneumonia, B-Hemolytic strep., Corynebacteria, Legionella, Mycoplasma, Ureaplasma, Chlamydia, Neisseria gonorrhea, Neisseria meningitides, Hemophilus influenza, Enterococcus faecalis, Proteus vulgaris, Proteus mirabilis, Helicobacter pylori, Treponema palladium, Borrelia burgdorferi, Borrelia This includes recurrentis, rickettsial pathogens, nocardia, and acitnomycetes.
[0168] The fungal infectious pathogens that can be detected by this disclosure include Cryptococcus neoformans, Blastomyces dermatitidis, Histoplasma capsulatum, Coccidioides immitis, Paracoccidioides brasiliensis, Candida albicans, Aspergillus fumigautus, Phycomycetes (Rhizopus), Sporothrix schenckii, Chromomycosis, and Maduromycosis.
[0169] The viral pathogens that can be detected by this disclosure include human immunodeficiency virus, human T-cell lymphotropic virus, hepatitis viruses (e.g., hepatitis B virus and hepatitis C virus), Epstein-Barr virus, cytomegalovirus, human papillomavirus, orthomyxovirus, paramyxovirus, adenovirus, coronavirus, rhabdovirus, poliovirus, togavirus, bunyavirus, arenavirus, rubella virus, and reovirus.
[0170] Parasitic agents that can be detected by this disclosure include Plasmodium falciparum, Plasmodium malaria, Plasmodium vivax, Plasmodium ovale, Onchoverva volvulus, Leishmania, Trypanosoma spp., Schistosoma spp., Entamoeba histolytica, Cryptosporidum, Giardia spp., Trichimonas spp., Balatidium coli, Wuchereria bancrofti, Toxoplasma spp., Enterobius vermicularis, Ascaris luMbricoides, Trichuris trichiura, Dracunculus medinesis, trematodes, Diphyllobothrium latum, Taenia spp., Pneumocystis carinii, and Necator americanis.
[0171] Furthermore, this disclosure is also useful for detecting drug resistance in infectious pathogens. For example, vicomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, multidrug-resistant Mycobacterium tuberculosis, and AZT-resistant human immunodeficiency virus can all be identified with this disclosure.
[0172] Therefore, target molecules detected using the compositions and methods of this disclosure may be patient markers (such as cancer markers) or infection markers using exogenous drugs such as bacterial or viral markers.
[0173] The compositions and methods of this disclosure can be used to identify and / or quantify target molecules whose abundance indicates a biological or disease state (e.g., blood markers that are upregulated or downregulated as a result of a disease state).
[0174] In some embodiments, the methods and compositions of this disclosure can be used for cytokine expression. The low sensitivity of the methods described herein is useful, for example, for the early detection of cytokines as biomarkers for certain diseases, for the diagnosis or prognosis of diseases such as cancer, and for the identification of subclinical conditions.
[0175] The various samples from which the target polynucleotide is derived may include multiple samples from the same individual, samples from different individuals, or combinations thereof. In some embodiments, the sample contains multiple polynucleotides from one individual. In some embodiments, the sample contains multiple polynucleotides from two or more individuals. An individual is any living organism or part thereof from which the target polynucleotide may originate, non-limiting examples of which include plants, animals, fungi, protists, Monera, viruses, mitochondria, and chloroplasts. The polynucleotide of a sample, including, for example, a cultured cell line containing cells, a biopsy, a blood sample, or a fluid sample, and the polynucleotide of a sample such as a cell sample, tissue sample, or organ sample derived therefrom, can be isolated from the subject. The subject may be any animal, including, but not limited to, cattle, pigs, mice, rats, birds, cats, dogs, etc., and is usually a mammal such as a human. The sample may be artificially derived by chemical synthesis or other means. In some embodiments, the sample contains DNA. In some embodiments, the sample contains genomic DNA. In some embodiments, the sample includes mitochondrial DNA, chloroplast DNA, plasmid DNA, bacterial artificial chromosomes, yeast artificial chromosomes, oligonucleotide tags, or combinations thereof. In some embodiments, the sample includes DNA produced by primer extension reactions, which also use any suitable combination of primers and DNA polymerase, including, but not limited to, polymerase chain reaction (PCR), reverse transcription, and combinations thereof. When the template for the primer extension reaction is RNA, the product of reverse transcription is called complementary DNA (cDNA). Primers useful for primer extension reactions may include sequences specific to one or more targets, random sequences, partially random sequences, and combinations thereof. Suitable reaction conditions for primer extension reactions are known in the art. Generally, the polynucleotides of the sample include any polynucleotides present in the sample, which may or may not include the target polynucleotide.
[0176] In some embodiments, nucleic acid template molecules (e.g., DNA or RNA) are isolated from biological samples containing various other components such as proteins, lipids, and non-template nucleic acids. Nucleic acid template molecules can be obtained from any cellular material obtained from living organisms such as animals, plants, bacteria, fungi, or other cellular organisms. Biological samples used in this disclosure include viral particles or preparations. Nucleic acid template molecules can be obtained directly from living organisms or from biological samples obtained from living organisms, for example, from blood, urine, cerebrospinal fluid, semen, saliva, sputum, stool, and tissue. Any tissue or bodily fluid sample may be used as a source of nucleic acids for use in this disclosure. Nucleic acid template molecules can further be isolated from cultured cells such as primary cell cultures or cell lines. Cells or tissues from which template nucleic acids are obtained may be infected with viruses or other intracellular pathogens. Samples can further be biological specimens, cDNA libraries, viruses, or total RNA extracted from genomic DNA. Samples may further be DNA isolated from non-cellular origins (e.g., amplified or isolated DNA from a freezer).
[0177] Methods for the extraction and purification of nucleic acids are well known in the art. For example, nucleic acids can be purified by organic extraction with phenol, phenol / chloroform / isoamyl alcohol, or similar formulations containing TRIzol and TriReagent. Other non-limiting examples of extraction techniques include: (1) organic extraction followed by ethanol precipitation using, or without, an automated nucleic acid extractor (e.g., the Model 341 DNA Extractor available from Applied Biosystems (Foster City, Calif.)) and a phenol / chloroform organic reagent (Ausubel et al., 1993); (2) stationary phase adsorption (US Patent Application 5,234,809; Walsh et al., 1991); and (3) salt-induced nucleic acid precipitation (Miller et al., (1988), such precipitation methods are generally called “salting-out” methods). Another example of nucleic acid isolation and / or purification involves the use of magnetic particles to which nucleic acids can bind specifically or nonspecifically, and subsequent separation of beads using a magnet, and washing and eluting the nucleic acids from the beads (see, for example, U.S. Patent Application 5,705,628). In some embodiments, the above isolation methods may be preceded by an enzymatic digestion step, e.g., digestion using proteinase K or other similar proteases, to facilitate the removal of undesirable proteins from the sample (see, for example, U.S. Patent Application 7,001,724). If desired, an RNase inhibitor may be added to the lysis buffer. For certain cell or sample types, it may be desirable to add a protein denaturation / digestion step to the protocol. Purification methods may also target the isolation of DNA, RNA, or both. If both DNA and RNA are isolated together during or after the extraction procedure, further steps may be employed to purify one or both separately from the other. Fractions of the extracted nucleic acids can also be produced by purification according to, for example, size, sequence, or other physical or chemical properties.In addition to the initial nucleic acid separation step, nucleic acid purification may be performed after any step of the method of this disclosure, for example, to remove excess or undesirable reagents, reactants, or products.
[0178] Nucleic acid template molecules can be obtained, as described in U.S. Patent Application Publication US2002 / 0190663A1, published on October 9, 2003. Generally, nucleic acids can be extracted from biological samples by various techniques, as described in Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY, pp. 280-281 (1982). In some cases, nucleic acids can be first extracted from biological samples and then crosslinked in vitro. In some cases, native binding proteins (e.g., histones) can be further removed from the nucleic acids.
[0179] In other embodiments, the disclosure is readily applicable to any high molecular weight double-stranded DNA, including DNA isolated from, for example, tissues, cell cultures, bodily fluids, animal tissues, plants, bacteria, fungi, viruses, and the like.
[0180] In some embodiments, each of several independent samples independently contains at least about 1 ng, 2 ng, 5 ng, 10 ng, 20 ng, 30 ng, 40 ng, 50 ng, 75 ng, 100 ng, 150 ng, 200 ng, 250 ng, 300 ng, 400 ng, 500 ng, 1 μg, 1.5 μg, 2 μg, 5 μg, 10 μg, 20 μg, 50 μg, 100 μg, 200 μg, 500 μg, or 1000 μg or more of nucleic acid material. In some embodiments, each of several independent samples may independently contain approximately 1 ng, 2 ng, 5 ng, 10 ng, 20 ng, 30 ng, 40 ng, 50 ng, 75 ng, 100 ng, 150 ng, 200 ng, 250 ng, 300 ng, 400 ng, 500 ng, 1 μg, 1.5 μg, 2 μg, 5 μg, 10 μg, 20 μg, 50 μg, 100 μg, 200 μg, 500 μg, or less than 1000 μg of nucleic acid.
[0181] In some embodiments, end repair is performed using commercially available kits, such as those available from Epicentre Biotechnologies (Madison, WI), to generate blunt-end 5' phosphorylated nucleic acid ends.
[0182] An adapter oligonucleotide comprises any oligonucleotide having a sequence that is capable of binding to a target polynucleotide and at least a portion of which is a known sequence. Adapter oligonucleotides may include DNA, RNA, nucleotide analogs, non-classical nucleotides, labeled nucleotides, modified nucleotides, or combinations thereof. Adapter oligonucleotides may be single-stranded, double-stranded, or partially double-stranded. Generally, a partially double-stranded adapter comprises one or more single-stranded regions and one or more double-stranded regions. A double-stranded adapter may comprise two other oligonucleotides hybridized with each other (referred to as “oligonucleotide duplexes”), and the hybridization may leave one or more blunt ends, one or more 3' overhangs, one or more 5' overhangs, one or more bulges derived from mismatched and / or unpaired nucleotides, or any combination thereof. In some embodiments, a single-stranded adapter comprises two or more sequences that can hybridize with each other. When two such hybridizable sequences are included in a single-stranded adapter, the hybridization results in a hairpin structure (hairpin adapter). A "bubble" structure is created when two hybridized regions of an adapter are separated from each other by a non-hybridized region. Adapters containing a bubble structure may consist of a single adapter oligonucleotide containing internal hybridization, or they may contain two or more adapter oligonucleotides that are hybridized to each other. Internal sequence hybridization, such as between two hybridizable sequences in an adapter, can generate a double-stranded structure in a single-stranded adapter oligonucleotide. Various types of adapters can be used in combination, such as hairpin adapters and double-stranded adapters with various sequences. The hybridizable sequences in a hairpin adapter may or may not contain one or both ends of the oligonucleotide.If neither end is included in a sequence that can hybridize, both ends are either "free" or "overhanging". When only one end is hybridizable with another sequence in the adapter, the other end forms an overhang, such as a 3' overhang or a 5' overhang. If both the 5'-terminal and 3'-terminal nucleotides are included in a sequence that can hybridize, so that the 5'-terminal and 3'-terminal nucleotides are complementary and hybridize with each other, the ends are called "blunt". Various adapters can be bound to target polynucleotides in sequential or simultaneous reactions. For example, the first and second adapters can be added to the same reaction. Adapters can be manipulated before being combined with the target polynucleotide. For example, terminal phosphates can be added or removed.
[0183] An adapter may include, but is not limited to, one or more amplification primer annealing sequences or their complements, one or more sequencing primer annealing sequences or their complements, one or more barcode sequences, one or more common sequences shared across multiple different adapters or subsets of different adapters, one or more restriction enzyme recognition sites, one or more overhangs or complements complementary to one or more target polynucleotide overhangs, one or more probe binding sites (for example, for binding to sequencing platforms such as flow cells for ultra-parallel sequencing, as developed by Illumina, Inc.), one or more random or nearly random sequences (for example, one or more nucleotides arbitrarily selected from sets of two or more different nucleotides at one or more positions, each of the various nucleotides being selected at one or more positions represented in a pool of adapters containing random sequences), and one or more of a variety of sequence elements including combinations thereof. Two or more sequence elements may not be adjacent to each other (e.g., separated by one or more nucleotides), may be adjacent to each other, may partially overlap, or may completely overlap. For example, an amplification primer annealing sequence can also serve as a sequencing primer annealing sequence. Sequence elements may be located at or near the 3' end, at or near the 5' end, or inside the adapter oligonucleotide. If the adapter oligonucleotide can form a secondary structure such as a hairpin, sequence elements may be located partially or completely outside the secondary structure, partially or completely inside the secondary structure, or between sequences involved in the secondary structure. For example, if the adapter oligonucleotide contains a hairpin structure, sequence elements may be located partially or completely inside or outside the hybridizable sequences ("base"), including sequences between hybridizable sequences ("loops").In some embodiments, the first adapter oligonucleotide in a plurality of first adapter oligonucleotides having various barcode sequences contains a sequence element common to all first adapter oligonucleotides in the plurality of first adapter oligonucleotides. In some embodiments, all second adapter oligonucleotides contain a common sequence element in all second adapter oligonucleotides that is different from the common sequence element shared by the first adapter oligonucleotides. The differences in sequence elements may be arbitrary such that at least some of the different adapters are not perfectly aligned, for example, by differences in sequence length, deletion or insertion of one or more nucleotides, or changes in nucleotide composition at one or more nucleotide positions (such as base changes or base modifications). In some embodiments, the adapter oligonucleotide contains a 5' overhang, a 3' overhang, or both of the above that are complementary to one or more target polynucleotides. The complementary overhang may be one or more nucleotides with lengths including, but not limited to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more nucleotide lengths. For example, a complementary overhang may be approximately 1, 2, 3, 4, 5, or 6 nucleotides long. A complementary overhang may contain a fixed sequence. A complementary overhang may contain a random sequence of one or more nucleotides such that one or more nucleotides are randomly selected from a set of two or more different nucleotides at one or more positions, each of which is selected at one or more positions represented in a pool of adapters having complementary overhangs containing random sequences. In some embodiments, the adapter overhang is complementary to a target polynucleotide overhang produced by restriction endonuclease digestion. In some embodiments, the adapter overhang consists of adenine or thymine.
[0184] Adapter oligonucleotides can have any suitable length, as short as the minimum necessary to fit one or more sequence elements that comprise them. In some embodiments, the adapter is as follows: less than, about, or 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 200, or more than 10 nucleotides in length. In some examples, the adapter may be about 10 for nucleotides of about 50 in length. In some examples, the adapter may be about 20 for nucleotides of about 40 in length.
[0185] As used herein, the term “barcode” refers to a known nucleic acid sequence that enables the identification of a feature of the polynucleotide to which the barcode is associated. In some embodiments, the polynucleotide feature to be identified is the sample from which the polynucleotide originates. In some embodiments, the barcode may have a nucleotide length of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more. For example, the barcode may have a nucleotide length of at least 10, 11, 12, 13, 14, or 15. In some embodiments, the barcode may be shorter than 10, 9, 8, 7, 6, 5, or 4 nucleotides. For example, the barcode may be shorter than 10 nucleotides. In some embodiments, the barcode associated with some polynucleotides may have a different length than the barcode associated with other polynucleotides. Generally, the barcodes are of sufficient length and contain sequences that are sufficiently different to enable the identification of a sample based on the barcode to which they are associated. In some embodiments, a barcode and the sample source associated with the barcode can be accurately identified after mutations, insertions, or deletions of one or more nucleotides in the barcode sequence, such as mutations, insertions, or deletions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleotides. In some examples, 1, 2, or 3 nucleotides can be mutated, inserted, and / or removed. In some embodiments, each barcode in a plurality of barcodes differs from every other barcode in the plurality of barcodes at at least two nucleotide positions, such as at least positions 2, 3, 4, 5, 6, 7, 8, 9, 10, or more. In some examples, each barcode may differ from every other barcode at at least positions 2, 3, 4, or 5. In some embodiments, both the first and second sites include at least one of the plurality of barcode sequences. In some embodiments, the barcode for the second site is selected independently of the barcode for the first adapter oligonucleotide.In some embodiments, the first and second sites having barcodes are paired, and multiple pairs of sequences contain one or more identical or different barcodes. In some embodiments, the method of the present disclosure further includes the step of identifying a sample from which a target polynucleotide originates based on the barcode sequence to which the target polynucleotide is bound. Generally, the barcode may contain a nucleic acid sequence, which, when bound to the target polynucleotide, serves as an identifier for the sample from which the target polynucleotide originates.
[0186] In eukaryotes, genomic DNA is packed into chromatin and exists as chromosomes in the nucleus. The basic structural unit of chromatin is the nucleosome, which consists of 146 base pairs (bp) of DNA wrapped around a histone octamer. The histone octamer consists of two copies each of the core histone H2A-H2B dimer and the H3-H4 dimer. Nucleosomes are arranged regularly at intervals along the DNA in what is commonly called a "beads-like structure."
[0187] The assembly of core histones and DNA into nucleosomes is mediated by chaperone proteins and associated assembly factors. Almost all of these factors are core histone-binding proteins. Some histone chaperones, such as nucleosome assembly protein-1 (NAP-1), show a preference for binding to histones H3 and H4. It has been observed that newly synthesized histones are acetylated and then deacetylated after assembly into chromatin. Therefore, factors that mediate histone acetylation or deacetylation play a crucial role in the chromatin assembly process.
[0188] Generally, two in vitro methods have been developed for chromatin reconstruction or assembly. One method is ATP-independent, while the second is ATP-dependent. The ATP-independent method for chromatin reconstruction involves DNA and core histones, as well as either a protein or salt such as NAP-1 to act as a histone chaperone. This method results in a random arrangement of histones on the DNA that does not precisely mimic the native core nucleosome particles in cells. These particles are often called mononucleosomes because they are not regularly ordered, extended nucleosome arrays, and the DNA sequence used is usually not as long as 250 bp (Kundu, TK et al., Mol. Cell 6: 551-561, 2000). To generate an extended array of ordered nucleosomes on a long single DNA sequence, chromatin must be assembled via an ATP-dependent process.
[0189] The ATP-dependent assembly of periodic nucleosome arrays, similar to those found in natural chromatin, requires DNA sequences, core histone particles, chaperone proteins, and ATP-utilizing chromatin assembly factors. ACFs (ATP-utilizing chromatin assembly and remodeling factors) or RSFs (remodeling and spacing factors) are two assembly factors studied later, used to generate ordered arrays of nucleosomes into in vitro chromatin (Fyodorov, DV, and Kadonaga, JT Method Enzymol. 371: 499-515, 2003; Kundu, TK et al. Mol. Cell 6: 551-561, 2000).
[0190] In certain embodiments, the methods of the present disclosure are readily applicable to any type of fragmented double-stranded DNA, including, but not limited to, free DNA isolated from plasma, serum, and / or urine; apoptotic DNA from cells and / or tissues; DNA enzymatically fragmented in vitro (e.g., by DNase I and / or restriction endonucleases); and / or DNA fragmented by mechanical forces (e.g., hydroshearing, sonication, atomization).
[0191] Nucleic acids obtained from biological samples can be fragmented to generate fragments suitable for analysis. Template nucleic acids may be fragmented or cut to desired lengths using various mechanical, chemical, and / or enzymatic methods. DNA may be randomly cut by sonication, e.g., the Covaris method, short-term exposure to DNase, or a mixture of one or more restriction enzymes, or using transposases or nicking enzymes. RNA may be fragmented by short-term exposure to RNase, heat and magnesium, or shear. RNA may be converted to cDNA. If cutting is used, RNA may be converted to cDNA before or after fragmentation. In some embodiments, nucleic acids from biological samples are fragmented by sonication. In other embodiments, nucleic acids are fragmented by a hild shear instrument. Generally, individual nucleic acid template molecules can range from about 2 kb to about 40 kb. In various embodiments, nucleic acids can be fragments of about 6 kb–10 kb. Nucleic acid molecules may be single-stranded, double-stranded, or double-stranded with a single-stranded region (e.g., base and loop structure).
[0192] In some embodiments, crosslinked DNA molecules may be subjected to a size selection process. Nucleic acid size selection may be performed on crosslinked DNA molecules below or above a certain size. Size selection may be further influenced by the frequency of crosslinking and / or the fragmentation method, for example, by selecting a frequent cutter or rare cutter restriction enzyme. In some embodiments, the composition may be prepared by a preparation method that includes crosslinking DNA molecules in the range of about 1kb to 5Mb, about 5kb to 5Mb, about 5kb to 2Mb, about 10kb to 2Mb, about 10kb to 1Mb, about 20kb to 1Mb, about 20kb to 500kb, about 50kb to 500kb, about 50kb to 200kb, about 60kb to 200kb, about 60kb to 150kb, about 80kb to 150kb, about 80kb to 120kb, or about 100kb to 120kb, or any range demarcated by any of these values (e.g., about 150kb to 1Mb).
[0193] In some embodiments, the polynucleotides of a sample are fragmented into a population of fragmented DNA molecules of one or more specific sizes. In some embodiments, the fragments may be generated from at least about 1, about 2, about 5, about 10, about 20, about 50, about 100, about 200, about 500, about 1000, about 2000, about 5000, about 10,000, about 20,000, about 50,000, about 10,000, about 20,000, about 50,000, about 100,000, about 200,000, about 500,000, about 1,000,000, about 2,000,000, about 5,000,000, about 10,000,000, or more genomic equivalents of the starting DNA. Fragmentation may be carried out by methods known in the art, including chemical, enzymatic, and mechanical fragmentation. In some embodiments, the fragments have nucleotides with an average length of approximately 10 to approximately 10,000, approximately 20,000, approximately 30,000, approximately 40,000, approximately 50,000, approximately 60,000, approximately 70,000, approximately 80,000, approximately 90,000, approximately 100,000, approximately 150,000, approximately 200,000, approximately 300,000, approximately 400,000, approximately 500,000, approximately 600,000, approximately 700,000, approximately 800,000, approximately 900,000, approximately 1,000,000, approximately 2,000,000, approximately 5,000,000, approximately 10,000,000, or more. In some embodiments, the fragments have an average length of about 1kb to about 10mb. In some embodiments, the fragments have an average length of about 1kb to 5Mb, about 5kb to 5Mb, about 5kb to 2Mb, about 10kb to 2Mb, about 10kb to 1Mb, about 20kb to 1Mb, about 20kb to 500kb, about 50kb to 500kb, about 50kb to 200kb, about 60kb to 200kb, about 60kb to 150kb, about 80kb to 150kb, about 80kb to 120kb, or about 100kb to 120kb, or any range (e.g., about 60 to 120kb) bounded by any of these values. In some embodiments, the fragments have an average length of less than about 10 Mb, less than about 5 Mb, less than about 1 Mb, less than about 500 kb, less than about 200 kb, less than about 100 kb, or less than about 50 kb.In other embodiments, the fragments have an average length of about 5kb, about 10kb, about 50kb, about 100kb, about 200kb, about 500kb, about 1Mb, about 5Mb, or about 10Mb. In some embodiments, fragmentation is carried out by mechanically exposing the sample DNA molecule to acoustic sonication. In some embodiments, fragmentation includes the step of treating the sample DNA molecule with one or more enzymes under conditions suitable for one or more enzymes to produce a breakdown of double-stranded nucleic acids. Examples of enzymes useful for generating DNA fragments include sequence-specific and sequence-independent nucleases. Not limited examples of nucleases include DNase I, fragmentases, restriction endonucleases, their variants, and combinations thereof. For example, DNase Ideno digestion is Mg. ++ The state of not having Mn ++ In the present state, random double-strand disruption in DNA can be induced. In some embodiments, fragmentation involves treating a sample DNA molecule with one or more restriction endonucleases. Fragmentation can produce fragments having 5' overhangs, 3' overhangs, blunt ends, or combinations thereof. In some embodiments, the cleavage of the sample DNA molecule, such as when fragmentation involves the use of one or more restriction endonucleases, gives the overhangs a predictable sequence. In some embodiments, the method includes a step of selecting the size of the fragments via a standard method such as column purification or isolation from an agarose gel.
[0194] In some embodiments, the 5' and / or 3' end nucleotide sequences of the fragmented DNA are not modified before ligation. For example, fragmentation with a restriction endonuclease is used to leave predictable overhangs, and then ligation of the nucleic acid ends containing overhangs complementary to the predictable overhangs is performed on the DNA fragment. In another example, enzymatic cleavage is performed to leave predictable blunt ends, and then ligation of the blunt-ended DNA fragment into nucleic acids such as adapters, oligonucleotides, or polynucleotides containing blunt ends may be performed. In some embodiments, the fragmented DNA molecule is polished (or "end-repaired") to produce a DNA fragment with blunt ends before binding to an adapter. The blunt-end polishing step can be achieved by incubation with a suitable enzyme, such as a DNA polymerase having 3'-5' exonuclease activity and 5'-3' polymerase activity, for example, T4 polymerase. In some embodiments, end repair may occur after the addition of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleotides, such as one or more adenines, one or more thymines, one or more guanines, or one or more cytosines, to generate an overhang. For example, end repair (end pairing) may occur after the addition of 1, 2, 3, 4, 5, or 6 nucleotides. DNA fragments with overhangs may be bound to one or more nucleic acids, such as oligonucleotides, adapter oligonucleotides, or polynucleotides, which have complementary overhangs, in reactions such as ligation. For example, a single adenine may be added to the 3' end of an end-repaired DNA fragment by ligation to one or more adapters, each having thymine at its 3' end, using an independent polymerase template. In some embodiments, nucleic acids such as oligonucleotides or polynucleotides can be bound to blunt-ended double-stranded DNA molecules modified by 3' end extension at one or more nucleotides, followed by 5' phosphorylation.In some cases, 3' end extension may be carried out by a polymerase such as Klenow polymerase or any suitable polymerase provided herein, in the presence of one or more dNTPs in a suitable buffer containing magnesium, or by the use of a terminal deoxynucleotide transferase. In some embodiments, a target polynucleotide having a blunt end is bound to one or more adapters containing the blunt end. Phosphorylation of the 5' end of the DNA fragment molecule may be carried out, for example, by T4 polynucleotide kinase in a suitable buffer containing ATP and magnesium. The fragmented DNA molecule may optionally be treated to dephosphorylate the 5' or 3' end using enzymes known in this art, such as phosphatases.
[0195] As used herein, the terms “connecting,” “joining,” and “ligation” refer to the covalent joining of two distinct DNA segments to produce a single, larger polynucleotide with adjacent backbones, with respect to two polynucleotides, such as an adapter oligonucleotide and a target polynucleotide. Methods for joining two DNA segments include, but are not limited to, enzymatic and non-enzymatic (e.g., chemical) methods known in the art. Examples of non-enzymatic ligation reactions include the non-enzymatic ligation techniques described in U.S. Patents 5,780,613 and 5,476,930, which are incorporated herein by reference. In some embodiments, the adapter oligonucleotide is joined to the target polynucleotide by a ligase, such as a DNA ligase or an RNA ligase. Multiple ligases, each with its own characterized reaction conditions, are known in the art and are not limited to, but include NAD+-dependent ligases, such as tRNA ligase, Taq DNA ligase, thermophilic DNA ligase, Escherichia coli DNA ligase, Tth DNA ligase, Thermus scotoductus DNA ligase (I and II), heat-stable ligase, Ampligase heat-stable DNA ligase, VanC-type ligase, 9°N DNA ligase, Tsp DNA ligase, and novel ligases discovered by bioprospecting; ATP-dependent ligases, such as T4 RNA ligase, T4 DNA ligase, T3 DNA ligase, T7 DNA ligase, Pfu DNA ligase, DNA ligase 1, DNA ligase III, DNA ligase IV, and novel ligases discovered by bioprospecting; and their wild types, mutant isoforms, and genetically engineered variants.
[0196] Ligation can occur between DNA segments having hybridizable sequences, such as complementary overhangs. Ligation can also occur between two blunt ends. Typically, a 5' phosphate is used in the ligation reaction. The 5' phosphate can be provided by a target polynucleotide, an adapter oligonucleotide, or both. The 5' phosphate can be added to or removed from the DNA segment to be ligated, as needed. Methods for adding or removing 5' phosphate are known in the art and include, but are not limited to, enzymatic and chemical processes. Enzymes useful for adding and / or removing 5' phosphate include kinases, phosphatases, and polymerases. In some embodiments, the two ends ligated in the ligation reaction (e.g., an adapter end and a target polynucleotide end) together provide a 5' phosphate so that the two covalent chains ligate the two ends. In some embodiments, a 5' phosphate is provided such that only one of the two joined ends (e.g., an adapter end and a target polynucleotide end) in a ligation reaction is formed when only one covalent chain is created when the two ends are joined.
[0197] In some embodiments, only one chain at one or both ends of the target polynucleotide is bound to the adapter oligonucleotide. In some embodiments, both chains at one or both ends of the target polynucleotide are bound to the adapter oligonucleotide. In some embodiments, the 3' phosphate is removed before ligation. In some embodiments, the adapter oligonucleotide is added to both ends of the target polynucleotide, where one or both chains at each end are bound to one or more adapter oligonucleotides. When both chains at both ends are bound to the adapter oligonucleotide, the binding may occur after a cleavage reaction that leaves a 5' overhang that can serve as a template for the extension of the corresponding 3' end, where the 3' end may or may not contain one or more nucleotides from the adapter oligonucleotide. In some embodiments, the target polynucleotide is bound to a first adapter oligonucleotide on one end and a second adapter oligonucleotide on the other end. In some embodiments, the two ends of the target polynucleotide are bound to opposite ends of a single adapter oligonucleotide. In some embodiments, the target polynucleotide and the adapter oligonucleotide to which it is bound contain blunt ends. In some embodiments, a separate ligation reaction may be performed for each sample using a different first adapter oligonucleotide containing at least one barcode sequence for each sample, so that the barcode sequence is not bound to more than one target polynucleotide in each sample. A DNA segment, or a target polynucleotide to which an adapter oligonucleotide is bound, is considered to be "tagged" by the bound adapter.
[0198] In some cases, the ligation reaction is about 0.1ng / μL, about 0.2ng / μL, about 0.3ng / μL, about 0.4ng / μL, about 0.5ng / μL, about 0.6ng / μL, about 0.7ng / μL, about 0.8ng / μL, about 0.9ng / μL, about 1.0ng / μL, about 1 .2ng / μL, approximately 1.4ng / μL, approximately 1.6ng / μL, approximately 1.8ng / μL, approximately 2.0ng / μL, approximately 2.5ng / μL, approximately 3.0ng / μL, approximately 3.5ng / μL, approximately 4.0ng / μL, approximately 4.5ng / μL, approximately 5.0ng / μL, approximately 6.0ng / μL, approximately 7. This can be performed at concentrations of 0 ng / μL, approximately 8.0 ng / μL, approximately 9.0 ng / μL, approximately 10 ng / μL, approximately 15 ng / μL, approximately 20 ng / μL, approximately 30 ng / μL, approximately 40 ng / μL, approximately 50 ng / μL, approximately 60 ng / μL, approximately 70 ng / μL, approximately 80 ng / μL, approximately 90 ng / μL, approximately 100 ng / μL, approximately 150 ng / μL, approximately 200 ng / μL, approximately 300 ng / μL, approximately 400 ng / μL, approximately 500 ng / μL, approximately 800 ng / μL, approximately 600 ng / μL, or approximately 1000 ng / μL of DNA segment or target polynucleotide. For example, ligation may be performed at concentrations of DNA segments or target polynucleotides of approximately 100 ng / μL, 150 ng / μL, 200 ng / μL, 300 ng / μL, 400 ng / μL, or 500 ng / μL.
[0199] In some cases, ligation reactions may be performed with DNA segment or target polynucleotide concentrations of approximately 0.1–1000 ng / μL, approximately 1–1000 ng / μL, approximately 1–800 ng / μL, approximately 10–800 ng / μL, approximately 10–600 ng / μL, approximately 100–600 ng / μL, or approximately 100–500 ng / μL.
[0200] In some cases, the ligation reaction may take longer than approximately 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, or 96 hours. In other cases, the ligation reaction may take longer than approximately 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, or 96 hours. For example, the ligation reaction may take between approximately 30 and 90 minutes. In some embodiments, the binding of an adapter to a target polynucleotide produces a conjugation product polynucleotide having a 3' overhang containing the nucleotide sequence derived from the adapter.
[0201] In some embodiments, after at least one adapter oligonucleotide is bound to a target polynucleotide, the 3' ends of one or more target polynucleotides are elongated using one or more bound adapter oligonucleotides as a template. For example, an adapter containing two hybridized oligonucleotides bound only to the 5' end of a target polynucleotide allows for the elongation of the unbound 3' end of the target using the bound strand of the adapter as a template, and simultaneously or subsequently, the displacement of the unbound strand. Both strands of an adapter containing two hybridized oligonucleotides may be bound to a target polynucleotide, resulting in a bound product with a 5' overhang, and the complementary 3' end can be elongated by using the 5' overhang as a template. As a further example, a hairpin adapter oligonucleotide may be bound to the 5' end of a target polynucleotide. In some embodiments, the 3' end of the target polynucleotide to be elongated contains one or more nucleotides from the adapter oligonucleotide. For target polynucleotides to which the adapter is bound on both ends, elongation may be performed on both 3' ends of a double-stranded target polynucleotide with a 5' overhang. This 3' end extension, or "fill-in," reaction generates a complementary sequence or "complement" in the template of the adapter oligonucleotide hybridized to the template, thereby filling the 5' overhang to create a double-stranded sequence region. The product is fully double-stranded if both ends of the double-stranded target polynucleotide have 5' overhangs filled by the 3' end extension of the complementary strand. Extension is carried out by any suitable polymerase known in the art, such as DNA polymerase, many of which are commercially available. DNA polymerases may have DNA-dependent DNA polymerase activity, RNA-dependent DNA polymerase activity, or DNA-dependent and RNA-dependent DNA polymerase activity. DNA polymerases may be thermally stable or non-thermally stable.Examples of DNA polymerases, though not limited to them, include Taq polymerase, Tth polymerase, Tli polymerase, Pfu polymerase, Pfutubo polymerase, Pyrobest polymerase, Pwo polymerase, KOD polymerase, Bst polymerase, Sac polymerase, Sso polymerase, Poc polymerase, Pab polymerase, Mth polymerase, Pho polymerase, ES4 polymerase, VENT polymerase, DEEPVENT polymerase, EX-Taq polymerase, LA-Taq polymerase, Expand polymerase, and Platinum polymerase. This includes Taq polymerase, Hi-Fi polymerase, Tbr polymerase, Tfl polymerase, Tru polymerase, Tac polymerase, Tne polymerase, Tma polymerase, Tih polymerase, Tfi polymerase, Klenow fragments, and their variants, modified products, and derivatives, and 3' end extension may be performed before or after pooling target polynucleotides from independent samples.
[0202] In certain embodiments, the disclosure provides methods for enriching and analyzing target nucleic acids. In some cases, the enrichment method is in a solution-based format. In some cases, the target nucleic acid may be labeled with a labeling agent. In other cases, the target nucleic acid may be crosslinked to one or more associated molecules that are labeled with a labeling agent. Examples of labeling agents include, but are not limited to, biotin, polyhistidine labeling, and chemical labeling (e.g., alkyne and azide derivatives used in click chemistry methods). Furthermore, the labeled target nucleic acid may be captured and thereby enriched by the use of a capture agent. The capture agent may be streptavidin and / or avidin, antibody, chemical moiety (e.g., alkyne, azide), and any biological, chemical, physical, or enzymatic agent used in affinity purification known in the art.
[0203] In some cases, immobilized or unimmobilized nucleic acid probes may be used to capture target nucleic acids. For example, target nucleic acids may be enriched from a sample by hybridization to the probe on a solid support or in solution. In some examples, the sample may be a genomic sample. In some examples, the probe may be an amplicon. The amplicon may contain a predetermined sequence. Furthermore, the hybridized target nucleic acid may be washed and / or eluted from the probe. The target nucleic acid may be a DNA, RNA, cDNA, or mRNA molecule.
[0204] In some cases, the enrichment method may include the steps of contacting a sample containing the target nucleic acid with a probe and binding the target nucleic acid to a solid support. In some cases, the sample may be fragmented using chemical, physical, or enzymatic methods to obtain the target nucleic acid. In some cases, the probe may be specifically hybridized to the target nucleic acid. In some cases, the target nucleic acid may have an average size of about 50–5000, about 50–2000, about 100–2000, about 100–1000, about 200–1000, about 200–800, about 300–800, about 300–600, or about 400–600 nucleotide residues. The target nucleic acid may further be separated from unbound nucleic acids in the sample. The solid support may be washed and / or eluted to obtain the enriched target nucleic acid. In some examples, the enrichment step may be repeated about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times. For example, the enrichment process may be repeated approximately one, two, or three times.
[0205] In some cases, the enrichment method includes the step of providing a probe-derived amplicon, where the probe for amplification is bound to a solid support. The solid support may include a nucleic acid probe immobilized on the support to capture a specific target nucleic acid from a sample. The probe-derived amplicon can be hybridized to the target nucleic acid. After hybridization to the probe amplicon, the target nucleic acid in the sample can be enriched by capturing the target nucleic acid hybridized from the captured probe (e.g., via a capture agent such as biotin or an antibody), and by washing and / or eluting (Figure 4). The target nucleic acid sequence can further be amplified, for example, using a PCR method to produce an amplified pool of enriched PCR products.
[0206] In some cases, the solid support may be a microarray, slide, chip, microwell, column, tube, particle, or bead. In some examples, the solid support may be coated with streptavidin and / or avidin. In other examples, the solid support may be coated with antibody. Furthermore, the solid support may include glass, metal, ceramic, or polymer material. In some embodiments, the solid support may be a nucleic acid microarray (e.g., a DNA microarray). In other embodiments, the solid support may be a paramagnetic bead.
[0207] In some cases, enrichment methods may include digestion with a second restriction enzyme, self-ligation (e.g., self-circularization), and re-digestion with the original restriction enzyme. In certain examples, only the ligation product is linearized and available for adapter ligation and sequencing. In other cases, the ligation binding sequence itself may be used for hybridization-based enrichment using a complementary bait probe.
[0208] In certain embodiments, the disclosure provides a method for amplifying enriched DNA. In some cases, the enriched DNA is a read pair. The read pair can be obtained by the method of the disclosure.
[0209] In some embodiments, one or more amplification and / or replication steps are used to prepare a library to be sequenced. Any amplification method known in the art may be used. Examples of amplification techniques that may be used include, but are not limited to, quantitative PCR, quantitative fluorescence PCR (QF-PCR), multiplex fluorescence PCR (MF-PCR), real-time PCR (RTPCR), single-cell PCR, restriction fragment length polymorphism PCR (PCR-RFLP), PCK-RFLPIRT-PCR-IRFLP, hot-start PCR, nested PCR, insights polony PCR, insights rolling circle amplification (RCA), cross-linking PCR, ligation-mediated PCR, Qb replicase amplification, reverse PCR, picotiter PCR, and emulsion PCR. Other suitable amplification methods include ligase chain reaction (LCR), transcriptional amplification, auto-persistent sequence replication, selective amplification of target polynucleotide sequences, consensus sequence-primed polymerase chain reaction (CP-PCR), arbitrary-primed polymerase chain reaction (AP-PCR), degenerate oligonucleotide-primed PCR (DOP-PCR), and nucleic acid sequence amplification (NABSA). Other amplification methods that may be used herein include those described in U.S. Patents 5,242,794; 5,494,810; 4,988,617; and 6,582,938.
[0210] In certain embodiments, PCR is used to amplify DNA molecules after they have been distributed into individual segments. In some cases, one or more specific priming sequences within an amplification adapter are utilized for PCR amplification. The amplification adapter can be ligated to the fragmented DNA molecules before or after distribution into individual segments. A polynucleotide containing an amplification adapter with appropriate priming sequences at both ends may undergo exponentially amplified PCR. A polynucleotide with only one appropriate priming sequence may only undergo linear amplification, for example, due to the incomplete ligation effect of the amplification adapter containing the priming sequence. Furthermore, if an adapter containing an appropriate priming sequence is not ligated, the polynucleotide may be removed en masse from amplification, such as PCR amplification. In some embodiments, the number of PCR cycles varies between 10 and 30, but can be as low as 9, 8, 7, 6, 5, 4, 3, 2, or fewer, or as high as 40, 45, 50, 55, 60, or more. As a result, exponentially amplifiable fragments carrying amplification adapters with appropriate priming sequences can be present at much higher concentrations (more than 1000 times) after PCR amplification compared to linearly amplifiable or non-amplifiable fragments.The advantages of PCR compared to whole genome amplification techniques (such as amplification with randomized primers or multiple displacement amplification using phi29 polymerase) include, but are not limited to, a more uniform range of relative sequence application (because each fragment can be copied at most once per cycle, and amplification is controlled by a thermal cycling program), substantially lower rates of chimeric molecule formation than MDA (Lasken et al., 2007, BMC Biotechnology) (because chimeric molecules raise significant problems regarding accurate sequence assembly by presenting non-biological sequences in the assembly graph, resulting in faster rates of misassembly or very obscure and fragmented assembly), reduced sequence-specific bias that can result from the binding of randomized primers commonly used in MDA compared to the use of specific priming sites with specific sequences, higher reproducibility in the amount of final amplified DNA product which can be controlled by the selection of the number of PCR cycles, and higher fidelity in replication using polymerases commonly used in PCR compared to common whole genome amplification techniques known in the art.
[0211] In some embodiments, the packing reaction is performed after or as part of the amplification of one or more target polynucleotides using first and second primers, wherein the first primer comprises a sequence that hybridizes to at least a portion of one or more complements of a first adapter oligonucleotide, and the second primer comprises a sequence that hybridizes to at least a portion of one or more complements of a second adapter oligonucleotide. Each of the first and second primers is a nucleotide of any suitable length, approximately 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, or 100 or more, or less, or longer, and some or all of them may be complementary to the corresponding target sequence (e.g., approximately 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more, or less, or longer). For example, approximately 10 to 50 nucleotides may be complementary to the corresponding target sequence.
[0212] In some cases, amplification adapters are used in the library generation process. An amplification adapter is an oligomer pair that shares partially inverse complementarity, thereby allowing the oligomer pair to anneal to form a molecule with both double-stranded and single-stranded portions. The use of amplification adapters allows for the linking of distinct annealing targets to each end of the library molecule. Because the single single-stranded portion of the amplification adapter contains a non-inversely complementary sequence, primers are available that anneal only to one or the other single-stranded arm of the amplification adapter, or to the inverse complementarity of the other. Thus, amplification adapters allow for the addition of a first distinct primer binding site to the first end of the library molecule and a second distinct primer binding site to the second end of the library molecule.
[0213] The oligos suitable for generating the amplification adapter are listed below (* indicates a phosphorothioate bond). The oligos are listed as P5 / P7 pairs, and each P7 oligo is synthesized to act with the P5 oligo directly preceding it. For each pair, the last 10 nucleotide bases before the phosphothioate bond of the P5 oligo are inversely complementary to the first 10 bases after / 5Phos / of the second oligo.
[0214] [Table 1]
[0215] "Amplification" refers to any process in which the copy number of a target sequence is increased. In some cases, a replication reaction may produce only a single complementary copy / replica of a polynucleotide. Methods for the amplification of a target polynucleotide directed toward primers are known in the art and include, but are not limited to, methods based on polymerase chain reaction (PCR). Preferred conditions for amplification of a target sequence by PCR known in the art are optimized at various steps in the process and depend on the characteristics of the elements in the reaction, such as the type of target, the concentration of the target, the length of the sequence to be amplified, the sequences of the target and / or one or more primers, the length of the primers, the concentration of the primers, the polymerase used, the reaction volume, the ratio of one or more elements to one or more other elements, and others, some or all of which may be modified. Generally, PCR involves the steps of denaturation of the target to be amplified (in the case of double-stranded sequences), hybridization of one or more primers toward the target, and extension of the primers by DNA polymerase, and the steps are repeated (or "cycled") to amplify the target sequence. The steps in this process can be optimized for various purposes, such as increasing yield, reducing the formation of false products, and / or increasing or decreasing the specificity of primer annealing. Methods of optimization are well known in the art and include adjustments to the type or amount of elements in the amplification reaction, and / or to the conditions of a given step in the process, such as the temperature in a particular step, the duration of a particular step, and / or the number of cycles.
[0216] In some embodiments, the amplification reaction may include at least about 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, or more cycles. In some examples, the amplification reaction may include at least about 20, 25, 30, 35, or 40 cycles. In some embodiments, the amplification reaction includes only about 5, 10, 15, 20, 25, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, or more cycles. A cycle may include any number of steps, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more. The process includes, but is not limited to, 3' end extension (e.g., adapter packing), primer annealing, primer extension, and chain denaturation, and includes a temperature or temperature gradient appropriate to achieve the objective of the given process. The process is of any duration, but is not limited to, approximately 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 180, 240, 300, 360, 420, 480, 540, 600, 1200, 1800 or more, or less or more. Any number of cycles containing different processes can be combined in any order. In some embodiments, different cycles involving different steps are combined, resulting in a total number of cycles in the combination being approximately 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, or 200 or more, or less or more. In some embodiments, amplification is performed after the packing reaction.
[0217] In some embodiments, the amplification reaction may be carried out on target DNA molecules of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 40, 50, 100, 200, 300, 400, 500, 600, 800, or 1000 ng. In other embodiments, the amplification reaction may be carried out on target DNA molecules of less than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 40, 50, 100, 200, 300, 400, 500, 600, 800, or 1000 ng.
[0218] Amplification can be performed before or after pooling target polynucleotides from independent samples.
[0219] The method of this disclosure includes the step of determining the amount of amplifiable nucleic acid present in a sample. Any known method is used to quantify amplifiable nucleic acid, and a typical method is polymerase chain reaction (PCR), specifically quantitative polymerase chain reaction (qPCR). qPCR is a polymerase chain reaction-based technique used to amplify and simultaneously quantify a targeted nucleic acid molecule. qPCR allows for both the detection and quantification of specific sequences in a DNA sample (as copies or absolute relative quantities when standardized to DNA input or additional standardized genes). The procedure follows the common principles of polymerase chain reaction, with the additional feature that the amplified DNA is quantified as it accumulates in the reaction in real time after each amplification cycle. QPCR is described, for example, by Kurnit et al. (US Patent No. 6,033,854), Wang et al. (US Patents No. 5,567,583 and 5,348,853), Ma et al. (The Journal of American Science, 2(3), 2006), Heid et al. (Genome Research 986-994, 1996), Sambrook and Russell (Quantitative PCR, Cold Spring Harbor Protocols, 2006), and Higuchi (US Patents No. 6,171,785 and 5,994,056). The contents of these are incorporated herein by reference in whole.
[0220] Other methods of quantification include the use of fluorescent dyes inserted into double-stranded DNA and modified DNA oligonucleotide probes that fluoresce when hybridized with complementary DNA. These methods are widely applicable, but are particularly suitable for real-time PCR, as described in more detail as an example. In the first method, the DNA-binding dye binds to all double-stranded (ds)DNA in PCR, resulting in the fluorescence of the dye. Therefore, the increase in DNA product during PCR leads to an increase in fluorescence intensity, which is measured in each cycle, thus enabling the quantification of DNA concentration. The reaction is prepared similarly to a standard PCR reaction by adding a fluorescent (ds)DNA dye. The reaction is performed in a thermocycler, and after each cycle, the fluorescence level is compared with a detector; the dye fluoresces only when bound to (ds)DNA (i.e., PCR product). With respect to a standard dilution, the (ds)DNA concentration in PCR can be measured. As with other real-time PCR methods, the obtained value does not have an absolute unit associated with it. Comparing a measured DNA / RNA sample with a standard dilution provides a fraction or ratio of the sample relative to the standard, enabling relative comparisons between different tissues or experimental conditions. Ensuring accuracy in the quantification and / or expression of target genes can be standardized with respect to stably expressed genes. The copy number of an unknown gene can similarly be standardized with respect to a gene with a known copy number.
[0221] The second method uses a sequence-specific RNA or DNA-based probe to quantify only the DNA containing the probe sequence; therefore, the use of a reporter probe significantly increases specificity, enabling quantification even in the presence of some nonspecific DNA amplification. This allows for multiplexing, i.e., assays for various genes in the same reaction using specific probes with differently colored labels, provided that all genes are amplified with a similar effect.
[0222] This method is commonly performed with DNA-based probes having a fluorescent reporter (e.g., 6-carboxyfluorescein) at one end and a quencher (e.g., 6-carboxytetramethylrhodamine) at the opposite end. The proximity of the reporter to the quencher prevents detection of its fluorescence. Destruction of the probe by the 5'-3' exonuclease activity of a polymerase (e.g., Taq polymerase) disrupts the reporter-quencher proximity, thus allowing unquenched fluorescence emission that can be detected. As a result of the increase in the product targeted by the reporter probe in each PCR cycle, a proportional increase in fluorescence occurs due to probe destruction and reporter release. The reaction is prepared similarly to a standard PCR reaction, and the reporter probe is added. Once the reaction begins, both the probe and primers are annealed to the DNA target during the annealing step of the PCR. Polymerization of the new DNA strand begins with the primer, and once the polymerase reaches the probe, its 5'-3'-exonuclease degrades the probe, physically separating the fluorescent reporter from the quencher, resulting in an increase in fluorescence. The fluorescence is detected and measured in a real-time PCR thermocycler, and the geometric increase in fluorescence corresponding to the exponential increase in the product is used to determine the threshold cycle in each reaction.
[0223] The relative concentration of DNA present during the logarithmic phase of the reaction is determined by plotting fluorescence against the number of cycles on a logarithmic scale (thus exponentially increasing quantities yield a straight line). A threshold for detecting fluorescence above the background is determined. The number of cycles at which fluorescence from the sample crosses the threshold is called the cycle threshold, Ct. Since the amount of DNA doubles in every cycle during the logarithmic phase, the relative amount of DNA can be calculated, for example, the Ct of three cycles that are faster than the others. t The sample that has 2 3 =Having a template of 8 times or more. Subsequently, the amount of nucleic acid (e.g., RNA or DNA) is determined by comparing the result with a standard curve (e.g., no dilution, 1:4, 1:16, 1:64) produced by real-time PCR of serial dilutions of known amounts of nucleic acid.
[0224] In certain embodiments, the qPCR reaction involves a dual fluorophore method utilizing fluorescence resonance energy transfer (FRET), such as a LIGHTCYCLER hybridization probe, where two oligonucleotide probes are annealed to an amplicon (see, for example, U.S. Patent No. 6,174,670). The oligonucleotides are designed to hybridize in a head-tail orientation with fluorophores separated by a distance suitable for effective energy transfer. Other examples of labeled oligonucleotides structured to emit a signal when bound to nucleic acids or incorporated into extension products include: SCORPIONS probes (e.g., Whitcombe et al., Nature Biotechnology 17:804-807, 1999, and U.S. Patent No. 6,326,145), Sunrise (or AMPLIFLOUR) primers (e.g., Nazarenko et al., Nuc. Acids Res. 25:2516-2521, 1997, and U.S. Patent No. 6,117,635), and LUX primers, as well as MOLECULAR BEACONS probes (e.g., Tyagi et al., Nature Biotechnology 14:303-308, 1996, and U.S. Patent No. 5,989,823).
[0225] In other embodiments, the qPCR reaction uses the fluorescent Taqman method and an instrument capable of measuring fluorescence in real time (e.g., an ABI Prism 7700 Sequence Detector). The Taqman reaction uses a hybridization probe labeled with two different fluorescent dyes. One dye is a reporter dye (6-carboxyfluorescein), and the other is a quench dye (6-carboxytetramethylrhodamine). When the probe is intact, a fluorescence energy transfer occurs, and the fluorescent emission of the reporter dye is absorbed by the quench dye. During the extension step of the PCR cycle, the fluorescent hybridization probe is cleaved by the 5'-3' nucleolytic activity of DNA polymerase. Upon cleavage of the probe, the emission of the reporter dye is no longer efficiently transferred to the quench dye, resulting in a fluorescence emission spectrum of the reporter dye. Any nucleic acid quantification method, including real-time methods or single-point detection methods, can be used to quantify the amount of nucleic acid in a sample. Detection can be performed by a variety of different methods (e.g., staining, hybridization with labeled probes; incorporation of biotinylated primers and subsequent detection of avidin-enzyme binding; incorporation of 32P-labeled deoxynucleotide triphosphates such as dCTP or dATP into the amplified segment), as well as other suitable detection methods known in the art for nucleic acid quantification. Quantification may or may not include an amplification step.
[0226] In some embodiments, the disclosure provides labels for identifying or quantifying ligated DNA segments. In some cases, ligated DNA segments may be labeled to assist in downstream applications such as array hybridization. For example, ligated DNA segments may be labeled using random priming or nick translation.
[0227] Various labels (e.g., reporters) may be used to label the nucleotide sequences described herein, including, but not limited to, during the amplification process. Suitable labels include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as ligands, cofactors, inhibitors, magnetic particles, and the like. Examples of such labels are included in U.S. Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241, which are incorporated by reference throughout.
[0228] Additional labels include, but are not limited to, β-galactosidase, invertase, green fluorescent protein, luciferase, chloramphenicol, acetyltransferase, β-glucuronidase, exo-glucanase, and glucoamylase. Fluorescent labels may also be used in the same way as fluorescent reagents specifically synthesized with particular chemical properties. A variety of methods for measuring fluorescence are available. For example, some fluorescent labels show changes in excitation or emission spectra, some fluorescent labels show resonance energy transitions where one fluorescent reporter loses fluorescence while a second fluorescent label increases fluorescence, some fluorescent labels show disappearance (quenching) or appearance of fluorescence, and some fluorescent labels report rotational motion.
[0229] Furthermore, to obtain sufficient material for labeling, multiple amplifications can be pooled instead of increasing the number of amplification cycles per reaction. Alternatively, labeled nucleotides can be incorporated in the final cycle of the amplification reaction, for example, 30 cycles of PCR (unlabeled) + 10 cycles of PCR (labeled).
[0230] In certain embodiments, the Disclosure provides probes capable of binding to linked DNA segments. As used herein, the term “probe” refers to a molecule capable of hybridizing to another molecule of interest (e.g., another oligonucleotide), whether spontaneously occurring in a purified restriction digest, or produced synthetically, recombinantly, or by PCR amplification. If the probe is an oligonucleotide, it may be single-stranded or double-stranded. Probes are useful for the detection, identification, and isolation of specific targets (e.g., gene sequences). In some cases, the probe may be associated with a label that makes it detectable in any detection system, including, but not limited to, enzymes (e.g., enzyme-based histochemical assays in addition to ELISA), fluorescence, radioactivity, and luminescence systems.
[0231] With respect to arrays and microarrays, the term “probe” is used to refer to any hybridizable material immobilized on the array for detecting nucleotide sequences hybridized to the probe. In some cases, the probe may be approximately 10 bp–500 bp, approximately 10 bp–250 bp, approximately 20 bp–250 bp, approximately 25 bp–200 bp, approximately 25 bp–100 bp, approximately 30 bp–100 bp, or approximately 30 bp–80 bp. In some cases, the probe may be approximately 10 bp, approximately 20 bp, approximately 30 bp, approximately 40 bp, approximately 50 bp, approximately 60 bp, approximately 70 bp, approximately 80 bp, approximately 90 bp, approximately 100 bp, approximately 150 bp, approximately 200 bp, approximately 250 bp, approximately 300 bp, approximately 400 bp, or approximately 500 bp in length. For example, the probe may be approximately 20–50 bp in length. Examples of probe designs and their rationale can be found in WO95 / 11995, EP717,113, and WO97 / 29212.
[0232] In some cases, one or more probes may be designed to hybridize to a site digested by restriction enzymes. For example, probes may be located within restriction enzyme recognition sites of approximately 10 bp, 20 bp, 30 bp, 40 bp, 50 bp, 60 bp, 70 bp, 80 bp, 90 bp, 100 bp, 150 bp, 200 bp, 250 bp, 300 bp, 400 bp, or 500 bp.
[0233] In other cases, a single, unique probe may be designed to be located at approximately 10 bp, 20 bp, 30 bp, 40 bp, 50 bp, 60 bp, 70 bp, 80 bp, 90 bp, 100 bp, 150 bp, 200 bp, 250 bp, 300 bp, 400 bp, or 500 bp on each side of the restriction enzyme-digested site. The probe may be designed to be hybridizable on any side of the restriction enzyme-digested site. For example, a single probe for each side of the major restriction enzyme recognition site can be used.
[0234] In some cases, two, three, four, five, six, seven, eight, or more probes may be designed on each side of a restriction enzyme recognition site that can later be used to investigate the same ligation event. For example, two or three probes may be designed on each side of a restriction enzyme recognition site. In some cases, the use of multiple probes (e.g., two, three, four, five, six, seven, or eight, or more) per major restriction enzyme recognition site may be useful in minimizing the problem of obtaining false negatives resulting from individual probes.
[0235] As used herein, the term “set of probes” refers to a set or collection of probes capable of hybridizing to one or more major restriction enzyme recognition sites for major restriction enzymes in the genome.
[0236] In some cases, a set of probes may be sequence-complementary to nucleic acid sequences adjacent to one or more major restriction enzyme recognition sites for restriction enzymes in genomic DNA. For example, a set of probes may be sequence-complementary to nucleotides of approximately 10 bp–500 bp, 10 bp–250 bp, 20 bp–250 bp, 25 bp–200 bp, 25 bp–100 bp, 30 bp–100 bp, or 30 bp–80 bp adjacent to one or more restriction enzyme recognition sites in genomic DNA. A set of probes may be sequence-complementary to one (e.g., any) side or both sides of a restriction enzyme recognition site. Therefore, probes may be sequence-complementary to nucleic acid sequences adjacent to each of one or more sides of major restriction enzyme recognition sites in genomic DNA. Furthermore, the probe set may be sequence-complementary for nucleic acid sequences where one or more major restriction enzyme recognition sites in genomic DNA are approximately 10 bp, 20 bp, 30 bp, 40 bp, 50 bp, 60 bp, 70 bp, 80 bp, 90 bp, 100 bp, 150 bp, 200 bp, 250 bp, 300 bp, 400 bp, or less than approximately 500 bp.
[0237] In some cases, two or more probes may be designed to hybridize to sequences adjacent to one or more restriction enzyme recognition sites in genomic DNA. The probes may overlap or partially overlap.
[0238] A probe, an array of probes, or a set of probes can be immobilized on a support. The support (e.g., a solid support) can be made of a variety of materials such as glass, silica, plastic, nylon, or nitrocellulose. The support is preferably rigid and has a flat surface. The support may have about 1 to 10,000,000 degraded gene loci. For example, a support material may have approximately 10–10,000,000, 10–5,000,000, 100–5,000,000, 100–4,000,000, 1,000–4,000,000, 1,000–3,000,000, 10,000–3,000,000, 10,000–2,000,000, 100,000–2,000,000, or approximately 100,000–1,000,000 degraded loci. The density of degraded loci may be at least approximately 10, 100, 1,000, 10,000, 100,000, or 1,000,000 degraded loci per square centimeter. In some cases, each degraded locus may be occupied by up to >95% of a single type of oligonucleotide. In other cases, each degraded locus may be occupied by a pooled mixture of probes or a set of probes. In some cases, several degraded loci are occupied by a pooled mixture of probes or a set of probes, while others are occupied by >95% of a single type of oligonucleotide.
[0239] In some cases, the number of probes for a given nucleotide sequence on an array may be far too excessive for the DNA sample being hybridized to such an array. For example, an array could have approximately 10, 100, 1,000, 10,000, 100,000, 1,000,000, or 100,000,000 times the amount of DNA in the input sample.
[0240] In some cases, the array may have approximately 10, 100, 1,000, 10,000, 100,000, 1,000,000, 10,000,000, or 1,000,000,000 probes.
[0241] Probe arrays or sets may be synthesized in a stepwise manner on a support or conjugated in a pre-synthesized form. One synthesis method is VLSIPS® (described in U.S. Patent No. 5,143,854 and EP476,014), which involves the use of light to direct the synthesis of oligonucleotide probes in a high-density, miniaturized array. Algorithms for designing masks to reduce the number of synthesis cycles are described in U.S. Patent Nos. 5,571,639 and 5,593,839. Arrays may also be synthesized in combination by delivering monomers to cells on a support via mechanically restricted channels, as described in EP624,059. Arrays may also be synthesized by spotting reagents onto a support using an inkjet printer (see, for example, EP728,520).
[0242] In some embodiments, the present disclosure provides a method for hybridizing DNA segments ligated onto an array. “Substrate” or “array” is a deliberately created collection of nucleic acids, prepared either synthetically or biosynthetically, and screened for biological activity in a variety of different formats (e.g., libraries of soluble molecules; and libraries of oligonucleotides constrained to resin beads, silica chips, or other solid supports). In addition, the term “array” includes such libraries of nucleic acids that can be prepared by ligating nucleic acids of substantially any length (e.g., nucleotide monomers ranging from 1 to about 1000 in length) onto a substrate.
[0243] Array technology, various related technologies, and their applications are commonly described in numerous textbooks and documents. For example, these documents include: Lemieux et al., 1998, Molecular Breeding 4, 277-289; Schena and Davis, Parallel Analysis with Biological Chips. in PCR Methods Manual (eds. M. Innis, D. Gelfand, J. Sninsky); Schena and Davis, 1999, Genes, Genomes and Chips. In DNA Microarrays: A Practical Approach (ed. M. Schena), Oxford University Press, Oxford, UK, 1999); The Chipping Forecast (Nature Genetics special issue; January 1999 Supplement); Mark Schena (Ed.), Microarray Biochip Technology, (Eaton Publishing Company); Cortes, 2000, The Scientist 14
[17] :25; Gwynn and Page, Microarray analysis: the next revolution in molecular biology, Science, 1999 Aug. 6; and Eakins and Chu, 1999, Trends in Biotechnology, 17, 217-218 is cited.
[0244] Typically, any library can be arranged in an orderly manner in an array by spatially separating the members of the library. Examples of libraries suitable for arrangement include, among other things, nucleic acid libraries (including libraries of DNA and cDNA, oligonucleotides, etc.), peptides, polypeptides, and protein libraries, as well as libraries containing any molecule, such as ligand libraries.
[0245] Libraries can be immobilized or fixed onto a solid phase (e.g., a solid substrate) to restrict the diffusion and mixing of members. In some cases, libraries of DNA-binding ligands can be prepared. In particular, libraries can be immobilized on substantially flat solid phases, including membranes and non-porous substrates such as plastics and glass. Furthermore, libraries can be arranged in a manner that facilitates indexing (i.e., reference to or access to specific members). In some examples, members of the library can be applied as spots in a lattice configuration. Common assay systems may be suitable for this purpose. For example, arrays can be immobilized on the surface of microplates having multiple members per well, or one member per well. Furthermore, the solid substrate may be a membrane, such as a nitrocellulose or nylon membrane (e.g., a membrane used to blot experiments). Alternative substrates include glass or silica-based substrates. Thus, libraries can be immobilized by suitable methods known in the art, e.g., charge interactions or chemical bonding to the walls or bottoms of the wells or to the surface of a membrane. In the case of silicon-based chips where other means of placement and fixation, such as pipetting, drop-touch, piezoelectric means, inkjet and bubble jet technologies, and electrostatic application may be used, photolithography may be used to place and fix libraries on the chip.
[0246] Libraries are deployed by "spotting" them onto a solid substrate; this may be done manually or by utilizing robotics to deposit the members. Generally, arrays may be described as macroarrays or microarrays, the difference being the size of the spots. Macroarrays contain spot sizes of approximately 300 microns or more and can be readily imaged with existing gel and blot scanners. Spot sizes in microarrays are less than 200 microns in diameter, and these arrays typically contain thousands of spots. Therefore, microarrays may require specialized robotics and imaging equipment, which are typically custom-made instruments as reported by Cortese, 2000, The Scientist 14
[11] :26.
[0247] Techniques for producing immobilized libraries of DNA molecules have been described in the art. Typically, most prior art methods describe methods for synthesizing single-stranded nucleic acid molecular libraries, for example, by using masking techniques to construct various sortings of sequences at various distinct locations on a solid substrate. U.S. Patent No. 5,837,832 describes an improved method for producing DNA arrays immobilized on a silicon substrate based on ultra-large-scale integrated circuit technology. In particular, U.S. Patent No. 5,837,832 describes a strategy called "tiling" for synthesizing a specific set of probes at spatially defined locations on a substrate that may be used to produce the immobilized DNA libraries of this disclosure. U.S. Patent No. 5,837,832 also provides references to earlier techniques that may be used. In other cases, arrays may also be constructed using photodeposition chemistry.
[0248] Arrays of peptides (or peptide mimes) can also be synthesized on a surface in which each member of a separate library (e.g., a unique peptide sequence) is placed at a separate, predetermined location within the array. The identity of each library member is determined by its spatial location within the array. The location within the array where a binding interaction occurs between a predetermined molecule (e.g., a target or probe) and a reactive library member is determined, thereby allowing for the spatial identification of the sequence of the reactive library member. These methods are described in U.S. Patent No. 5,143,854; WO90 / 15070 and WO92 / 10092; Fodor et al. (1991) Science, 251: 767; Dower and Fodor (1991) Ann. Rep. Med. Chem., 26: 271.
[0249] To aid detection, any readily detectable reporter can be used, such as fluorescent, bioluminescent, phosphorescent, or radioactive reporters (as discussed above). Such reporters, their detection, and binding to targets / probes are discussed elsewhere in this document. Labeling of probes and targets is also disclosed in Shalon et al., 1996, Genome Res 6(7):639-45.
[0250] Examples of some commercially available microarray formats are listed in Table 1 below (see also Marshall and Hodgson, 1998, Nature Biotechnology, 16(1), 27-31).
[0251] [Table 2-1]
[0252] [Table 2-2]
[0253] To generate data from array-based assays, signals may be detected to indicate the presence or absence of hybridization between the probe and the nucleotide sequence. Furthermore, direct and indirect labeling techniques may also be utilized. For example, direct labeling involves directly incorporating a fluorescent dye into the nucleotide sequence that hybridizes to the array-associated probe (e.g., the dye is incorporated into the nucleotide sequence by enzymatic synthesis in the presence of labeled nucleotides or PCR primers). Direct labeling schemes can be easily implemented and yield robust hybridization signals, for example, by using a family of fluorescent dyes with similar chemical structures and characteristics. When direct labeling of nucleic acids is involved, cyanine or Alexa analogs may be used in multiple-fluor comparative array analyses. In other embodiments, indirect labeling schemes may be used to incorporate epitopes into nucleic acids before or after hybridization to microarray probes. One or more staining procedures and reagents may be used to label hybridized complexes (e.g., fluorescent molecules that bind to epitopes, thereby producing a fluorescent signal through the binding of the dye molecule to the epitope of the hybridized species).
[0254] In various embodiments, suitable sequencing methods described herein or known in the art are used to obtain sequence information from nucleic acid molecules in a sample. Sequencing may be performed through classical Sanger sequencing methods well known in the art. Sequencing may also be performed using high-throughput systems, some of which enable the detection of sequenced nucleotides immediately or at the time of incorporation into the growing chain, i.e., real-time or near-real-time sequence detection. In some cases, high-throughput sequencing generates at least 1,000, at least 5,000, at least 10,000, at least 20,000, at least 30,000, at least 40,000, at least 50,000, at least 100,000, or at least 500,000 sequence reads per hour; where a sequence read may have at least about 50, about 60, about 70, about 80, about 90, about 100, about 120, about 150, about 180, about 210, about 240, about 270, about 300, about 350, about 400, about 450, about 500, about 600, about 700, about 800, or about 1000 bases per read.
[0255] In some embodiments, high-throughput sequencing involves using techniques available through Illumina's Genome Analyzer IIX, MiSeq personal sequencers, or HiSeq systems, such as using HiSeq 2500, HiSeq 1500, HiSeq 2000, or HiSeq 1000 machines. These machines use reversible terminator-based sequences derived from synthetic chemistry. These machines can read more than 200 billion DNA samples in 8 days. Smaller systems may be available for execution within 3, 2, or 1 day or less.
[0256] In some embodiments, high-throughput sequencing involves the use of techniques available through the ABI Solid System. This gene analysis platform, which enables ultra-parallel sequencing of cloned amplified DNA fragments, is linked to beads. The sequencing methodology is based on sequential ligation with dye-labeled oligonucleotides.
[0257] Next-generation sequencing may include ion-semiconductor sequencing (e.g., using Life Technologies (Ion Torrent) technology). Ion-semiconductor sequencing can utilize the fact that ions can be released when nucleotides are incorporated into the DNA strand. To perform ion-semiconductor sequencing, a high-density array of microfabricated wells can be formed. Each well can hold a single DNA template. Below the wells is an ion-sensitive layer, and below the ion-sensitive layer may be an ion sensor. When a nucleotide is added to the DNA, H+ is released, which can be measured as a change in pH. The H+ ions can be converted into a voltage and recorded by the semiconductor sensor. The array chip may be continuously flooded with one nucleotide at a time. Scanning, light, or a camera is not required. In some cases, an IONPROTON® sequencer is used to sequence nucleic acids. In some cases, an IONPGM® sequencer is used. Ion Torrent Personal Genome Machine (PGM). The PGM can perform 10 million reads in 2 hours.
[0258] In some embodiments, high-throughput sequencing involves the use of techniques available from Helicos BioSciences Corporation (Cambridge, Massachusetts), such as the Single Molecule Sequencing by Synthesis (SMSS) method. SMSS is unique because it enables sequencing of the entire human genome in up to 24 hours. Ultimately, SMSS is partially described in U.S. Patent Applications Publications 20060024711; 20060024678; 20060012793; 20060012784; and 20050100932.
[0259] In some embodiments, high-throughput sequencing involves the use of technology available from 454 Lifesciences, Inc. (Branford, Connecticut), such as the PicoTiterPlate instrument, which includes a fiber optic plate that transmits a chemiluminescent signal generated by the sequencing reaction recorded by a CCD camera in the instrument. The use of this fiber optic enables the detection of at least 20 million base pairs in 4.5 hours.
[0260] The method using bead amplification followed by fiber optics detection is described in Marguiles, M., et al. “Genome sequencing in microfabricated high-density picolitre reactors”, Nature, doi:10.1038 / nature03959; Similarly, as described in U.S. Patent Application Publications No. 20020012930; No. 20030068629; No. 20030100102; No. 20030148344; No. 20040248161; No. 20050079510; No. 20050124022; and No. 20060078909.
[0261] In some embodiments, high-throughput sequencing is performed using a Clonal Single Molecule Array (Solexa, Inc.) or sequencing-by-synthesis (SBS) utilizing reversible terminator chemistry. These techniques are partially described in U.S. Patent Nos. 6,969,488; 6,897,023; 6,833,246; 6,787,308; and U.S. Patent Publication Nos. 20040106110; 20030064398; 20030022207; and Constans, A., The Scientist 2003, 17(13):36.
[0262] Next-generation sequencing technologies may include real-time sequencing (SMRT®) technology from Pacific Biosciences. In SMRT, each of the four DNA bases can be attached to one of four different fluorescent dyes. These dyes can be phospho-linked. A single DNA polymerase can be immobilized on a single molecule of template single-stranded DNA at the bottom of a zero-mode waveguide (ZMW). The ZMW can be a constraint structure that allows observation of the incorporation of a single nucleotide by DNA polymerase against a background of fluorescent nucleotides that can rapidly diffuse (in microseconds) in and out of the ZMW. Incorporation of the nucleotide into the growing strand may take several milliseconds. During this time, the fluorescent label can be excited and produce a fluorescent signal, and the fluorescent label can be cleaved. The ZMW can be illuminated from below. Attenuated light from the excitation beam can penetrate each of the lower 20-30 nm ZMWs. A microscope with a detection limit of 20 zeptolters (10" liters) can be constructed. Small detection volumes can result in a 1000-fold improvement in reducing background noise. Detection of the corresponding fluorescence of the dye can indicate which bases are incorporated. This process can be repeated.
[0263] In some cases, next-generation sequencing is nanopore sequencing (see, e.g., Soni GV and Meller A. (2007) Clin Chem 53: 1996-2001). Nanopores can be tiny holes with a diameter of about 1 nanometer. Immersion of nanopores in a conductive fluid and the application of a potential across them can result in a small current due to the conduction of ions dissolving the nanopores. The amount of current flowing can be sensitive to the size of the nanopore. As a DNA molecule passes through a nanopore, each nucleotide on the DNA molecule can block the nanopore to a different degree. Therefore, changes in the current passing through the nanopore as a DNA molecule passes through it can represent reads of the DNA sequence. Nanopore sequencing techniques may originate from Oxford Nanopore Technologies; for example, the GridlON system. A single nanopore can be inserted into a polymer membrane spanning the top of a microwell. Each microwell may have an electrode for individual sensing. Microwells can be assembled into array chips with more than 100,000 microwells per chip (e.g., 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, or more than 1,000,000). Instruments (or nodes) can be used to analyze the chips. Data can be analyzed in real time. One or more instruments can be operated simultaneously. Nanopores can be protein nanopores, e.g., protein alpha-hemolysin, heptameric protein pores. Nanopores can be solid-state nanopores, e.g., synthetic membranes (e.g., SiN). xThese can be nanometer-sized holes formed in (or SiO2). Nanopores can be hybrid pores (e.g., integration of protein pores into a solid-state membrane). Nanopores can have integrated sensors (e.g., tunnel electrode detectors, volume detectors, or graphene nanogap or edge-state detectors (see, e.g., Garaj et al. (2010) Nature vol. 67, doi: 10.1038 / nature09379)). Nanopores can be functionalized to analyze specific types of molecules (e.g., DNA, RNA, or protein). Nanopore sequencing can include "strand sequencing," where a complete DNA polymer can pass through protein nanopores while being sequenced in real time as the DNA moves through the pores. Enzymes can separate the strands of double-stranded DNA and provide the strands through the nanopores. The DNA may have a hairpin at one end, and the system can read both strands. In some cases, nanopore sequencing is "exonuclease sequencing," where individual nucleotides can be cleaved from the DNA strand by a forward-moving exonuclease, and these nucleotides can then pass through protein nanopores. The nucleotides can transiently bind to molecules within the pore (e.g., cyclodextran). Characteristic discontinuities of electric current are used to identify the bases.
[0264] GENIA's nanopore sequencing technology can be used. Manipulated protein pores can be embedded in a lipid bilayer membrane. Active control technology is used to enable effective nanopore-membrane assembly and control of DNA movement through channels. In some cases, the nanopore sequencing technology is from NABsys. Genomic DNA can be fragmented into strands with an average length of approximately 100kb. 100kb fragments can be single-stranded and then hybridized with 6-mer probes. Genomic fragments with probes can pass through nanopores, creating current-vs-time tracks. Current tracking can provide probe positions on each genomic fragment. Genomic fragments can be aligned to create probe maps for the genome. This process can be performed in parallel with the probe library. Probe maps of genome length for each probe can be generated. Errors can be corrected in a process called "Sequencing By Hybridization (mwSBH)". In some cases, the nanopore sequencing technology is from IBM / Roche. Using an electron beam, nanopore-sized openings can be fabricated in a microchip. An electric field can be used to attract or twist DNA through these nanopores. DNA transistor devices within nanopores can include nanometer-sized layers of alternating metals and dielectrics. Separate charges within the DNA backbone can be confined within the DNA nanopores by the electric field. The DNA sequence can be read by switching the gate voltage on and off.
[0265] Next-generation sequencing can include DNA nanoball sequencing (e.g., as performed by Complete Genomics; see, e.g., Drmanac et al. (2010) Science 327: 78-81). DNA can be isolated, fragmented, and size-selected. For example, DNA can be fragmented into average lengths of approximately 500 bp (e.g., by sonication). Adapters (Adl) can be attached to the ends of the fragments. Adapters can be used to hybridize to anchors for sequencing reactions. DNA with adapters attached to each end can be PCR amplified. Adapter sequences can be modified so that complementary single-stranded ends join together to form circular DNA. DNA can be methylated to protect it from cleavage by IIS-type restriction enzymes used in subsequent steps. Adapters (e.g., the adapter on the right) can have restriction recognition sites, which may remain unmethylated. The unmethylated restriction recognition sites in the adapters can be recognized by restriction enzymes (e.g., Acul), and the DNA can be cleaved by Acul at 13 bp to the right of the right adapter to form linear double-stranded DNA. The second rounds (Ad2) of the right and left adapters can be ligated to either end of the linear DNA, and all DNA to which both adapters are bound can be amplified by PCR (e.g., by PCR). The Ad2 sequences can be modified to allow them to bind to each other and form circular DNA. The DNA can be methylated, but the restriction enzyme recognition sites may remain unmethylated in the left Ad1 adapter. Restriction enzymes (e.g., Acul) can be applied, and the DNA can be cleaved at 13 bp to the left of Ad1 to form linear DNA fragments. The third rounds (Ad3) of the right and left adapters can be ligated to the right and left sides of the linear DNA, and the resulting fragments can be amplified by PCR. The adapters can be modified so that they bind to each other and form circular DNA.A type III restriction enzyme (e.g., EcoP15) can be added, and EcoP15 can cleave the DNA at 26 bp on the left side of Ad3 and 26 bp on the right side of Ad2. This cleavage removes large segments of DNA, allowing the DNA to be linearized again. The fourth round (Ad4) of the right and left adapters can be ligated to the DNA, and the DNA can be amplified and modified (e.g., by PCR), so that they join together and form a completed circular DNA template.
[0266] Small fragments of DNA can be amplified using rolling circle replication (e.g., using Phi29 DNA polymerase). The four adapter sequences may contain palindrome sequences that can hybridize, and the single strands can fold over themselves to form DNA nanoballs (DNBs™) that can have an average diameter of approximately 200-300 nanometers. The DNA nanoballs can be attached to a microarray (sequencing flow cell) (e.g., by adsorption). The flow cell may be a silicon wafer coated with silicon dioxide, titanium, and hexamethyldisilazane (HMDS) and photoresist materials. Sequencing can be performed by non-linking sequencing by linking fluorescent probes to the DNA. The fluorescence color at the queried position can be visualized by a high-resolution camera. The identity of nucleotide sequences between adapter sequences can be determined.
[0267] In some embodiments, high-throughput sequencing can be performed using AnyDot.chips (Genovoxx, Germany). In particular, AnyDot.chips can enhance nucleotide fluorescence signal detection by 10×-50×. AnyDot.chips and methods of using the same are described to some extent in International Publications WO 02088382, WO 03020968, WO 03031947, WO 2005044836, PCT / EP05 / 05657, PCT / EP05 / 05655, as well as German Patent Applications No. DE 101 49 786, DE 102 14 395, DE 103 56 837, DE 10 2004 009 704, DE 10 2004 025 696, DE 10 2004 025 746, DE 10 2004 025 694, DE 10 2004 025 695, DE 10 2004 025 744, DE 10 2004 025 745, and DE 10 2005 012 301.
[0268] Other high-throughput sequencing systems are disclosed in Venter, J., et al. Science 16 February 2001; Adams, M. et al. Science 24 March 2000; and MJ Levene, et al. Science 299:682-686, January 2003; and in U.S. Patent Application Publications 2003 / 0044781 and 2006 / 0078937. Such systems involve sequencing a target nucleic acid molecule having multiple bases by the time-dependent addition of bases via polymerization reactions measured on the nucleic acid molecule, i.e., the activity of the nucleic acid polymerase on the template nucleic acid molecule being sequenced is tracked in real time. The sequence can then be inferred by identifying which bases are incorporated into the growth phase complementary chain of the target nucleic acid by the catalytic activity of the nucleic acid polymerase at each step of the sequence addition. The polymerase on the target nucleic acid molecule complex moves along the target nucleic acid molecule and is positioned to extend oligonucleotide primers at the active site. Multiple labeled nucleotide analogs are provided near the active site, each of which is complementary to a different nucleotide in the target nucleic acid sequence, and each is a distinct type of nucleotide analog. The growing nucleic acid chain is extended by adding nucleotide analogs to the nucleic acid chain at the active site using polymerase, and the added nucleotide analogs are complementary to the nucleotides of the target nucleic acid at the active site. The nucleotide analogs added to the oligonucleotide primers as a result of the polymerization process are identified. The steps of providing labeled nucleotide analogs, polymerizing the growing nucleic acid chain, and identifying the added nucleotide analogs are repeated, thereby further extending the nucleic acid chain and determining the sequence of the target nucleic acid.
[0269] The present disclosure provides a haplotype phasing method comprising the steps of generating a plurality of read pairs from a single DNA molecule, and assembling a plurality of contigs of the DNA molecule using the read pairs, wherein at least 1% of the read pairs span a distance greater than 50 kB on the single DNA molecule, and the haplotype phasing is performed with an accuracy of over 70%. In some embodiments, at least 10% of the read pairs span a distance greater than 50 kB on a single DNA molecule. In other embodiments, at least 1% of the read pairs span a distance greater than 100 kB on a single DNA molecule. In some embodiments, the haplotype phasing is performed with an accuracy of over 90%.
[0270] In a further embodiment, the present disclosure provides a haplotype phasing method comprising the steps of generating a plurality of read pairs from a single DNA molecule (e.g., in vitro), and assembling a plurality of contigs of the DNA molecule using the read pairs, wherein at least 1% of the read pairs span a distance greater than 30 kB on the single DNA molecule, and the haplotype phasing is performed with an accuracy of over 70%. In some embodiments, at least 10% of the read pairs span a distance greater than 30 kB on a single DNA molecule. In other embodiments, at least 1% of the read pairs span a distance greater than 50 kB on a single DNA molecule. In still other embodiments, the haplotype phasing is performed with an accuracy of over 90%. In some embodiments, the haplotype phasing is performed with an accuracy of over 70%.
[0271] In certain embodiments, the present disclosure further provides a kit comprising one or more components of the present disclosure. The kit can be used for any application apparent to those skilled in the art, including those described above. The kit can comprise, for example, a plurality of association molecules, a fixative, an endonuclease (e.g., a restriction endonuclease), a ligase, and / or combinations thereof. In some cases, the association molecule can be a protein including, for example, a histone. In some cases, the fixative can be formaldehyde or any other DNA crosslinking agent.
[0272] In some cases, the kit may further include multiple beads. The beads are paramagnetic and / or coated with a scavenging agent. For example, the beads may be coated with streptavidin and / or antibody.
[0273] In some cases, the kit may include adapter oligonucleotides and / or sequencing primers. Furthermore, the kit may include a device capable of amplifying read pairs using the adapter oligonucleotides and / or sequencing primers.
[0274] In some cases, the kit may include, but is not limited to, other reagents such as lysis buffer, ligation reagents (e.g., dNTPs, polymerases, polynucleotide kinases, and / or ligase buffers), and PCR reagents (e.g., dNTPs, polymerases, and / or PCR buffers).
[0275] The kit may also include instructions for using the kit's components and / or for generating lead pairs.
[0276] The technology of this disclosure can offer many advantages compared to other technologies, such as other chromatin assembly procedures. These advantages include, but are not limited to, a reduction in the amount of input DNA required, a reduction in overall time to complete the protocol, a reduction in on-the-ground time to complete the protocol, improved DNA recovery, elimination of expensive and / or time-consuming steps, easier automation, easier scale-up, and higher throughput.
[0277] The techniques disclosed herein may require small amounts of input DNA. For example, the required input DNA may be less than about 5 micrograms (μg), less than about 4.5 μg, less than about 4 μg, less than about 3.5 μg, less than about 3 μg, less than about 2.5 μg, less than about 2 μg, less than about 1.5 μg, less than about 1 μg, less than about 900 nanograms (ng), less than about 800 ng, less than about 700 ng, less than about 600 ng, less than about 500 ng, less than about 400 ng, less than about 300 ng, less than about 200 ng, or less than about 100 ng. In some cases, the required input DNA may be less than about 500 ng.
[0278] The total elapsed time (i.e., "real time") required to prepare a sequencing library from a sample can be reduced. For example, the total time required to prepare a sequencing library (e.g., a chromatin assembly library) from a sample may be less than approximately 5.5 days, less than approximately 5 days, less than approximately 4.5 days, less than approximately 4 days, less than approximately 3.5 days, less than approximately 3 days, less than approximately 2.5 days, less than approximately 2 days, less than approximately 1.5 days, less than approximately 1 day, or less than approximately 0.5 days. In some cases, the total time required to prepare a sequencing library may be less than approximately 2 days.
[0279] The amount of activity time (i.e., "implementation time") required by the user (e.g., a scientist or expert) to prepare a sequencing library can be reduced. For example, the amount of implementation time may be less than approximately 8 hours, less than approximately 7 hours, less than approximately 6 hours, less than approximately 5 hours, less than approximately 4 hours, less than approximately 3 hours, less than approximately 2 hours, or less than approximately 1 hour. In some cases, the amount of implementation time to prepare a sequencing library may be less than approximately 4 hours.
[0280] For example, the amount of DNA recovered after a cross-link reversal step can be improved using the techniques disclosed herein. For instance, the DNA recovery after a cross-link reversal step may be at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. In some cases, the DNA recovery after a cross-link reversal step may be at least 30% to at least 50%.
[0281] Certain steps, including expensive or time-consuming ones, can be avoided using the techniques of this disclosure. For example, sequencing libraries can be prepared without requiring dialysis. Sequencing libraries can be prepared without requiring biotinylation of chromatin. Sequencing libraries can be prepared without requiring chromatin pulldown. Sequencing libraries can be prepared without requiring the occupation step of biotin beads. Sequencing libraries can be prepared without requiring certain digests, such as digests of ExoIII. The amount of chromatin required can also be reduced. For example, compared to the preparation of previous chromatin assembly libraries, the amount of chromatin required can be reduced by at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 times. The required amount of chromatin may be less than approximately 5 units, less than approximately 4.5 units, less than approximately 4 units, less than approximately 3.5 units, less than approximately 3 units, less than approximately 2.5 units, less than approximately 2 units, less than approximately 1.5 units, less than approximately 1 unit, less than approximately 0.9 units, less than approximately 0.8 units, less than approximately 0.7 units, less than approximately 0.6 units, less than approximately 0.5 units, less than approximately 0.4 units, less than approximately 0.3 units, less than approximately 0.2 units, or less than approximately 0.1 units. One unit of chromatin is equivalent to one microgram (μg) of DNA assembled into chromatin.
[0282] The computer system (500) illustrated in Figure 8 is understood as a logical device capable of reading instructions from a medium (511) and / or a network port (505), and may be optionally connected to a server (509) having a fixed medium (512). A system such as that shown in Figure 8 may include a CPU (501), a disk drive (503), optional input devices such as a keyboard (515) and / or a mouse (516), and an optional monitor (507). Data communication may be achieved through a communication medium indicated to the server at a local or remote location. The communication medium may include any means for transmitting and / or receiving data. For example, the communication medium may be a network connection, a wireless connection, or an Internet connection. Such a connection may provide communication over the World Wide Web. Data relating to this disclosure may be transmitted by such a network or connection for acceptance and / or consideration by a party (522), as illustrated in Figure 8.
[0283] Figure 9 is a block diagram showing the architecture of a first example of a computer system (100) that may be used in connection with examples of embodiments of the present disclosure. As shown in Figure 9, the example computer system may include a processor (102) for processing instructions. Examples of processors, not limited to these, include: Intel Xeon® processors, AMD Opteron® processors, Samsung 32-bit RISC ARM 1176JZ(F)-S v1.0® processors, ARM Cortex-A8 Samsung S5PC100® processors, ARM Cortex-A8 Apple A4® processors, Marvell PXA 930® processors, or functionally equivalent processors. Execution of multiple threads may be used for parallel processing. In some embodiments, multiple processors, or processors having multiple cores, may also be used in a single computer system, in a cluster, or distributed across a network system including multiple computers, mobile phones, and / or personal digital assistants.
[0284] As illustrated in Figure 9, the high-speed cache (104) can be connected to or incorporated into the processor (102) to provide high-speed memory for instructions or data that have been used or are frequently used by the processor (102) in recent years. The processor (102) is connected to the northbridge (106) by the processor bus (108). The northbridge (106) is connected to the random access memory (RAM) (110) by the memory bus (112) and manages the processor (102)'s access to the RAM (110). The northbridge (106) is also connected to the southbridge (114) by the chipset bus (116). The southbridge (114) is then connected to the peripheral bus (118). The peripheral bus may be, for example, PCI, PCI-X, PCI Express, or other peripheral buses. The northbridge and southbridge are often referred to as the processor chipset and manage data transfer between the processor, RAM, and peripheral components on the peripheral bus (118). In some alternative architectures, the functionality of the northbridge can be integrated into the processor instead of using a separate northbridge chip.
[0285] In some embodiments, the system (100) may include an accelerator card (122) attached to a peripheral bus (118). The accelerator may include a field-programmable gate array (FPGA) or other hardware to facilitate specific processing. For example, the accelerator may be used for reconstructing adaptive data or for evaluating algebraic expressions used in extended configuration processing.
[0286] Software and data are stored in an external storage device (124) and can be loaded into RAM (110) and / or cache (104) for use by the processor. The system (100) includes an operating system for managing system resources; examples of operating systems, not limited to these, include: Linux®, Windows®, MACOS®, BlackBerry OS®, iOS®, and other functionally equivalent operating systems, as well as application software running on the operating system for managing data storage and optimization in accordance with examples of embodiments of the present disclosure.
[0287] In this example, the system (100) also includes network interface cards (NICs) (120) and (121) connected to a peripheral bus to provide network interfaces to external storage devices such as network-attached storage (NAS) and other computer systems that may be used for distributed parallel processing.
[0288] Figure 10 is a schematic diagram showing a network (200) including multiple computer systems (202a) and (202b), multiple mobile phones and personal digital assistants (202c), and network-attached storage (NAS) (204a) and (204b). In an example of the embodiment, systems (202a), (202b), and (202c) can manage data storage and optimize data access to data stored in network-attached storage (NAS) (204a) and (204b). A mathematical model can be used on this data and evaluated using distributed parallel processing across computer systems (202a) and (202b), as well as mobile phones and personal digital assistant systems (202c). Computer systems (202a) and (202b), as well as mobile phones and personal information terminal systems (202c), can also provide parallel processing for adaptive data reconstruction of data stored in network-attached storage (NAS) (204a) and (204b). Figure 10 illustrates only one example, and various other computer architectures and systems may be used with various embodiments of this disclosure. For example, a blade server may be used to provide parallel processing. Processor blades may be connected through a backplane to provide parallel processing. Storage may also be connected to the backplane through a separate network interface or as network-attached storage (NAS).
[0289] In some embodiments, the processors may maintain separate memory spaces and transmit data through network interfaces, backplanes, or other connectors for parallel processing by other processors. In other embodiments, some or all of the processors may use a shared virtual address memory space.
[0290] FIG. 11 is a block diagram of a multiprocessor computer system (300) using a shared virtual address memory space in accordance with example embodiments. The system includes a plurality of processors (302a-f) that can access a shared memory subsystem (304). The system incorporates a plurality of programmable hardware memory algorithm processors (MAPs) (306a-f) in the memory subsystem (304). Each of the MAPs (306a-f) may include a respective memory (308a-f) and one or more field programmable gate arrays (FPGAs) (310a-f). The MAPs provide configurable functional units, and a specific algorithm or a portion thereof may be provided to the FPGAs (310a-f) to perform processing in close cooperation with each processor. For example, the MAPs may be used to evaluate algebraic expressions related to data models and perform adaptive data reconstruction in example embodiments. In this example, each of the MAPs is globally accessible by all processors for such purposes. In one configuration, each of the MAPs can use direct memory access (DMA) to access the associated memory (308a-f), which makes it possible to execute tasks independently of and asynchronously from each of the microprocessors (302a-f). In this configuration, the MAPs can directly supply results to another MAP for pipelining and parallel execution of algorithms.
[0291] The computer architectures and systems described above are merely examples, and various other computer, mobile phone, and personal information terminal architectures and systems may be used in conjunction with examples of embodiments that include systems using any combination of common processors, coprocessors, FPGAs, and other programmable logic circuits, system-on-a-chip (SOCs), application-specific integrated circuits (ASICs), and other processing elements and logic elements. In some embodiments, all or part of the computer system may be implemented in software or hardware. Various data storage media may be used in conjunction with examples of embodiments that include, for example, random access memory, hard drives, flash memory, tape drives, disk arrays, network-attached storage (NAS), and other local or distributed data storage devices and systems.
[0292] In an example of the embodiment, the computer system may be implemented using software modules that run on any of the above-described or other computer architectures and systems. In other embodiments, the functions of the system may be implemented in part or all of firmware, programmable logic circuits such as field-programmable gate arrays (FPGAs) as referred to in Figure 11, a system-on-a-chip (SOC), an application-specific integrated circuit (ASIC), or other processing elements and logic elements. For example, the set processor and optimizer may be implemented by hardware acceleration using a hardware accelerator card such as the accelerator card (122) shown in Figure 9.
[0293] Metagenomics and composite samples The microbial content of biological or biomedical samples, ecological or environmental samples, and food samples is frequently identified or quantified by culture-dependent methods. Because many microorganisms are not cultureable or cannot be cultured in the laboratory, a considerable amount of microbial biodiversity can be overlooked by culture-based methods. Shotgun metagenomic sequencing, in which thousands of organisms are sequenced in parallel, allows researchers to comprehensively sample the majority of genes from the majority of organisms present in a given composite sample. This method can enable the assessment of bacterial diversity and research on unculturable microorganisms that may otherwise be difficult to analyze. However, unsupported shotgun sequencing methods generate a significant number of reads, including short read sequences, which can be difficult to assemble without a reference sequence or without some source of long-term linkage information that requires de novo sequencing. Bioinformatics analysis of short-read shotgun data (e.g., ConStrains) may only require shotgun data; however, the output consists of contigs that are binned by sequence function but not assembled, and recent horizontally shifted segments may be inaccurately binned. Long-read sequencing of single molecules (e.g., Pacific Biosciences & Oxford Nanopore Technologies MinION) offers the possibility of long-range assembly; however, these can provide low-abundance genomes with limited applicability, and the cost per assembled base is relatively high. 16S RNA amplification can be used to deeply sample community 16S RNA; however, this technique only provides coarse classification information without resolving phylogenetic differences, pathogenicity types, etc. Synthetic long-read sequencing (e.g., Moleculo, 10X) can provide a true scaffold for contigs; however, sample preparation can be complex and potentially standardized, the cost per sample is higher, and high levels of contamination have been reported in Moleculo studies.In vivo proximity ligation can provide a long-range scaffold and allow for the placement of extragenomic elements (e.g., plasmids) with a host; however, this requires intact cells, which can result in uneven representation of community components in proximity data due to uneven compaction of the genome or even binding with DNA-binding proteins.
[0294] Microbial communities are often composed of tens, hundreds, or even thousands of recognizable operational taxa (OTUs) in highly unequal abundances, each with varying degrees of distortion. Further exacerbating this problem, microorganisms frequently exchange genetic material through various means of conjugal exchange, and such segments of genetic material can be incorporated into their host chromosomes, resulting in intense horizontal gene transfer within bacterial communities. Therefore, microbial genomes are often described in terms of the core genomes of widely present genes and others that may or may not be present in specific strains. Describing the constituent molecular genomes from complex microbial communities, such as the human gut microbiome, and the dynamics of these complex microbial communities, is a crucial and challenging problem.
[0295] Because de novo metagenomic assembly has been difficult, various simpler methods have been developed and widely adopted to examine and describe their components. For example, 16S RNA amplification and sequencing are common methods for assessing community composition. While this method can be used in a relative framework to describe the dynamics of microbial communities before and after various stimuli or treatments, it yields a very narrow view of the actual community composition because it learns nothing about the actual genome outside of their 16S regions. Binning methods have also proven useful for classifying shotgun reads or contigs assembled from them. These methods help to obtain a tentative assignment of isolated genomic fragments to OTUs. However, these methods are substantially hypothetical and do not have the power to order and orient these fragments or assign them to strains within an OTU. Importantly, these methods are unsuitable for identifying horizontally shifted sequences because they detect the originating OTU rather than the current linkage. From this perspective, such binning methods, based on k-mer generation, sequencing depth, and other characteristics, are a stopgap approach to understanding isolated metagenomic components, as highly contiguous assemblies have not been possible in reliable, fast, and economically rational ways until now.
[0296] The techniques disclosed herein offer several significant advantages over existing techniques. First, our "Chicago" library can provide a wide range of genomic linkage information and can be prepared rapidly and reliably. As described herein, the protocol can address the specific characteristics of DNA derived from metagenomic communities. Sequence libraries can be produced ready for sequencing in less than two days. In addition, since these libraries can be prepared using entirely in vitro protocols, culture may be unnecessary in any case. Subsequently, in principle, these techniques can assemble members of any microbiome community from which DNA can be recovered. Third, this method is simpler, faster, and more complete than other methods for de novo assembly and scaffolding.
[0297] This specification discloses methods and tools for genetic analysis of organisms in metagenomic samples, such as microorganisms that cannot be cultured in a laboratory environment and are present in various environments. This disclosure provides a method for de novo genome assembly of read data from complex metagenomics datasets, including connectability data. The methods and compositions disclosed herein generate scaffold data that uniformly and completely represent complex species in a metagenomics sample.
[0298] Figure 12A outlines the procedure for proximity ligation. DNA, such as high molecular weight DNA (1201), is incubated with histones (1202), then crosslinked (e.g., with formaldehyde) (1203) to form a chromatin assembly (1204). This locks the DNA molecule to a scaffold for further manipulation and analysis. Subsequently, the DNA is digested (1205), and the digested ends are filled with a marker such as biotin (1206). The marked ends are then randomly ligated together (1207), and the ligated assemblies are then released, for example, by protein digestion (1208). Subsequently, DNA molecules containing ligation bonds (1209) via streptavidin-biotin links, etc., can be selected using the marker. These molecules can then be sequenced, with each read pair originating from two different regions of the source molecule and separated to the size of the input DNA by several inserts.
[0299] Figure 12B shows two pipelines for sample preparation for metagenomic analysis, which can be used separately or together. A single DNA preparation (1210) (e.g., derived from a fecal sample) is input to the process. In the case of a fecal sample, the collected DNA may be a fragment of approximately 50 kilobases, derived from preparations using Qiagen's fecal DNA kit, for example. From this DNA, preparations for in vitro chromatin assembly (1211) (e.g., "Chicago") and shotgun (1212) libraries can be made. The chromatin assembly library (1213) and the shotgun library (1214) can use different barcodes (1215) and (1216) from each other. These two libraries can then be pooled for sequencing (1217). Using such a protocol, a single DNA preparation can serve as input for two sequencing libraries, shotgun and in vitro chromatin assembly. Input DNA of less than 1 μg is required to generate both libraries, and these libraries can be individually barcoded for pooling during sequencing. These data can then be assembled first into contigs and then scaffolded using long-range linkage information from the in vitro chromatin assembly libraries. These data generate many scaffolds larger than 1 megabase, enabling a more comprehensive view of microbial genome structure and dynamics than currently available. Processing time from sample to highly adjacent assembly can be less than one week.
[0300] Figure 12C shows a typical overview of scaffolding techniques that may be used in the procedures of this disclosure. Using read pairs of chromatin assemblies in vitro, a spanning tree of contigs (not shown) can be generated to determine which contigs (colored arrows) are close to each other in the exact assembly. Then, within a local window (e.g., (1220)), all possible orderings and orientations can be tested against the chromatin assembly data in vitro. As shown in Figure 1C, in two possible orientations of the green contig (1221), the chromatin assembly pair in vitro (1222) spans either a short distance (top) or a longer distance (bottom). The likelihood of each can be compared to a model of chromatin assembly distances in vitro trained for each library. During proximity ligation, the probability of two segments ligating can be described by a slowly decreasing function of how far apart the two segments are along the linear polymer of DNA. Therefore, pairs spanning short, medium, and long distances from the same single library are retrieved. The probability of a particular distance can be well modeled by a decreasing exponential law function; that is, observing read pairs spanning increasingly longer distances becomes less and less likely. The assembly techniques disclosed herein (e.g., "HiRise") can develop this facet of data to precisely order and orient the contigs to the scaffold.
[0301] Some embodiments of the method in question involve proximity ligation and sequencing of an assembled chromatin assembly in vitro, the assembly including a metagenomic DNA sample or a non-culturing microbial DNA sample obtained directly from a sample such as a biomedical or biological sample, an ecological or environmental sample, or a food sample. In an interchangeable embodiment, nucleic acids are assembled into a complex, bound, cleaved to expose internal double-strand breaks, isolated and labeled to facilitate cleavage ligation, and rejoined to produce paired ends to be sequenced. In some such paired-end sequences, it is assumed that both ends of the paired-end reads map to a common nucleic acid molecule, even if the sequences of the paired reads map to separate contigs.
[0302] In a similar preferred embodiment, the exposed ends of the bound complex are tagged with an identifier such as a nucleic acid barcode, thereby tagging or barcoding the complex, and it is presumed that the sequence adjacent to the tag presumably arises from a single nucleic acid. Again, the commonly barcoded sequence may be mapped to a number of contigs, which are then presumably mapped to a common nucleic acid molecule.
[0303] In a similar preferred embodiment, the complex is assembled by adding non-histone nucleic acid-binding proteins, such as nucleoproteins, transposases, transcription factors, topoisomerases, specific or nonspecific double-stranded DNA-binding proteins, or other suitable proteins. Alternatively or in combination, the complex is assembled using nanoparticles instead of histones or other nucleic acid-binding proteins.
[0304] In a similar preferred embodiment, the naturally occurring complex relies on preserving the linkage information of the nucleic acid complex. In some such cases, the nucleic acid is isolated to preserve the naturally assembled complex, or treated with a stabilizer such as a fixative before treatment or isolation.
[0305] In any assembled or isolated complex, crosslinking may, in some cases, be dependent on stabilizing nucleic acid complex formation, while in other cases, the interactions of the nucleic acid binding sites are sufficient to maintain the integrity of the complex in the absence of crosslinking.
[0306] The methods and compositions described herein, either alone or in combination with independently obtained or generated sequence data, such as shotgun sequencing data, can generate assemblies of genomic information relating to genomes, chromosomes, or independent nucleic acid molecules in heterogeneous nucleic acid samples. Genomics can be assembled representing cultureable or uncultureable organisms, such as abundant or rare organisms in a broad metagenomic community, including those in the human mouth or intestinal microbiome and organisms that do not grow in culture. Organisms may also be individuals in samples containing genetic material from a mixture of other individuals or populations, such as samples containing cells or nucleic acids from a large number of different human individuals. The methods of this disclosure provide a rapid and simple method for high-throughput, culture-free assembly of genomes, using potentially widely available high-throughput sequencing techniques.
[0307] Application of target-independent microbial detection The microbial content of biological or biomedical samples, ecological or environmental samples, industrial microbial samples, and food samples is frequently identified or quantified by culture-dependent methods. Microbial culture can depend on a variety of factors, including but not limited to pH, temperature, humidity, and nutrients. Determining culture conditions for unknown or previously uncultured organisms is often a time-consuming and difficult process.
[0308] Many microorganisms cannot currently be cultured in laboratories. A considerable amount of microbial biodiversity is overlooked by culture-based methods. The methods and compositions of this disclosure can be applied to the genetic analysis of organisms in metagenomic samples, such as microorganisms or viruses that cannot be cultured in a laboratory environment and are present in a variety of environments. Examples of metagenomic samples that are not limited to these include biological samples, including tissues, urine, sweat, saliva, sputum, and feces; air and atmosphere; water samples from bodies of water such as ponds, lakes, seas, and oceans; ecological samples such as soil and mud; and food. Analysis of microbial content in various metagenomic samples is useful for applications including, but not limited to, medicine, forensic science, environmental monitoring, and food science.
[0309] Individual microorganisms, including a panel of microorganisms, or “microbial signatures” or “microbial fingerprints” are identified in biological or biomedical samples obtained from subjects, such as mammalian subjects, including humans or other animals. In some embodiments, such information is used for medical purposes. In some embodiments, identification involves determining the presence or absence of a genus or species of microorganism, or a genus or species of microorganism with previously unidentified or non-common genetic mutations, such as mutations that can confer antibiotic resistance to bacterial strains. In some embodiments, identification involves determining the level of microbial DNA from one or more microbial species or one or more microbial genera. In some cases, a microbial signature or fingerprint indicates a level of microbial DNA of a particular genus or species that is increased or significantly higher compared to the level of microbial DNA from different genera or species in the sample. In some embodiments, a microbial signature or fingerprint of a sample indicates a level of microbial DNA of a particular genus or species that is decreased or significantly lower compared to the level of microbial DNA from other genera or species in the sample. In some embodiments, the microbial signature or fingerprint of a sample is determined by quantifying the levels of microbial DNA of various types of microorganisms (e.g., different genera or species) present in the sample. In some embodiments, the levels of microbial DNA of various genera or species present in the sample are determined and compared to those of a control sample or standard.
[0310] In some embodiments, the presence of a genus or species of microorganism in a suspected diseased subject leads to a confident diagnosis of a disease caused by that genus or species of microorganism. In some cases, this information is used to isolate an individual from other individuals if the genus or species of microorganism is suspected to be transmissible to other individuals, for example, by contact or proximity. In some cases, information about the microorganism or microbial species present in a sample is used to determine specific medical actions to eliminate the microorganism from the subject and treat, for example, a bacterial infection.
[0311] In some embodiments, if the level of microbial DNA of a particular genus or species in a sample is reduced, or significantly lower than that of a control sample or standard, the subject from whom the sample was taken is diagnosed with a disease such as cancer (e.g., breast cancer). In some embodiments, the levels of microbial DNA of various genera or species present in a sample are determined and compared with other various genera or species present in the sample. In some embodiments, if the level of microbial DNA of a particular genus or species in a sample is reduced, or significantly lower than that of other microbial genera or species detected in the sample, the subject from whom the DNA was taken is likely suffering from a disease such as cancer.
[0312] Individual microorganisms, including panels of microorganisms, or "microbial signatures" or "microbial fingerprints," are identified in environmental or ecological samples, such as air samples, water samples, and soil or mud samples. In some embodiments, microbial identification and analysis of microbial diversity in environmental or ecological samples are used to monitor the impact of pollutants on ecosystems and improve strategies for cleaning up contaminated environments. A better understanding of how microbial communities cope with pollutants improves the assessment of the likelihood of a contaminated site recovering from contamination and increases the potential for bioenhancement or biostimulation. Such information provides valuable insights into the functional ecology of environmental communities. Microbial analysis is also used, in some cases more broadly, to identify species present in air, water, specific bodies of water, and soil and mud samples. This can be used, for example, to establish the range of invasive and endangered species and to track seasonal populations.
[0313] The identification and analysis of microbial communities in environmental or ecological samples are also useful for agricultural applications. Microbial consortia perform a variety of ecological roles necessary for plant growth, including nitrogen fixation, nutrient cycling, disease suppression, and sequestration of iron and other metals. Such information is useful, for example, for disease detection in crops and livestock, and for improving the adaptation of enhanced agricultural practices that improve crop health by utilizing the relationship between microorganisms and plants.
[0314] In some embodiments, individual microorganisms, including a panel of microorganisms, or "microbial signatures" or "microbial fingerprints," are identified in industrial samples of microorganisms, such as microbial communities used to produce a variety of biologically active chemicals, including fine chemicals, pesticides, and pharmaceutical formulations. Microbial communities produce many biologically active chemicals.
[0315] Microbial detection and identification based on sequence analysis also contribute to food safety, food integrity, and fraud detection. For example, detection and identification of microorganisms in metagenomic samples allows for the detection and identification of unculturable and previously unknown pathogens, including bacteria, viruses, and parasites, in food suspected of spoilage or contamination. Given the estimate that approximately 80 percent of foodborne illnesses in the United States are caused by unspecified agents, including known agents not recognized as causing food poisoning, substances present in food but not proven to be pathogenic, and unknown agents, analyzing microorganisms in the entire population can offer an opportunity to reduce food poisoning. With increasing awareness of the overall food supply and growing awareness of sustainable practices in sourcing foods such as seafood and crustaceans, microbial detection is useful in assessing food integrity, for example, in determining whether fish claimed to be from a specific region of the world is truly from that region.
[0316] Application of chain measurement in heterogeneous samples The application of the methods described herein also relates to linkage measurements for known or unknown molecules in heterologous samples. Furthermore, applications relating to the measurement of linkage information in heterologous samples, in addition to novel biodetection, are also considered herein. In some embodiments, linkage information is determined for nucleic acids, such as chromosomes, in heterologous nucleic acid samples. Samples containing DNA from multiple individuals are obtained, such as from crime scenes, toilets or latrines, battlefields, sinks, or garbage. Nucleic acid sequence information is obtained, for example, via shotgun sequencing, and linkage information is determined. Frequently, information about an individual's unique genome is not identified by a single locus, but by combinations of loci such as single nucleotide polymorphisms (SNPs), insertions or deletions (in / del), or point mutations, or alleles that collectively represent a unique or substantially unique combination of genes for a trait. Often, the individual's traits are not sufficient to identify a specific individual. However, using linkage information available through the execution of the methods herein, not only are aggregated alleles present in heterologous samples identified, but shotgun or alternative high-throughput sequencing methods available in the art also identify specific combinations of alleles present in specific molecules within the sample. Thus, not only are specific alleles in the sample identified, but also combinations of these alleles on chromosomes necessary to map those combinations to a specific individual whose genomic information is available through previously obtained genomic sequences or sequence information available from relatives. Linkage information is also useful when the gene is known to be present in a heterologous sample, but the genomic context is unknown. For example, in some cases, an individual is known to have a harmful infection resistant to antibiotic treatment. Shotgun sequencing will likely identify the antibiotic resistance gene. However, through the execution of the methods herein, useful information is obtained regarding the genomic context of the antibiotic resistance gene. Thus, by identifying not only the antibiotic resistance gene but also the genome of the organism in which it resides, alternative treatments for targeting the antibiotic resistance gene host can be identified in light of the rest of that genomic information.For example, metabolic pathways that are not present in resistant bacteria, or that make them vulnerable to the second antibiotic, are targeted, thereby eliminating resistant bacteria despite their resistance to the antibiotic in the case of the first option. Alternatively, more complete genomic information about the host of the antibiotic resistance gene in the patient is used to determine whether the resistance gene originates from a “wild” microbial organism or likely from a laboratory strain of a microbial organism that “escaped” from the laboratory or was deliberately released.
[0317] sample Samples in which microorganisms are detected may be any sample containing a population of microorganisms or a population of heterogeneous nucleic acids. Examples include biological or biomedical samples from human or animal subjects; environmental and ecological samples, including but not limited to soil and water samples such as water samples from ponds, lakes, seas, and oceans; or food suspected to be spoiled or contaminated.
[0318] Biological samples can be obtained from biological subjects. Subjects can refer to any animal (e.g., mammals), including but not limited to humans, non-human primates, rodents, dogs, cats, pigs, and fish. Samples can be obtained from any subject, individual, or from a biological source including humans or non-human animals, including mammals and non-mammals, vertebrates and invertebrates. Samples may include infected or contaminated tissue samples, such as tissue samples including skin, heart, lungs, kidneys, breasts, pancreas, liver, muscle, smooth muscle, bladder, gallbladder, colon, intestines, brain, prostate, esophagus, and thyroid. Samples may include infected or contaminated biological samples, such as blood, urine, cerebrospinal fluid, semen, saliva, sputum, and feces.
[0319] In some cases, heterogeneous samples include samples containing nucleic acids from at least two individuals, such as toilets or latrines used by two or more individuals, or samples obtained from locations where the blood or tissues of at least two individuals are mixed, such as battlefields or crime scenes.
[0320] Chain information for a sample obtained by performing the methods disclosed herein. The method of obtaining a sample can be selected for the appropriate sample type and desired application. For example, tissue samples can be obtained by biopsy or excision during a surgical procedure; blood can be obtained by venous aspiration; and saliva, sputum, and stool can be self-provided by the individual at the receptacle.
[0321] In some embodiments, the fecal sample is derived from an animal such as a mammal (e.g., non-human primates, horses, cattle, dogs, cats, pigs, and humans). The fecal sample can be of any appropriate weight. The fecal sample may be at least 50g, 60g, 70g, 80g, 90g, 100g, 110g, 120g, 130g, 140g, 150g or more. The fecal sample may contain water. In some embodiments, the fecal sample may contain at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more water. In some embodiments, the fecal sample is stored. The fecal sample may be stored at 2-8°C for several days (3-5 days) or at a temperature of -20°C for a longer period (e.g., longer than 5 days). In some embodiments, the fecal sample may be provided by an individual or subject. In some embodiments, the fecal sample may be collected from a place where feces are accumulated. In some embodiments, the stool sample may include multiple samples collected from a single individual over a predetermined period. Using stool samples collected over a period at multiple points in time, biodiversity in an individual's stool can be monitored, for example, during the course of treatment for infection. In some embodiments, the stool sample may include samples from various individuals, for example, various individuals suspected of being infected with the same pathogen or suffering from the same disease.
[0322] In some cases, the sample may include environmental or ecological samples containing a population or community of microorganisms. Examples of environmental samples, not limited to those mentioned above, include air or atmosphere samples, soil or mud samples, and water samples. Air samples can be analyzed to determine the microbial composition of air, for example, in an area suspected of containing microorganisms that are considered to threaten health, such as disease-causing viruses. In some embodiments, understanding the microbial composition of air samples can be used to monitor environmental changes.
[0323] Water samples may be analyzed for purposes including, but not limited to, monitoring public safety and the environment. Water samples, for example, from drinking water supply reservoirs, can be analyzed to measure microbial diversity in drinking water supplies and their potential impact on human health. Water samples can also be analyzed to measure the impact on the microbial environment resulting from localized changes in the temperature and composition of atmospheric gases. Water samples, such as those from ponds, lakes, seas, oceans, or other bodies of water, can be sampled at various points in time throughout the year. In some embodiments, multiple samples may be obtained at different points in time throughout the year. Water samples can be collected at various depths from the surface of the body. For example, water samples can be collected at the surface of the body or at least 1 meter (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9 meters or more) from the surface. In some embodiments, water samples can be collected from the bottom of the body.
[0324] Soil and mud samples can be sampled to study microbial diversity. Soil samples can provide information about the behavior of viruses and bacteria in soil and water and are useful for biological environmental remediation, where genetic engineering can be applied to develop soil microorganisms that can decompose hazardous pollutants. Soil microbial communities can have thousands of different organisms, containing a substantial number of genetic information, for example, 2,000 to 18,000 different genomes estimated in 1 gram of soil. Soil samples can be collected from the surface at various depths. In some embodiments, soil is collected at the surface. In some embodiments, soil is collected at a depth of at least 1 (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) below the surface. In some embodiments, soil is collected at a depth between 1 and 10 (e.g., 2-9, 3-8, 4-7, or 5-6) below the surface. Soil samples can be collected at various points in time throughout the year. In some embodiments, soil samples are collected in specific seasons, such as winter, spring, summer, or autumn. In some embodiments, soil samples are collected in specific months. In some embodiments, soil samples are collected after environmental events, including but not limited to tornadoes, hurricanes, or thunderstorms. In some cases, multiple soil samples are collected over a period to allow monitoring of microbial diversity over time. Soil samples can be collected from a variety of ecosystems, such as agricultural ecosystems, forest ecosystems, and ecosystems in various geographical regions.
[0325] Food samples may be food that is contaminated, spoiled, suspected of being a source of human disease, or suspected of containing the target microorganism or nucleic acid. Food samples may be produced on a small scale, such as in a single factory. Food samples may be produced on an industrial scale, such as in a large food production or food processing plant. Examples of food samples, not limited to, include animal products, such as raw or cooked seafood, shellfish, raw or cooked eggs, undercooked meat including beef, pork and chicken, unpasteurized milk, unpasteurized soft cheese, unprocessed hot dogs, and deli meats; plant products, such as fresh produce and salads; fruit products, such as fresh produce and fruit juices; and processed and / or cooked foods, such as homemade canned goods, mass-produced canned goods, and sandwiches. In some embodiments, food samples for analysis, such as food samples suspected of being contaminated or spoiled, may be stored at room temperature, for example, 20°C to 25°C. In some embodiments, food samples were stored at temperatures below room temperature, such as 20°C, 18°C, 16°C, 14°C, 12°C, 10°C, 8°C, 6°C, 4°C, 2°C, 0°C, -10°C, -20°C, -40°C, -60°C, or below -80°C. In some embodiments, food samples were stored at temperatures above room temperature, such as 26°C, 28°C, 30°C, 32°C, 34°C, 36°C, 38°C, 40°C, or above 50°C. In some embodiments, food samples were stored at unknown temperatures. Food samples may be stored for specific periods, such as one day, one week, one month, or one year. In some cases, food samples were stored for at least one day, one week, one month, six months, one year, two years, or longer. Food samples are perishable and have limited storage periods. Food samples produced in manufacturing plants may be obtained from specific production lots or production periods. Food samples can be obtained from various shops in various communities, as well as from various manufacturing plants.
[0326] nucleic acid molecule Nucleic acid molecules (e.g., DNA or RNA) can be isolated from metagenomic samples containing various other components, such as proteins, lipids, and non-template nucleic acids. Nucleic acid molecules can be obtained from any cellular material, including animals, plants, bacteria, fungi, or other cellular organisms. Biological samples for use in this disclosure also include viral particles or preparations. Nucleic acid molecules can be obtained directly from living organisms or from biological samples obtained from living organisms, such as blood, urine, cerebrospinal fluid, semen, saliva, sputum, feces, and tissues. Nucleic acid molecules can be obtained directly from living organisms or from environmental samples obtained from living organisms, such as air samples, water samples, and soil samples. Nucleic acid templates can be obtained directly from spoiled or suspected contaminated food samples, such as meat samples, agricultural product samples, fruit samples, raw food samples, processed food samples, and frozen food samples.
[0327] Nucleic acids are extracted and purified using a variety of methods. In some cases, nucleic acids are purified by organic extraction with phenol, phenol / chloroform / isoamyl alcohol, or similar formulations including TRIzol and TriReagent. Other, not limited, examples of extraction techniques include: (1) organic extraction with ethanol precipitation, with or without the use of an automated nucleic acid extractor, e.g., the Model 341 DNA Extractor available from Applied Biosystems (Foster City, Calif.), e.g., using an organic reagent such as phenol / chloroform (Ausubel et al., 1993); (2) stationary phase adsorption (U.S. Patent No. 5,234,809; Walsh et al., 1991); and (3) salt-induced nucleic acid precipitation, such as precipitation methods typically referred to as "salting-out" methods (Miller et al., 1988). The isolation and / or purification of nucleic acids may involve the use of magnetic particles, to which nucleic acids may bind specifically or nonspecifically, and then the beads may be isolated and washed using a magnet, and the nucleic acids may be eluted from the beads (see, for example, U.S. Patent No. 5,705,628). In some embodiments, the above isolation method may be followed by an enzymatic digestion step, e.g., digestion with proteinase K or other proteases, which helps to remove unwanted proteins from the sample (see, for example, U.S. Patent No. 7,001,724). If necessary, an RNase inhibitor may be added to the lysis buffer. For specific cell or sample types, a protein denaturation / digestion step may be added to the procedure. The purification method may aim to isolate DNA, RNA, or both. If both DNA and RNA are isolated together during or after the extraction procedure, further steps may be used to purify one or both separately from the other. For example, purification based on size, sequence, or other physical or chemical properties may also produce fractions of the extracted nucleic acids. In addition to the initial nucleic acid isolation step, nucleic acid purification may be performed after any step in the method of this disclosure, for example, to remove excess or unwanted reagents, reactants, or products.In some cases, such as when the detection of RNA-encoded genomes is considered, nucleic acid samples are treated with reverse transcriptase, and as a result, the RNA molecules in the nucleic acid sample serve as templates for the synthesis of complementary DNA molecules. In some cases, such treatment facilitates downstream analysis of the nucleic acid sample.
[0328] Nucleic acid template molecules can be obtained as described in U.S. Patent Application Publication No. 2002 / 0,190,663A1, published on October 9, 2003. In some cases, nucleic acids are extracted from biological samples by various techniques, including those described in Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY, pp. 280-281 (1982), and recent updates to well-known laboratory resources. Nucleic acids can first be extracted from biological samples and then crosslinked in vitro. Native associated proteins (e.g., histones) can be further removed from the nucleic acids.
[0329] The methods disclosed herein can be readily applied to any high molecular weight double-stranded DNA, including DNA isolated from, for example, tissues, cell cultures, bodily fluids, animal tissues, plants, bacteria, fungi, viruses, and the like.
[0330] Each of several independent samples may independently contain at least approximately 1 ng, 2 ng, 5 ng, 10 ng, 20 ng, 30 ng, 40 ng, 50 ng, 75 ng, 100 ng, 150 ng, 200 ng, 250 ng, 300 ng, 400 ng, 500 ng, 1 μg, 1.5 μg, 2 μg, 5 μg, 10 μg, 20 μg, 50 μg, 100 μg, 200 μg, 500 μg, or 1000 μg or more of nucleic acid material. In some cases, each of several independent samples may independently contain approximately 1 ng, 2 ng, 5 ng, 10 ng, 20 ng, 30 ng, 40 ng, 50 ng, 75 ng, 100 ng, 150 ng, 200 ng, 250 ng, 300 ng, 400 ng, 500 ng, 1 μg, 1.5 μg, 2 μg, 5 μg, 10 μg, 20 μg, 50 μg, 100 μg, 200 μg, 500 μg, or less than or greater than 1000 μg of nucleic acid.
[0331] Various methods are available for quantifying nucleic acids. Examples of methods for quantifying nucleic acids include spectrophotometric analysis and measurement of the fluorescence intensity of dyes that bind to nucleic acids and fluoresce upon binding, such as ethidium bromide.
[0332] nucleic acid complex Nucleic acids, including DNA from a metagenomic or other heterologous sample(s), may be bound to association molecules or nucleic acid binding sites to form nucleic acid complexes. In some cases, the nucleic acid complex may consist of nucleic acids bound to multiple association molecules or sites, such as polypeptides; non-protein organic molecules; and nanoparticles, which may bind to individual nucleic acids at multiple points of contact, thereby holding together independently of their common phosphate diester backbone.
[0333] In some cases, nucleic acid binding involves linking between segments of nucleic acid molecules, such as the formation of covalent bonds. Linking can be formed between distant segments of nucleic acid molecules. In some cases, nucleic acid binding for the formation of a nucleic acid complex involves crosslinking to an associated molecule or portion of the nucleic acid (also referred to as a nucleic acid binding molecule or portion). In some cases, the associated molecule includes amino acids, including but not limited to peptides and proteins such as DNA-binding proteins. Typical DNA-binding proteins include natural chromatin components such as histones, e.g., histones 2A, 2B, 3A, 3B, 4A, and 4B. In some cases, multiple nucleic acid binding portions include reconstituted chromatin or chromatin assembled in vitro. Chromatin can be reconstituted from DNA molecules with a length of approximately 150 kbp. In some cases, chromatin is reconstituted from DNA molecules with a length of at least 50, 100, 125, 150, 200, or 250 kbp. In some cases, binding proteins include transcription factors or transposases. Non-protein organic molecules are also compatible with the disclosures herein and include protamines, spermine, spermidine, or other positively charged molecules. In some cases, the associated molecules include nanoparticles, such as nanoparticles with a positively charged surface. Many nanoparticle compositions are compatible with the disclosures herein. In some embodiments, the nanoparticles include silicon, such as silicon coated with a positive coating to bind negatively charged nucleic acids. In some cases, the nanoparticles are platinum-based nanoparticles. The nanoparticles are magnetic, which may facilitate the isolation of crosslinked sequence segments.
[0334] Nucleic acids are bound to the associated molecule by various method...
Claims
1. A method for determining the genomic information of a crosslinked heterologous nucleic acid sample, wherein the method is: (a) A step of providing the crosslinked heterogeneous nucleic acid sample, wherein the crosslinked heterogeneous nucleic acid sample comprises nucleic acids from a plurality of unique genomes, wherein the crosslinked heterogeneous nucleic acid sample is crosslinked with respect to the associated molecule by intermolecular interactions such that the nucleic acid and the associated molecule are bound together in a manner resistant to molecular manipulation such as restriction endonuclease treatment, DNA shearing, nucleic acid cleavage labeling, or ligation, and wherein the crosslinked heterogeneous nucleic acid sample comprises a plurality of DNA segments, each of the plurality of DNA segments being complexed together independently of a common phosphodiester backbone, and each common phosphodiester backbone of the plurality of DNA segments is cleaved to create a plurality of exposed DNA ends. (b) A step of labeling a plurality of exposed DNA ends with a plurality of labels in order to form labeled exposed DNA ends, wherein the labeled exposed end of each DNA segment is identifiable as originating from a common genome in the plurality of unique genomes. (c) A step of ligating the labeled exposed DNA ends to form a pair of labeled ends, (d) A step of determining the sequence of the ends of the labeled pair and generating a plurality of sequence read pairs, (e) A method comprising the step of assigning one sequence read pair of the plurality of sequence read pairs to a common nucleic acid molecule of one unique genome of the plurality of unique genomes, wherein the sequence read pair comprises sequences from at least two DNA segments of the plurality of DNA segments.
2. The method according to claim 1, wherein the cross-linked heterologous nucleic acid sample is from a cancer sample.
3. The method according to claim 1, wherein the cross-linked heterogeneous nucleic acid sample is from a metagenomic sample.
4. The method according to claim 1, wherein step (b) includes adding a plurality of oligonucleotides to the plurality of exposed DNA ends.
5. The method according to claim 1, further comprising the step of assigning each half of the sequence read pair to a contig dataset.
6. The method according to claim 5, wherein the contig dataset is generated simultaneously.
7. The method according to claim 5, wherein the contig dataset is obtained from a database.
8. The method according to claim 1, wherein step (b) comprises ligating at least a first exposed DNA end of the plurality of DNA segments to at least a second exposed DNA end of the plurality of DNA segments.
9. The method according to claim 1, further comprising the step of cleaving the common phosphodiester skeleton.
10. The method according to claim 1, further comprising the step of generating the cross-linked heterologous nucleic acid sample.
11. The method according to claim 1, wherein the cross-linked heterogeneous nucleic acid sample is a formalin-fixed paraffin-embedded (FFPE) sample.
12. The method according to claim 1, further comprising the step of contacting the crosslinked heterogeneous nucleic acid sample with reverse transcriptase.
13. The method according to claim 1, further comprising the step of contacting the plurality of DNA segments with reversible immobilization (SPRI) beads of a solid phase.
14. The method according to claim 1, wherein the cross-linked heterogeneous nucleic acid sample comprises DNA not exceeding approximately 5 micrograms.
Citation Information
Patent Citations
Methods for genome assembly and haplotype phasing
WO2014121091A1
